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Abstract

The ability to respond to anti-growth signals is critical to maintain tissue
homeostasis and loss of this proliferative control mechanism is considered a hallmark of
cancer. Negative growth regulation generally occurs during the G0/G1 phase of the cell
cycle, yet the redundancy and complexity among components of this regulatory network
have made it difficult to discern how negative growth cues protect cells from aberrant
proliferation.

.

Transforming growth factor (3 (TGF-P) is a crucial mediator of mammary
epithelial morphogenesis and can negatively regulate cell cycle progression. TGF-P has
been shown to inhibit cyclin dependent kinase activity, which leads to activation of the
retinoblastoma protein (pRB) and growth arrest. However, unlike other components of
TGF-P cytostatic signalling, pRB is thought to be dispensable for mammary
development. Using gene-targeted mice where the LXCXE binding cleft on pRB has
been disrupted (R b l^ and R blNF), we have discovered that pRB plays a crucial role in
mammary gland development. In particular, Rbl and RblNF mutant female mice have
hyperplastic mammary epithelium due to insensitivity to TGF-P growth inhibition. In
contrast with previous studies that highlight the inhibition of cyclin/CDK activity by
TGF-P signalling, these experiments reveal that active transcriptional repression of E2F
target genes by pRB is also a key component of TGF-p cytostatic signalling. However,
loss of pRB-LXCXE interactions does not cause overt defects in other TGF-P signalling
pathways such as apoptosis and differentiation. Taken together, this work demonstrates a
unique functional connection between pRB and TGF-p in growth control and mammary
development.

iii

These findings were extended to explore the importance of the pRB anti
proliferative response during tumour formation and progression. Cytostatic control is
considered a key tumour suppressive mechanism in the mammary gland. Here I show that
LXCXE-dependent growth control by pRB blocks formation of mammary tumours in
Wap-p53R172Htransgenic mice. In contrast, the same growth control mechanism is
unnecessary to protect against Neu or 7,72-dimethylbenz[a]anthracene-induced mammary
tumorigenesis. Taken together, this work demonstrates that anti-proliferative control by
pRB can act as a barrier against oncogenic transformation. Strikingly, these data also
reveals that this tumour suppressive effect is context-dependent.

Key Words
Retinoblastoma, TGF-P, mammary gland, proliferation, LXCXE, cell cycle, breast
cancer, metastasis
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Chapter 1: Introduction

1.1 General Introduction
The ability to control growth is essential during development and maintenance of
homeostasis; loss of this control is considered one of the hallmarks of cancer (76). The
mammalian cell has developed a network of pathways to safeguard the cell against
aberrant proliferative cues (137). The retinoblastoma protein (pRB) and transforming
growth factor beta (TGF-P) are key components in this web of cellular growth control, so
it is not surprising that their activities are subverted in many forms of cancer, including
breast cancer (20, 138). Despite the wealth of knowledge that has been gathered since the
discovery of these two proteins (6, 40, 61, 62, 123), many questions remain about how
they function both during development and tumorigenesis. It is becoming increasingly
clear that cellular context plays an important role in how cells respond to both tumour
suppressive and oncogenic signals. For that reason, this thesis examines the role of pRB
dependent proliferative control in mammary gland development and tumorigenesis, and
demonstrates a unique connection with the TGF-p pathway.

1.2 Identification and Cloning of the Retinoblastoma Tumour Suppressor Protein
The first tumour suppressor system identified in humans was that governing the
formation of the childhood eye cancer, retinoblastoma. This cancer occured sporadically
in some patients, but appeared to be inherited in others (114). Based on the genetic data,
Knudson proposed a “two-hit” hypothesis, suggesting that retinoblastoma was caused by
two mutational events. In familial cases, one mutation conferring susceptibility to
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retinoblastoma was inherited through the germ line, while the second, rate-limiting step
occurred in somatic cells. In sporadic cases, both mutations occurred in somatic cells.
This initial observation led to the mapping of the putative retinoblastoma susceptibility
gene to chromosome 13ql4, and the subsequent cloning of the retinoblastoma tumour
suppressor gene (RBI) (58, 61, 62, 123, 201). As predicted by Knudson’s hypothesis,
both alleles of the RBI gene were frequently deleted or mutated in cases of both sporadic
and familial retinoblastoma (61, 62, 123). Consistently, there was little to no expression
of the mRNA transcript in retinoblastoma cells, while transcripts were readily detected in
human retinal and placental tissue (61, 62, 123). This strongly implicated the loss of RBI
as causative in the development of retinoblastoma tumours. Mutations in RBI were also
identified in osteosarcoma cell lines, linking loss of pRB to other human cancers (61, 62).
Inactivation of the RBI gene is now known to occur with variable incidence in other
tumours, including 90% of small cell lung carcinomas (SCLC) and 20-30% of breast
cancers (14, 20). In other cancers, upstream components of the pRB pathway are
disrupted, leading to loss of pRB function (14, 20, 54, 137). Thus, pRB appears to play a
tumour suppressive role in many forms of human cancers. Nearly 25 years after the initial
cloning of RBI, many cellular functions and interacting partners of pRB have been
determined. However, it remains unclear which of these functions are physiologically
relevant and are involved in suppression of tumorigenesis.

3
1.3 pRB Structure
1.3.1 The Pocket Protein Family
pRB is a member of the pocket protein family which also includes pi 07 and pi 30.
All three pocket proteins can induce similar phenotypes when overexpressed in culture
(31, 232) and in some cancers, upstream regulators of all three pocket proteins are altered
(14, 54, 137). The pocket proteins have also been shown to compensate for the loss of
one another in at least some cell types (149), so it is possible that in some cellular
contexts, all three pocket proteins need to be disrupted to allow tumour progression.
However, there are also several important differences between the members of the pocket
protein family. For instance, sequence alignment has shown that p i07 and p i30 are more
closely related to one another than to pRB (29). Furthermore, their cellular expression
varies, p i07 is mainly controlled at the transcriptional level and is expressed in cycling
cells, p i30 is most abundant in quiescent and differentiated cells, and its levels drop as
quiescent cells re-enter the cell cycle (29). In contrast, pRB is expressed in both cycling
and non-cycling cells, suggesting that it is ubiquitously required while pl07 and pl30 are
used in more specialized situations. Importantly, pRB is unique among the pocket
proteins in that it is the only one that is commonly mutated in human cancers (20). For
these reasons, this thesis will focus on the functions and physiological roles of pRB.
1.3.2 General Structure
pRB shares the same general structure as all pocket proteins and is conserved
across many different species (29, 122, 148). RBI encodes a 928 amino acid long nuclear
phosphoprotein (124) which can be divided into N-terminal, “small pocket”, and Cterminal regions (Fig. 1.1a) (29). The small pocket was originally identified as the

Figure 1.1 pRB structure and binding partners. (A) The general structure of pRB is
outlined. (B) The large pocket of pRB can interact with many cellular proteins. Details of
many of these cellular interactions are discussed in section 1.3.3 of the text. (Figure
adapted from Classon and Dyson, Exp. Cell Research, 2001 and Dick, Cell Division,
2007)
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minimal region of pRB that is necessary for interactions with viral oncoproteins such as
human papilloma virus (HPV) E7, adenovirus El A, and simian virus large T antigen
(SV40 TAg) (92, 93, 110). This region consists of an A and B box which are joined by a
spacer region (68, 122). The A and B boxes make extensive contacts with each other to
form an intertwined globular small pocket (122). The interface between the A and B
boxes is critical for protein stability, as demonstrated by several cancer-derived mutations
that disrupt multiple interaction sites found within the small pocket (88, 113, 159, 160,
187,219, 229).
While the small pocket is sufficient for binding of viral oncoproteins, the Cterminus of pRB is additionally required for growth suppression (173). Together, the
small pocket and C-terminus form the large pocket of pRB, which can complement
pRB’s tumour suppressive activity in vivo when expressed in place of full length pRB
(230). This highlights the importance of the large pocket for pRB function and suggests
that growth control via interactions at the large pocket may act as a barrier to tumour
formation. Below, several of the binding sites located within the large pocket will be
outlined, followed by discussion of their known functions in section 1.4.
1.3.3 Sites of Interaction on pRB
(A) Cyclin Dependent Kinase and Protein Phosphatase 1 Binding Domains
While pRB contains no obvious protein interaction domains, it can interact with
many cellular proteins (44). Phosphorylation of pRB is mediated by cyclin dependent
kinase (CDK) complexes. Both cyclin D-CDK4/6 and cyclin E-CDK2 complexes can
bind to and phosphorylate pRB (1). Interactions of cyclin E-CDK2 complexes with their
substrates depend on contacts between an RXL motif on the substrate and a hydrophobic

7
patch on the cyclin (3). Several RXL related motifs are present within the last 100
residues of pRB, and deletion of the RXL motif starting at residue 870 diminishes
phosphorylation (2). Under certain conditions, phosphorylation of pRB by cyclin D lCDK4 also depends on an intact pRB RXL motif. However, cyclin D-CDK4 appears to
recognize pRB by a mechanism that is distinct from that used by cyclin E-CDK2
complexes (1). CDK4 recognizes a 19 amino acid long sequence at the C-terminus of
pRB that is necessary for binding and CDK4-dependent phosphorylation of pRB (217).
Several studies suggest that not only do these two cyclin-CDK complexes interact with
different regions of pRB, but that they can act in a non-redundant manner to
phosphorylate pRB (52, 134). Taken together, these data identify regions on pRB that are
necessary for interactions with multiple cyclin-CDK complexes and their catalytic
activities.
Intriguingly, Protein Phosphatase 1 (PP1) can also bind to the C-terminus of pRB.
Amino acids 792 to 928 are both necessary and sufficient for binding to PPla (206).
Surprisingly, PP1 appears to bind both hyper and hypophosphorylated forms of pRB
(207), suggesting the possibility that it may regulate the phosphorylation status of pRB
both by catalytic removal of phosphate groups and by competition with CDK complexes
for access to the C-terminus. Further work to define the PP1 interaction site and
mechanism of action should shed light on this possibility.
(B) E2F Interactions
pRB does not possess any recognizable DNA binding domains (44). Instead, pRB
appears to be recruited to DNA through its interactions with cellular proteins, such as
E2F transcription factors, which regulate expression of genes necessary for cell cycle
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progression. E2F1 was one of the first identified cellular interacting partners for pRB (82,
109). Further work has identified interactions between pRB and the first four members of
the E2F family of transcription factors. Amino acids throughout the large pocket are
necessary for interactions with E2Fs (Fig. 1.1). Interestingly, the pRB-binding site on
E2Fs appears to overlap with their transactivation domain (44, 120, 226). This suggests
that pRB may interact with E2Fs in order to regulate their activity.
(C) Skp2 Interactions
pRB can also bind to the S-phase kinase-associated protein 2 (SKP2). SKP2 is a
subunit for the SKPl-CULl-F-box protein (SCF) E3 ubiquitin ligase complex. The
SCFSKP2 complex targets many cell cycle regulatory proteins, such as p27KIP1, p21CIP1,
p57, cyclin E, and p i30 for degradation during the G1 to S phase transition. (21, 59, 203,
214). As an F-box protein, SKP2 provides substrate specificity to the SCF complex.
However, SKP2 does not contact pRB using its substrate-recognition motif (59). Instead,
it interacts with the C-terminus of pRB using amino acids in its N-terminus (104). This
suggests that SKP2 may not target pRB for degradation, but that pRB may regulate its
activity in some way.
(D) LXCXE Binding Cleft
As mentioned above, diverse classes of viral oncoproteins can interact with the
small pocket of pRB. These viral oncoproteins use a conserved LXCXE motif that
facilitates binding to pRB (48, 74, 151). This interaction maps to a shallow hydrophobic
groove on the B box of pRB, termed the LXCXE binding cleft, which is one of the most
highly conserved regions of the protein (Fig. 1.2) (122). Four amino acids within the
LXCXE binding cleft make direct contact with the HPV E7 LXCXE peptide: Y709,

Figure 1.2 The LXCXE binding cleft on pRB is highly conserved. The crystal
structure of pRB bound to the HPV-E7 LXCXE peptide. Based on this crystal structure,
LXCXE-containing proteins are predicted to sit within a shallow groove on the surface of
the B box on pRB. This is one of the most highly conserved regions on pRB, as denoted
by the dark green shading in the pocket region. Below, the sequence alignment from
multiple species is shown. Residue numbering corresponds to the murine amino acid
sequence and residues that were mutated in the mutant mice used in this thesis are
highlighted in red. (Figure adapted from Lee, et al., Nature, 1998)
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Amino acid #:
Homologue:

745
pRB
p107
p130
RB1
RBF
LIN-35
Mat3p

757
IIVFYNSVFMQRL
LIKFYNTIYVGRV
LIQFYNNIYIKQI
IIT FYNEVFVPAA
IIHFYNHTYVPLM
IIKYYNIEFRDRI
IIGFYNAVFVPAM

ALXCXE
I746A, N750A, M754A
NF
N750F

Homo sapiens
Homo sapiens
Homo sapiens
Mus musculus
Drosophila malanogaster
Caenorhabditis elegans
Chlamydomonas reinhardti
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K713, Y756, and N757 (Y702, K706, Y749, and N750 in mice). N757 also adds to the
distinct curvature of the binding cleft. This asparagine residue is located within a helix
that forms one side of this shallow pocket, and its presence within the helix creates a kink
that gives the cleft its unique shape (122).
Both the convergent evolution of the viral oncoproteins to contact this site and the
high conservation of the LXCXE binding cleft across species suggests that it must have
important roles within the cell. In fact, the cleft region has been shown to interact with
over 30 cellular proteins (reviewed in (44)). Many of these proteins have the ability to
modify chromatin, including HDAC1 and 2 , BRG1, hBRM, DNMT1, and Suv39hl (16,
46, 55, 135, 136, 157, 178, 200, 231). However, this site is also used for binding to a
diverse array of proteins: transcription factors like CtIP, HBP1, and ELF1 (119, 142, 208,
218); the anaphase promoting complex through interactions with the CDH1 subunit (13);
and Cap-D3, a condensin subunit involved in chromosome condensation during mitosis
(129).
While some of these interacting proteins contain an LXCXE-like motif, work is
still needed to validate these sites as the region on cellular proteins that make contact with
the LXCXE binding cleft. It is also possible that cellular proteins do not use an LXCXElike motif at all or that it is part of a larger binding motif needed to interact with the
LXCXE binding cleft. This is plausible given the fact that some of the interacting partner
sequences do not contain a classic LXCXE domain, yet require the binding cleft to
interact with pRB (13, 129, 157).
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1.4 pRB and Cell Cycle Control
The interaction between pRB and viral oncoproteins also provided some of the
first indications about how pRB functions. Viral oncoproteins such as HPV E7 hijack the
cellular replication machinery in order to drive viral DNA synthesis. By binding to pRB,
it was thought that they were preventing pRB from regulating cell proliferation (37, 151,
220). Direct evidence that pRB is involved in cell cycle regulation came from single cell
microinjection experiments (70). Injection of hypophosphorylated pRB into RBI' Saos-2
cells early in G1 resulted in cell cycle arrest. However, when added in late G1 or early S
phase cells, pRB was unable to inhibit progression. Similar experiments using
transfection of RBI into Saos-2 cells also resulted in a G1 arrest (87). Conversely, pRB
depletion accelerated progression into S phase (70, 85). This gave rise to the concept of
pRB as an important negative regulator of cell cycle progression.
1.4.1 Transcriptional Control of the Cell Cycle
If viral oncoproteins could regulate pRB activity, it was likely that cellular
proteins could play a similar role during the normal cell cycle. In the most basic sense,
this role is filled by E2Fs, and pRB acts as a switch turning on and off E2F-dependent
transcription (32). During quiescence (GO) or Gl, pRB can bind to activator E2Fs,
masking their transactivation domain to inhibit the transcription of genes that are
necessary for cell cycle advancement (Fig. 1.3a) (56, 81, 86). In support of this,
overexpression of E2Fs can drive transcription of target genes and aberrant entry into S
phase (reviewed in (45)). pRB can also bind to E2F4, which is a repressor E2F. E2F4 can
recruit pRB to E2F target genes to actively repress their transcription (45). Additionally,
pRB can recruit chromatin remodelling factors to these repressor complexes through

Figure 1.3 Model of pRB proliferative control. (A) In early to mid-Gl of the cell cycle,
pRB can bind E2F transcription factors, preventing the transcription of genes necessary
for progression into S phase. Chromatin remodelling factors (CRFs) can also interact with
pRB at its LXCXE binding cleft to further repress transcription of these genes. Upon
mitogenic stimulation, cyclin dependent kinase (CDK) complexes phosphorylate pRB,
releasing E2Fs and allowing the transcription of genes that are necessary for cell cycle
progression. (B) In response to cellular stresses such as DNA damage or TGF-P
signalling, cells in the G1 phase of the cell cycle can arrest in a pRB-dependent manner.
This requires the inhibition of CDK complexes by cyclin dependent kinase inhibitors
(CKIs). pRB can also complex with the anaphase promoting complex/cyclosome
(APC/C) through the CDH1 subunit to mediate the degradation of SKP2. This prevents
the SCFSICP2 E3 ubiquitin ligase from degrading p27KIP1. The coordinated action of these
different pathways results in hypophosphorylation of pRB, which can then recruit CRFs
to form repressive complexes at E2F target genes.
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interactions at the LXCXE binding cleft. These chromatin remodelling factors are then
thought to modify the chromatin structure to further silence E2F transcription (16, 46,
117, 136, 157, 178,215,231).
E2F targets include genes directly involved in the Gl/S phase transition such as
cyclin E, CDK2, and E2F1, and components of the replication machinery such as MCM
proteins, ORCs, thymidine synthase, and DNA polymerase alpha (65, 85, 90, 198).
Interestingly, E2Fs can also regulate a subset of genes involved in DNA repair and
apoptosis, such as p73, Chkl, Apafl, and p53 (97, 128, 147, 174, 199), as well as genes
involved in mitosis, such as cyclin B1 and B2, Bubl, Cdkl, Cdc20, Smc2 and Smc4, and
Mad2 (99, 147). Of note, both pRB and pi 07 are E2F target genes. This may account for
the increase in pi 07 during S phase, as well as the ability of pi 07 to compensate for the
loss of pRB, which results in deregulated E2F transcription. This may also create a
negative feedback loop to prevent aberrant proliferation.
1.4.2 Regulation of pRB Activity
While pRB appears to be active in the G1 phase, pRB is synthesized throughout
the cell cycle (19), suggesting that its activity is regulated in some manner. Again the
viral oncoproteins provided early insight into this regulation with the discovery that SV40
TAg preferentially bound to a hypophosphorylated form of pRB (130). The
demonstration that pRB appeared to be hypophosphorylated during G0/G1 in multiple
cell types, and was predominantly hyperphosphorylated during other phases, helped to
solidify that pRB activity was related to its phosphorylation status (19, 24, 38, 144). pRB
contains 16 putative phosphorylation sites which can be phosphorylated by cyclin DCDK4/6 and cyclin E-CDK2 complexes (51, 87, 112, 125). Upon mitogenic signalling at
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early and mid Gl, cyclin D-CDK4/6 complexes phosphorylate pRB at a number of sites.
This is thought to allow low level transcription of E2F target genes, including cyclin E.
Along with its catalytic subunit, CDK2, cyclin E can then phosphorylate additional sites
on pRB at the Gl/S phase boundary (Fig. 1.3a) (30). This hyperphosphorylation
inactivates pRB, releasing it from E2Fs, and allowing cell cycle advancement.
The half life of pRB ranges from 10 to 12 hours (144, 177) and pulse chase
experiments have shown that pRB from a preceding cell cycle is carried over into the
next Gl phase (132, 133).Thus, in order for the cell to advance through a subsequent cell
cycle, pRB must be returned to its hypophosphorylated state. This dephosphorylation
occurs between anaphase and Gl and is mediated by interactions between PP1 and the Cterminus of pRB (4, 47, 131). Protein phosphatase 2A (PP2A) can also dephosphorylate
pRB, though this appears to occur in response to growth inhibitory signals such as
irradiation and oxidative stress (7, 27). Thus, PP1 and PP2 can dephosphorylate pRB to
modulate various aspects of proliferative control. Together, the coordination of
phosphatases and CDK complexes regulate the phosphorylation and activity of pRB in a
cell cycle-dependent manner.
1.4.3 pRB-Dependent Cell Cycle Arrest
Gl progression and proliferation are limited by extracellular factors that maintain
cytostasis. Just as the cell cycle advances by mitogenic stimulation, it can be arrested
during Gl by growth-inhibiting cytokines, DNA damage, and other cellular stresses (Fig.
1.3b) (137). Experiments using Rbl^' fibroblasts demonstrated that pRB is essential for
the cell cycle arrest response induced by DNA damage or TGF-pi (17, 78, 84).
Fundamentally, these processes work by stimulating members of the CIP/KIP and/or
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INK4 families of cyclin dependent kinase inhibitors (CKIs) (141). The INK4 family
includes pl5INK4b, pl6INK4a, pl8,NK4c, and pl9INK4d(encoded by Cdkn2b, Cdkn2a, Cdkn2c,
and Cdkn2d, respectively). These CKIs bind to cyclin D-CDK4 complexes and inhibit
their kinase activity (191). The CIP/KIP family is comprised of p21CIP1, p27K1P1, and
p57KIP2 (encoded by Cdknla, Cdknlb, and Cdknlc respectively) which interact with and
inhibit cyclin E-CDK2 complexes (190). The cell has evolved complex mechanisms of
regulation of CDKs and CKIs in order to tightly control proliferation. For instance,
during cell cycle advancement, p27KIP1 is sequestered by cyclin D-CDK4/6 complexes,
preventing inhibition of cyclin E-CDK2 activity (191). In response to cellular stress,
pi6INK4a is induced, which has two effects. First, pi6rNK4a can bind to and inhibit the
catalytic activity of its target, cyclin D-CDK4/6. Second, binding of pl6 INK4a disrupts the
cyclin D-CDK4/6- p27Klpl interaction, freeing p27KIP1 to inhibit CDK2 activity (191). The
specific CKIs used to induce cell cycle arrest vary depending on the stress signal and cell
type in question. Regardless of which CKIs are used, the net result is the same: CKIs
block CDK phosphorylation of their substrates, which include pRB. Thus, pRB remains
in an active state, allowing it to block E2F transcription, and preventing cell cycle
progression (Fig. 1.3b).
Several LXCXE interacting proteins have also been implicated in the induction
of cell cycle arrest. The general model suggests that pRB recruits chromatin remodelling
factors to its LXCXE binding cleft and create a closed chromatin structure at E2F target
genes. While many of these interacting partners have been shown to repress E2Fmediated transcription in a pRB-dependent manner, their role in pRB growth arrest has
yet to be validated (16, 46, 117, 136, 157, 178, 215). This type of validation is required
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given one group demonstrated that while pRB can recruit HDAC activity to repress
transcription of E2F target genes, the human SWI-SNF ATP-dependent nucleosome
remodelling complex was required for full cell cycle arrest (231). Thus, while some of
the known LXCXE-interacting partners are necessary for pRB proliferative control, more
work is required to understand the necessity of other interacting proteins in this process.
It is possible that pRB can interact with multiple chromatin remodelling complexes,
based on the cellular availability of the different complexes and external cell signals. This
could allow for some of the cell-type and context specificity of pRB activities.
Interplay between pRB, SKJP2, and CDH1 provides an alternative mechanism to
induce cell cycle arrest. pRB can inhibit CDK activity and G1 to S progression by
increasing the expression of p27KIP1 (5, 104). Work in RB1';' Saos-2 cells demonstrated
that the increase in p27KIP1 levels preceded, and was required for, cell cycle arrest (104).
Several elegant studies outlined the mechanism for this growth arrest paradigm. As
mentioned earlier, p27

is targeted for degradation by the SCF

E3 ubiquitin ligase.

pRB can block this degradation by simultaneously binding SKP2 at the C-terminus, and
CDH1 in an LXCXE-dependent manner. This allows APC/C-mediated degradation of
SKP2, preventing SCFskp2 from ubiquitinating p27KIP1 (13, 104). The accumulated
p27KIP1 is then free to inhibit CDK activity and block cell cycle progression.
Collectively, this work illustrates the coordinated mechanisms used by pRB and
its interacting proteins to induce cell cycle arrest. First, pRB can bind to E2Fs, blocking
transactivation of cell cycle genes. Second, it can recruit chromatin remodelling factors to
E2F repressor complexes. These chromatin modifiers can then alter the chromatin
architecture to further repress E2F-dependent transcription. Finally, pRB can act as a
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scaffold to bring an E3 ubiquitin ligase into contact with its substrate to increase the
levels of CKIs upstream of E2F-mediated transcription. Together, these studies reveal the
complexity of pRB-mediated growth arrest. However, the relative contribution of each of
these interactions in a given growth arrest paradigm have been unclear. Work in chapter
two of this thesis will address the necessity of pRB-LXCXE interactions in proliferative
control in mammary epithelial cells.
1.5 Physiological Roles for pRB in the Mammary Gland
pRB interacts with a myriad of proteins in the cell in order to elicit cell cycle
control. While the scope of this thesis prevents an in depth review of all the different
functions of pRB, it is becoming abundantly clear that pRB also has roles in a wide
variety of cellular processes, including DNA replication, differentiation, apoptosis, and
mitotic control (reviewed in (20)). Despite this knowledge, it is still unclear which, if
any, of these functions are part of pRB’s tumour suppressive actions. This has been
difficult to discern because of the high number of interacting proteins and the lack of a
clear functional relevance for many of these interactions. Furthermore, most tumourderived mutations of pRB result in a truncated or unstable protein, making it difficult to
determine which specific interactions are most important for its tumour suppressive
function (30). While the work of many labs has led to an extensive knowledge of the
biochemical functions of pRB, in particular its role in growth control, the development of
transgenic and gene-targeted mouse models has allowed the field to address which of
these biochemical functions are sufficient and necessary, both during development and
tumorigenesis. Genetic studies have provided a plethora of information about pRB
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function, however, for the purposes of this thesis, our knowledge of pRB in mammary
gland development and cancer will be emphasized.
1.5.1 Roles for Cell Cycle Proteins in Mammary Development
Transgenic mouse models that either overexpress or disrupt expression of key
components of the cell cycle machinery have highlighted the importance of the pRB
pathway in mammary gland development. Complete loss of cyclin D1 results in viable
mice with surprisingly few defects. However, they do have defects in mammary gland
development (193, 194). In the absence of cyclin Dl, ductal development occurs
normally but lobuloalveolar development is impaired and females fail to lactate. This
phenotype is recapitulated when the epithelium is transplanted into cleared wild-type
mammary glands, demonstrating the epithelial-specific necessity for cyclin D (53, 66).
Sufficient mammary-specific overexpression of pl6 INK4a, which inhibits cyclin D-CDK4
activity, results in a similar phenotype (63). This demonstrates that cyclin Dl activity
must be carefully regulated for proper mammary gland development. A lack of more
dramatic defects at multiple stages of mammary gland development may reflect the
ability of other cyclins to compensate for loss of cyclin Dl at certain stages of mammary
gland development.
Cyclin D can also sequester p27KIP1 to prevent it from inhibiting cyclin E-CDK2
activity. Interestingly, loss of p27lclpl restores normal mammary development in the
cyclin D r /_background (67, 210), demonstrating the need for p27KIP1 in mammary gland
development. Consequently, several groups developed mammary-specific Cdknlb'1'
models. These studies have yielded conflicting results, from increased proliferation and
apoptosis to decreased proliferation and impaired development (reviewed in (155)).
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However, even in the studies where loss of p27KIP1 resulted in decreased proliferation,
p27KIPI heterozygosity was associated with increased proliferation (36, 154). While more
work is required to resolve these differences, the data demonstrate that p27KIP1 plays a
role during mammary gland development.
All of the cell cycle regulators discussed above lie genetically and biochemically
upstream of pRB. The cyclin D-CDK4/6 complex phosphorylates pRB in order to
inactivate it, while pl6INK4a and p27KIP1 counter CDK acitivity via several different
mechanisms (Fig. 1.3). As the point of convergence among these pathways, it would
seem logical that pRB would play an important role in mammary gland development.
Studies that address this possibility are discussed below.
1.5.2 Complete loss of pRB
The initial examination of the physiological roles for pRB began with complete
ablation of the Rbl gene. Germ line loss of Rbl is embryonic lethal between day 13.5 and
15.5 of gestation (28, 100, 121). During embryogenesis, pRB is most highly expressed in
the nervous system, blood cells, skeletal muscle, and lens (105, 107). Not surprisingly,
Rbl'1' mice have pronounced defects in the development of these tissues. Strikingly, Rbl ' '
embryos provided with normal placentae can survive to birth (224). Many of the R b l"
defects are rescued in these animals, identifying key function for pRB in extraembryonic
cell lineages that are required for embryonic development and viability. However, the
skeletal muscle defect persists and the mice die shortly after birth (224). This precludes
study of the role of pRB in mammary gland development, which occurs almost entirely
post-natally (Fig. 1.4).

Figure 1.4 Stages of murine mammary gland development. Mammary gland
development occurs almost entirely post-natally. The newborn mouse has only a
rudimentary mammary anlage, which sits within the mammary fat pad. At the onset of
puberty, hormonal stimulation results in ductal extension from large clusters of highly
proliferative epithelial cells, known as terminal end buds (TEBs). In the adult virgin
female, the fat pad is filled with ducts. With the influx of hormones and growth factors
during pregnancy, there is extensive side-branching, proliferation, and differentiation of
the epithelial population to form lobuloalveolar (LA) structures, which become the milkproducing units during lactation. After pups are weaned, the mammary gland reverts back
to a virgin-like state through a process of apoptosis and tissue remodelling, known as
involution. (Figure adapted from Hennighausen and Robinson, Genes Dev., 1998)
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Study of heterozygous mice has yielded little more insight into the importance of
pRB during mammary gland development and cancer. R bl+/~mice are viable and display
very few phenotypic abnormalities (91, 101). These mice develop primarily pituitary
tumours by 11 months of age, with almost 100% penetrance. The formation of these
pituitary tumours is associated with loss of the wild type Rbl allele. However, the onset
of pituitary tumours may preclude the development of slower growing mammary tumours
in these mice.
1.5.3

R b l ' /'

Transplant Studies

While R bl"Aand R b lf/' mice have provided some insights into the role of pRB in
the cell cycle and development, they have not been able to shed light on the importance
of pRB during breast development, which occurs after birth. The only stage of mammary
gland development that occurs in utero is the formation of the anlage within the
surrounding fat pad (Fig. 1.4). However, this structure contains only a few rudimentary
ducts near the nipple, and it is not until the onset of puberty that hormonal signals induce
elongation and branching of the mammary ducts from terminal end buds (TEBs) into the
fat pad (83). This precludes the study of mammary gland development in the embryonic
lethal Rbl null mice.
It seems likely that pRB would have a role in mammary gland development, given
that many other members of the G1 cell cycle machinery are necessary for the formation
and function of the mammary gland. Furthermore, pRB, pi 07, and pi 30 are expressed in
both ductal and alveolar epithelial cells, which is consistent with pocket proteins playing
a functional role there (106). To gain further insight into the role of pRB during
mammary gland development, one group took advantage of the fact that development of
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the primitive mammary anlage begins between day post-coital (dpc) 10 and 11, before the
death of Rbl'1' embryos (176). They transplanted anlagen from knockout embryos into
the cleared fat pads of wild type females (179). Surprisingly, they did not find any defects
in mammary gland development or a predisposition to cancer. However, caution must be
taken when interpreting these results. First, transplanted mammary glands are not able to
make a functional connection to the host nipple, and therefore, the group was unable to
assess the ability of these mice to nurse their young. Second, complete loss of pRB can
result in the upregulation of other members of the pocket protein family, which can
functionally compensate for the loss of pRB (182, 183). Since pl07 and pi 30 are also
expressed in the mammary gland, it is possible that they serve to protect this highly
proliferative tissue from loss of a single pocket protein. In support of this idea,
overexpression of a form of SV40 TAg that specifically disrupts pRB interactions in the
mammary gland, which disrupts all three pocket proteins, results in hyperplasia of
mammary epithelial tissue and tumorigenesis (73). Therefore, the role of pRB during
mammary gland development and tumorigenesis remains an open question. New
techniques and models are necessary to address the role of pRB in the function of the
mammary gland without compensation by other pocket proteins. This thesis will outline
the use of two gene-targeted mouse models that have provided new insight into the
importance of pRB, both during development of the mammary gland and during tumour
formation.
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1.6 The TGF-P Family

1.6.1 The TGF-p Superfamily
TGF-P is the prototypic member of a superfamily of over 30 cytokines that
includes the TGF-ps, activins, inhibins, bone morphogenetic proteins (BMPs), and
growth and differentiation factors (GDFs) (79). This superfamily emerged with the
evolution of multicellular organisms, potentially as a way to establish communication and
order within the organism (225). These proteins are regulated both spatially and
temporally to control a diverse number of cellular processes including proliferation,
differentiation, migration, immune responses, and cell death. Because of their roles in
mammary gland development and cell cycle arrest, this thesis will focus on the function
of the TGF-P subfamily of proteins.
1.6.2 The TGF-p Isoforms
The TGF-P subfamily is made up of three related isoforms, TGF-pi, TGF-P2, and
TGF-P3. These proteins are highly conserved between species, which suggests they play
important roles within the cell. This is further supported by the fact that loss of any of the
isoforms in the mouse results in peri-natal death from a variety of defects including
inflammatory, cardiovascular, pulmonary, and neural crest abnormalities (108, 116, 172,
185, 192). The differences in phenotype are likely the result of the distinct, though
sometimes overlapping, spatial and temporal patterns of expression for each isoform in
the developing embryo and adult tissue (145, 164, 186). While each isoform may have
unique properties and functions, acting in culture, all three isoforms display similar
activity (139, 196). Therefore, for the purposes of this thesis, the term TGF-P will be used
to refer to the isoforms in a general sense, unless specified.
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1.7 The TGF-P Signalling Cascade
1.7.1 Secretion and Extracellular Regulation of TGF-P
TGF-P is a secreted protein that consists of two identical chains of 112 amino
acids linked by disulfide bonds. Each chain is synthesized as the C-terminal region of a
390 amino acid precursor protein. Upon secretion, the pro-region of this precursor,
termed the latency associated protein (LAP), is cleaved, yet remains associated with the
bioactive dimer, forming a biologically inactive complex (139). LAP can interact non
covalently with latent TGF-P binding partners that facilitate the storage, secretion, and
localization of the latent complex (140).
Physiological activation of the latent LAP-TGF-P complex is only partially
understood, although many different pathways have been implicated in the process (140).
The strongest evidence implicates thrombospondin and the avP6 integrin.
Thrombospondin appears to activate TGF-P through a conformational modification of
LAP, activating a large proportion of TGF-P in vivo (33). LAP-TGF-P is also a ligand for
the avp6 integrin, which appears to induce spatially restricted expression of TGF-P (150).
It remains to be determined if there are other mechanisms of TGF-P activation, and what
triggers this reaction within the extracellular matrix. It is clear, however, that release of
the active ligand initiates a chain of signalling events in the recipient cell that results in a
diverse range of biological outcomes in the mammary gland.
1.7.2 Sensing TGF-p Signals - Receptor Binding and Activation
Liberated TGF-P initiates a signalling cascade by binding to a complex of two
pairs of receptor subunits, the TGF-P type II (TpRII) and TGF-P type I receptors (TpRI,
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also known as ALK5) (Fig. 1.5) (22, 222). A membrane-bound proteoglycan, betaglycan,
can aid in the presentation of TGF-P to its receptors (141). Both the TPRII and TpRI are
receptor threonine/serine kinases (204, 212), and when complexed to TGF-P, the TpRII
phosphorylates threonine and serine residues in the Glycine/Serine (GS) region of the
TpRI (223).This phosphorylation event switches this region from acting as a binding site
for an inhibitor, FKBP12, to a docking site for its substrates (94, 95).
1.7.3 Propagating TGF-P Signals - Smad Signalling
SMAD proteins are the main substrate of the TGF-P receptor complex. There are
at least nine members of the SMAD family, which can be subdivided into three groups:
receptor-activated SMADs (R-SMADs), partner SMADs (or co-SMADs), and inhibitor
SMADs. SMAD2 and 3 act as the R-SMADs for the three TGF-P isoforms (80).
SMAD7, an inhibitory SMAD, can compete for binding at the TpRI receptor, thus
blocking recruitment and phosphorylation of the R-SMADs (41). In the basal state,
SMAD2 and 3 can also be retained in the cytoplasm through interaction with the Smad
Anchor for Receptor Activation (SARA) (213). Interactions with SARA block the
exposure of the nuclear import signal on SMAD2 and 3 (227). Receptor-mediated
phosphorylation at C-terminal serine residues on SMAD2 or 3 destabilizes SMAD
interactions with SARA, exposing the nuclear import signal. The phosphorylation of RSMADs also augments their affinity for the co-SMAD, SMAD4 (227). The combined
effect is rapid accumulation of activated SMADs in the nucleus, where they can interact
with a variety of DNA-binding cofactors, co-activators, and co-repressors to regulate
target gene transcription.

Figure 1.5 Model of TGF-P signalling to the nucleus. Activated TGF-p is presented to
the TGF-P type II and I receptors (TpRII and TPRI) by betaglycan. In the presence of
their ligand, two copies of each receptor subunit come together, allowing the
phosphorylation of TpRI by TpRII. This frees TPRI to phosphorylate receptor SMADs
(R-SMADs). Phosphorylation of R-SMADS allows them to interact with SMAD4 and
translocate to the nucleus, where they recruit co-factors to regulate target gene
expression. SMADs can be sequestered in the cytoplasm by SARA, while FKBP12 and
SMAD7 inhibit receptor and SMAD phosphorylation. These functions are described in
sections 1.7.2 and 1.7.3 of the text.
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1.7.4 The Transcriptional Response to TGF-P
The relative simplicity of the TGF-p signalling cascade is in apparent
contradiction to its ability to regulate multiple cellular processes. The key to the diversity
of TGF-p signalling lies in the cellular context and the coordination of a large set of
transcriptional regulators that can interact with SMAD proteins (138). TGF-P signalling
is context-dependent. Cells of different types or exposed to different conditions express
different SMAD-interacting proteins. Thus, distinct groups of cofactors can interact with
SMAD proteins in various cellular contexts to either up-regulate or down-regulate
transcription (Fig. 1.5). This allows TGF-P to elicit responses from proliferative control
to epithelial-to-mesenchymal transition (EMT) to apoptosis. Common co-factors for
SMADs include FoxO transcription factors and C/EBPP (69, 141). Specific combinations
of these and other factors are recruited along with SMADs to induce or repress gene
transcription. This large number of combinations of SMADs and cofactors that form
complexes based on cellular availability allow for the diversity in TGF-P signalling. This
point will be illustrated further in the context of the TGF-P cytostatic response (see
section 1.8.1 A).
1.7.5 Non-canonical TGF-p Signalling Pathways
There are variant branches of TGF-P signalling that do not involve all of the
components of the canonical pathway. For instance, TGF-P can activate SMAD2/3 to
bind p68, a component of the microRNA processing complex DROSHA, in a SMAD4independent manner (35). This targets production of miR-21 in vascular smooth muscle
cells. The net result is induction of a contractile cell phenotype by downregulation of the
suppressor PDCD4. Like many of the non-canonical TGF-P pathways, this phenomenon
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has been demonstrated in one specific cell type, so it remains unclear if TGF-|3 elicits
similar responses in other cell lineages.
SMADs mediate most, but not all, TGF-P gene responses. TGF-P has been shown
to activate other mediators such as mitogen-activated protein kinases (MAPKs), ERK,
Jun N-terminal kinase (JNK), phosphatidylinositol-3 kinase (PI3K), p38, members of the
Rho family, and PP2A phosphatases (41, 141). Again, many of these interactions appear
to be cell type-dependent. An exception of note is the phosphorylation of PAR6 by
T|3RII, which frees PAR6 from a preformed PAR6-TpRI complex in many epithelial cell
types. This allows PAR6 to dissolve tight junctions in the context of EMT (161). Studies
using breast cancer cell lines have demonstrated that TGF-P can lead to the rapid
activation of ERK2 and sustained activation of JNK (60, 146). Activation of the MAPK
pathway appears to be linked to the ability of cells to respond to TGF-P-dependent
growth arrest signals, suggesting that this signalling pathway may be intact in primary
mammary epithelial cells. However, little work has been done in primary cells to
formally prove this. Thus, the relative impact of these alternative pathways versus SMAD
signalling in MECs remains unclear.

1.8 TGF-p Signalling in the Mammary Gland
As mentioned above, the specific combination of available nuclear co-factors
within the cell determines which genes SMADs will regulate and this allows TGF-P to
regulate a wide array of cellular processes within a given tissue. This emphasizes the
importance of studying TGF-P function within a given cell of interest, since there is a
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high degree of variation from cell type to cell type. For the purposes of this thesis, data
relevant to mammary epithelial cells will be discussed.
All three TGF-P isoforms are expressed in the mammary epithelium, although
they are expressed differentially throughout mammary gland development and display
unique expression patterns (Fig. 1.6) (181). TGF-P 1 and TGF-P3 transcripts are strongly
expressed in the mammary gland throughout all stages of mammary gland development,
with the notable exception of lactation. TGF-P2, on the other hand, is expressed at very
low levels except during pregnancy. During ductal outgrowth, both TGF-P 1 and TGF-P3
are expressed in epithelial cells of the TEBs, with TGF-pi expression concentrated at the
tips of the end buds and TGF-P3 at the flank region. All three isoforms show overlapping
epithelial expression in quiescent ducts. TGF-P 1 mRNA expression is fairly consistent
throughout pregnancy, while TGF-P2 and TGF-P3 increase throughout pregnancy and
peak at dpc 15. However, all three isoforms show a dramatic post-natal reduction in
expression (180, 181). In the case of TGF-pi, this correlates with a decrease in overall
TGF-P 1 protein levels in the ductal epithelium (50). Only TGF-P3 is upregulated during
involution, a period of marked apoptosis and tissue remodelling that returns the postweaned mammary gland to a virgin-like state (Fig. 1.4) (181).
This expression data must be interpreted carefully, since several of the
experiments used RNA antisense labelling or used antibodies that do not reliably
distinguish between latent and active protein. However, the expression of the TGF-P
family transcripts suggests that they play important roles in the various stages of
mammary gland development; the temporal and spatial differences in expression patterns
suggests

Figure 1.6 Differential expression of TGF-0 isoforms in the mammary gland. In the
virgin mammary gland, TGF-pi and TGF-P3 are expressed at high levels, while TGF-P2
is expressed at very low levels. TGF-pi expression remains fairly constant throughout
pregnancy, while TGF-P2 and TGF-P3 peak during mid-pregnancy. Upon parturition,
expression of all three isoforms drops to low levels. Expression of TGF-P3 peaks again
during involution, while TGF-pl levels rise again in the quiescent virgin-like mammary
gland.

Mammary Specific
Isoform Expression
Adult Virgin| Pregnancy | Lactation | Involution | Virgin-like |
Phase
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that the various isoforms may have both overlapping and unique signalling roles within
the mammary gland.
1.8.1 Mouse Models of TGF-p in the Mammary Gland
Our current understanding of TGF-P signalling in the mammary gland is the
culmination of many biochemical, molecular, and biological studies. The overwhelming
evidence suggests that TGF-P is crucial for mammary gland development. Cell culture
studies have indicated a role for TGF-p in many processes, including growth control,
differentiation, EMT, and apoptosis (138). Mouse models have revealed a need for TGFP during all stages of mammary development: morphogenesis, quiescence, pregnancy,
lactation, and involution (11). However, it has been difficult to correlate the various
biochemical and molecular data with specific biological outcomes. The fact that multiple
cell types secrete and respond to TGF-P signalling in the breast have added a further layer
of complexity to this puzzle. Below, the various mouse models that have been used to
elucidate the role of TGF-P in the mammary epithelial compartment are briefly outlined,
followed by dissection of the various molecular and biological roles associated with
TGF-P signalling in mammary epithelial cells.
(A) Gain-of-Function Models
Two basic strategies have been employed to determine the role of TGF-P in the
mammary gland: systems where TGF-p signalling is stimulated, and systems where the
pathway is disrupted (Table 1.1). Gain-of-function models come in two different
varieties. The first is overexpression of a TGF-P isoform, using transgenic models where
expression is driven by mammary-specific promoters such as the mouse mammary
tumour virus (MMTV) promoter or the whey acidic protein {Wap) promoter. MMTV
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Table 1.1 Known physiological roles for TGF-P in the mammary gland
R ef

Wap-TGF-fil

D e v e lo p m e n ta l p h en o typ es

T u m o u r p h en o typ es

• aberrant LA apoptosis during
pregnancy

ND

(103,
115)

MMTV-TGFpjS223K25

• reduced ductal outgrowth

• no spontaneous tumours
-DMBA
• increased latency
-Neu cross
• decreased tumour proliferation
• increased lung metastasis

(153,
166,
167)

(3-LG-TGF-/33

• aberrant apoptosis of LA cells

ND

(156)

MMTVTfiRI(AAD)

• decreased proliferation
• increased apoptosis, especially
during late pregnancy

• no spontaneous tumours
-Activated Neu cross
• increased latency
• increased metastatic extravasation

(195)

MMTVAlk5T204°

• delayed ductal outgrowth
• reduced apoptosis in TEBs and
during involution
• nursing defect

• no spontaneous tumours
-Neu cross
• increased lung metastasis

(152)

Tgf-pr'-

• increased proliferation/accelerated
ductal outgrowth
• accelerated LA differentiation during
pregnancy

ND

(50)

MMTV-dnIIR

• lobuloalveolar formation in virgins

• no spontaneous tumours
-DMBA
• decreased latency

(15)

MMTV-dnIIR

• LA formation in virgins
• impaired development during late
pregnancy
• delayed involution
• nursing defect

• spontaneous tumours (median
latency 27.5 months)
MMTV-TGF-a cross
• reduced tumour cell invasion

(71,
72)

Wap- dnIIR

• delay in second phase of involution

ND

(12)

T g fb r^GK0

• increased proliferation of LA cells
• increased apoptosis

• no spontaneous tumours
-MMTV-PyVmT cross
• decreased latency
• increased lung metastasis

(57)

Tgf-p3v(transplant)

• decreased apoptosis during
involution

ND

(156)

• no spontaneous tumours
-Activated Neu crosses
• decreased latency
• decreased extravasation of lung
metastases

(195)

G e n o ty p e

MMTVT/3RII(ACyt)
ND - no data
LA - lobuloalveolar
LG - lactoglobulin
DMBA - 7,12-dimethylbenz[a]anthracene
PyVmT- polyomavirus middle T antigen

38

targets expression in the mammary gland, but is also expressed in the salivary gland and
other tissues. MMTV has the benefit of being expressed in virgin as well as lactating
mammary glands. Wap, on the other hand, is very specific for the mammary gland, but is
only expressed during pregnancy and lactation (216). Thus, use of each model results in
different spatial and temporal expression of TGF-P in the mammary gland. Since TGF-P
is secreted as a latent protein, groups have used a constitutively active form of TGF-P
(TGF-pi

) in order to ensure activity of the transgene (18). However, phenotypic

outcomes must be weighed carefully, since TGF-P is no longer subject to all of the
normal regulatory processes. To date, Wap and MMTV transgenic models overexpressing
active TGF-pi have been developed (103, 115, 166). Overexpression of wild typeTGF-P3
has also been achieved using the promoter for P-lactoglobulin, another milk protein
(156).
The second approach involves activating downstream components of the TGF-P
pathway. Two groups have used this type of strategy to create mice with a constitutively
active form of the TpRI (ALK5). Both groups used a mutant form of the TpRI where
threonine 204 is substituted for an aspartic acid residue, resulting in constitutive
activation of the receptor kinase (221). The first group drove expression of the transgene
(Alk5T204D) using the MMTV promoter (152). The second group introduced two
secondary point mutations to prevent binding of the inhibitor FKBP12 (195). Expression
of this mutant form of TpRI, termed TpRI(AAD) was also driven by the MMTV
promoter.
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(B) Loss-of-Function Models
Since loss of any of the TGF-p isoforms results in neonatal death, knockout
studies have provided little information about the requirement for these proteins in the
developing mammary gland. Nonetheless, studies using Tgf-pi+/~females have yielded
some clues, since they express only 10% of the TGF-P 1 found in wild type mice (50).
Two groups have driven expression of a dominant negative type II receptor (dnIIR) using
the MMTVpromoter in order to block TGF-P activity (15, 72). These dnIIRs can bind
TGF-P and TPRI, but lack the kinase domain, preventing phosphorylation of TPRI and
SMAD proteins (15, 25). Recently, TpRII has also been conditionally knocked out in the
mammary epithelium (termed Tgfbr2MGKO) (57).
Collectively, this group of mouse models has provided insight into the roles that
TGF-P plays in the mammary gland. One of the main challenges remaining is to connect
the molecular understanding of TGF-P functions with the phenotypic data that has
emerged. Below, the evidence for various TGF-P functions that influence the different
stages of mammary development is discussed.
1.8.2 TGF-P-Mediated Growth Arrest
One of the most studied functions of TGF-P is its control of epithelial
proliferation through regulation of a cytostatic gene response. TGF-P arrests many cells,
including breast epithelial cells, in the G1 phase of the cell cycle (89, 118, 168). This
response is elicited by the coordinated upregulation of cell cycle inhibitors and repression
of cell cycle promoters (Fig. 1.7) (141). Treatment with TGF-P results in an increase in
CKIs, but the choice of CKI appears to be cell type-dependent. For instance, both
P15INK4b and p21CIP1 are induced in keratinocytes, while only pl5INK4b is induced in

Figure 1.7 Model of TGF-ß proliferative control. (A) In order to induce a TGF-ß
cytostatic response, SMAD complexes upregulate the expression of CKIs while
repressing c-MYC. Repression of c-MYC has two purposes: first, it prevents
transcription of pro-proliferative genes, and second, it releases c-MYC repressive
complexes from CKI promoters. CKIs can then inhibit the CDK-dependent
phosphorylation of pRB, activating pRB, and inducing a cell cycle arrest. (B) The
differential availability of cellular cofactors allows specificity of TGF-ß signalling. In the
case of TGF-ß growth control, activation of both p21CIP1 and pi 5INK4b requires FoxO
binding, while p l5 INK4b induction requires additional binding of C/EBPß. Repression of
c-MYC also requires C/EBPß recruitment, as well as binding of a pl07-E2F4 complex.
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human breast epithelial cells (34, 77, 175, 184). p27KIP1 also plays an important, though
non-transcriptional, role in this process (77, 170, 171,211). Upon induction of pi 5rNK4b
by TGF-p, pi5INK4b displaces p27KIP1 from CDK4/6, freeing p27KIP1 to inhibit CDK2
(175).
Concomitant with the upregulation of CKIs, TGF-0 induces repression of c-MYC,
a transcription factor that drives proliferation (168, 169). Not only does this prevent
transcription of positive regulators of the cell cycle, but also relieves c-MYC-mediated
repression of Cdkn2a and Cdknla promoters (encoding pl5INK4a and p21CIP1), rendering
them competent for activation (189, 197). TGF-P has also been shown to repress
transcription of the phosphatase Cdc25a in MCFlOa mammary epithelial cells (96). This
prevents the removal of inhibitory phosphorylation marks on CDK4/6. Together, this
coordinated induction of CKIs and inhibition of cell cycle promoters provides an elegant
mechanism for TGF-P-mediated growth suppression.
Transcriptional regulation of these genes is SMAD-dependent and involves the
recruitment of specific cofactors to each promoter region (Fig. 1.7b). A SMAD-FoxO
complex mediates p21CIP1 induction, while induction of pi 5INK4b additionally requires
C/EBPP (69, 188). Repression of c-MYC, on the other hand, involves transcriptional
repression from a Smad3/4-pl07-E2F4-C/EBPp complex (23). The use of different co
factor complexes provides an elegant system to initiate a cell cycle arrest: SMAD3/4pl07-E2F4-C/EBPP repression of c-MYC inhibits the induction of pro-proliferative
genes and relieves c-MYC-dependent repression of pl5[NK4b and p21CIP1 while SMADFoxO and SMAD-FoxO-C/EBPP complexes further stimulate CKI expression. CKIs can
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then inhibit CDK phosphorylation of their target substrates. Thus, the cellular availability
of co-factors allows for a careful orchestration of events that results in cell cycle arrest.
pRB is one of the main targets for CDKs, and as the final barrier to cell cycle
progression in G1, it stands to reason that it should play a large part in the TGF-P
cytostatic response. Treatment with TGF-P does correlate with the expression of
hypophosphorylated pRB (118) and work in RbV' MEFs also demonstrated that pRB is
required for TGF-P growth inhibition (84). It is presumed that pRB induces growth arrest
by an E2F-dependent mechanism, however, at the outset of this work, little had been
done to prove or disprove this theory. In chapter 2 ,1 examine how pRB elicits the TGF-P
cytostatic response.
Regardless of the specific mechanism, the physiological data demonstrates that
TGF-P controls proliferation in vivo. Overexpression of MMTV-TGF-fi 1 inhibits ductal
outgrowth in the virgin mouse (166). Conversely, Tgf-fil+/', Tgfbr2MGK0 !'AGK(>and
MMTV-dnIIR mice display increased proliferation of the ductal epithelium (49, 50, 57,
71, 72). Thus, evidence from both the gain-of-function and loss-of-function models
supports an important role for TGF-P in growth control of the mammary epithelial
population.
1.8.3 TGF-P Signalling in Differentiation
Members of the TGF-P family have been implicated in the differentiation of many
vertebrate tissues, including the immune, haematopoietic, neuronal, and epithelial
compartments (39). At the molecular level, TGF-P has been shown to repress members of
the Inhibitor of Differentiation (ID) family of proteins in multiple cell lines, including the
immortalized MCFlOa breast cell line (111). ID proteins act in a conserved manner to
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negatively control cell cycle arrest and commitment to differentiation in many cell
lineages (43). In the case of ID1, TGF-P controls expression both directly and indirectly.
Initial treatment with TGF-P results in the upregulation of the transcriptional repressor,
ATF3, which then acts as a cofactor for SMAD3-dependent repression of ID1 (111).
Consistently, ID1 expression decreases in SCp2 mammary epithelial cells stimulated to
differentiate by lactogenic hormone treatment (42), suggesting that TGF-P inhibits ID1 in
order to induce differentiation.
Physiological evidence also suggests that TGF-P is important for differentiation in
the mammary gland, although it is somewhat at odds with the biochemical data. Roles in
differentiation are most clearly seen during pregnancy and lactation in the mammary
gland, when epithelial cells undergo differentiation into lobuloalveolar structures that
become the milk producing units following parturition (Fig. 1.4) (176). Ectopic
expression of a constitutively active form of TGF-p 1 leads to stunted alveolar
development during pregnancy (115) while MMTV-dnIIR virgin females develop
lobuloalveolar structures and express milk protein prematurely (15, 72). Similarly, TGFpi suppresses the expression of the milk protein P-casein in mammary explants and
murine mammary epithelial cell lines stimulated with lactogenic hormones (143, 180,
202). The concept that TGF-P suppresses differentiation correlates well with the changes
in expression levels of the three isoforms during pregnancy and lactation (Fig. 1.6).
Together, these data suggest that members of the TGF-P family prevent full
differentiation of epithelia into milk producing units, and downregulation of the isoforms
at birth allows lactation to commence.
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The biochemical and mouse model data present an apparent paradox. How can
TGF-P both allow differentiation of MCFlOa cells while preventing differentiation in the
mammary gland? The ability of TGF-P to inhibit or stimulate differentiation of mammary
epithelial cells likely depends on the cellular environment. TGF-P 1 can restrain
proliferation of ER-a-positive cells and in turn, ovarian hormones can regulate ductal and
alveolar proliferation (49, 50). Furthermore, work on mammary explants demonstrates
that TGF-P inhibits casein secretion in differentiating mammary gland explants, but not
ones isolated from lactating females (202). Therefore, TGF-P’s role in differentiation is
likely to be influenced by the combinations of hormones and growth factors that are
present in the microenvironment at each stage of development.

1.8.4 TGF-p Signalling in Apoptosis
TGF-P can also trigger apoptosis, although the environmental stimuli that induce
this process have not been identified. NMuMG mammary epithelial cells can be induced
to apoptose after several days of TGF-P 1 exposure (64), via undefined mechanisms.
Work with other cell types has implicated both SMAD-dependent and -independent proapoptotic mechanisms. SMADs can regulate expression of genes implicated in the
apoptotic response such as TIEG1, GADD45, BIM, DAPK, and SHIP (163). In
lymphocytes and hepatocytes, the TpRII can also directly associate with the FAS receptor
adaptor protein, DAXX, in response to TGF-P and during apoptosis (165). DAXX then
mediates activation of the JNK-p38-MAPK kinase pathway, resulting in the expression of
genes involved in the apoptotic response (165). Which, if any, of these pathways are used
to induce apoptosis in the mammary epithelial compartment have yet to be determined.
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While the exact pro-apoptotic mechanism remains elusive, there is strong
physiological evidence that TGF-P plays an important pro-apoptotic role in the ductal
epithelia. This is most evident during involution of the mammary gland, the process of
programmed cell death and remodelling of the mammary epithelium to a virgin-like state
after weaning. TGF-P3 is rapidly induced upon weaning and precedes apoptosis (156).
Expression of fi-lactoglobulin-TGF-f}3 in the alveolar epithelium induces apoptosis of
these cells, but not tissue remodelling. Furthermore, transplantation experiments
demonstrated that loss of TGF-p3 in the mammary tissue leads to prolonged involution
(156). Studies driving TGF-P3 expression with the Wap promoter demonstrated that it
also plays a pro-apoptotic role in the later stages of involution (12). Conversely, blocking
TGF-P signalling using the MMTV-dnIIR results in delayed involution of the mammary
gland (71). Interestingly, in Wap-TGF-/31 mice, alveolar development was compromised
because of an increase in apoptosis during pregnancy (103, 115), implying that other
isoforms may play a role in mediating apoptosis. However, this may result from the
inappropriate expression of TGF-pi in the mammary gland rather than a true
physiological role in apoptosis. Further work will be required to ascertain this. While it is
possible that multiple TGF-P isoforms can induce apoptosis within the mammary gland,
the expression patterns strongly implicate TGF-P3 as the isoform responsible for
apoptosis during involution.
There is also evidence that TGF-P can act as a pro-survival factor in the mammary
epithelial compartment. NMuMG cells become resistant to apoptosis after prolonged
exposure to TGF-p, in contrast to the pro-apoptotic response induced by shorter-term
exposure to TGF-P (64). The reason behind this shift is not immediately clear, since
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downstream components of each pathway are expressed at low levels in these cells.
However, there is some indication from mouse models that TGF-P can also activate
survival pathways. For instance, in mammary glands of females from MMTV-Alk5T204D
females, there are decreased levels of apoptosis both in the TEBs and during involution
(152). MECs derived from these mammary glands have increased PI3K and AKT
activities. In contrast, in the MMTV-T^RI(AAD) model, there was increased apoptosis of
the mammary epithelium (195). While this discrepancy has not been reconciled in full, it
is apparent that TGF-P can induce or suppress apoptosis. However, much more work is
needed to clarify the cellular and environmental contexts where TGF-P induces each
pathway and the mechanisms behind them.
1.8.5 TGF-P Signalling in EMT, Invasion, and Motility
TGF-P is also a potent inducer of the transdifferentiation of epithelial cells to
mesenchymal cells. EMT occurs naturally during vertebrate development as well as
during disease states such as fibrosis and cancer (39). TGF-P promotes EMT through
Smad-dependent and -independent mechanisms. First, SMAD-mediated expression of
high-mobility group A2 (HMGA2) can induce expression of SNAIL, SLUG, ZEB1 and
2, and TWIST, which are potent repressors of the cell adhesion receptor, E-Cadherin (79,
209). As outlined above, TpRII can also phosphorylate PAR6, which leads to the
dissolution of cell junction complexes (161). Recently, the E3 ubiquitin ligase TRAF6
has also been shown to interact with the TGF-p receptor complex and treatment with
TGF-P 1 induces EMT in NMuMG cells in a TRAF6-dependent manner (228). Finally,
activation of the RAS pathway in conjunction with TGF-P appears to be required for
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induction of complete EMT and invasion in the EpH4 murine mammary epithelial cell
line (102, 158).
The net result of these as well as TGF-p-independent effects is the production of a
more mesenchymal type cell with acquired motility and invasive properties. In the most
extreme case, TGF-P can further promote the differentiation of these fibroblastic-like
cells into myofibroblasts, which are contractile and can produce pro-metastatic factors,
such as matrix metalloproteinases, vascular endothelial growth factor, and chemokine
receptors (39). While there are no clear examples of TGF-p-mediated EMT during
normal mammary gland development, it appears to play a role in invasion and metastasis
of cancer cells (see section 1.9.2 and 1.9.3). In the future, it will be important to
determine if signalling pathways are differentially required for EMT during development
and pathogenesis. It was also previously unknown if primary mammary cells induce an
EMT response in a similar manner to immortalized cell lines. This concept was
addressed in this thesis.

1.9 TGF-p and Breast Cancer
As outlined in the preceding sections, careful orchestration and balancing of proand anti-growth TGF-P signals is critical for mammary gland development and
homeostasis (Fig. 1.8). However, in many cancers, including breast cancer, this balance is
disrupted. In some cases genetic mutations within the core TGF-P machinery result in
disruption of all TGF-P signalling, and are associated with increased risk of breast cancer
(reviewed in (10). More commonly, core signalling is retained, and in many cases
elevated, suggesting there is a lack of selective pressure to lose TGF-P signalling

Figure 1.8 Duality of TGF-P signalling. TGF-P is involved in many signalling
pathways, both during development and disease states. In normal mammary epithelial
cells, homeostasis is maintained by a balance of tumour suppressive TGF-P functions and
those considered pro-oncogenic. In contrast, the pro-oncogenic activities of TGF-P seem
to dominate in cancer cells. At the same time, many breast cancer cell lines become
insensitive to TGF-P growth arrest, leading to the hypothesis that TGF-P growth control
is an important tumour suppressive mechanism, and that specific loss of the cytostatic
response allows expression of TGF-P to drive breast cancer progression and metastasis.
The different functions of TGF-P and their roles in cancer prevention and progression are
discussed in sections 1.8 and 1.9 of the text. (Figure adapted from Roberts and
Wakefield, Proc. Natl. Acad. Sci. USA, 2003)
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completely. In fact, a growing body of evidence suggests that in breast cancer, TGF-P
tumour suppressive functions are lost, while the majority of TGF-P signalling is retained
and subverted to drive tumorigenesis and metastasis.
1.9.1 TGF-p as a Tumour Suppressor
Early in breast cancer progression, TGF-P appears to protect against tumour
formation and growth. While MMTV-dnIIR mice either do not develop spontaneous
tumours (15) or do so after a very long latency (71), MMTV-dnIIR females have an
increased rate of tumorigenesis when treated with 7,12-dimethylbenz[a]anthracene
(DMBA) (Table 1.1) (15). Tgfbr2MGK0/MGK0 females do not undergo spontaneous
tumorigenesis either, but develop tumours faster than wild type animals when crossed
with the mouse mammary tumour virus-polyomavirus middle T antigen (PyVmT)
transgenic strain (57). Finally, crossing mice with a truncated form of TpRII to mice
expressing an active form of the Neu proto-oncogene in the mammary gland leads to
earlier tumour onset (195). Conversely, when crossed into the Neu oncogenic
background, overexpression of active TGF-p results in decreased proliferation of tumours
(153). Similarly, active TGF-P protects against mammary tumour formation in mice
treated with DMBA (167). Constitutive activation of TpRI led to delayed tumour
formation in one study (195), although it did not affect primary tumour latency in another
(152). This discordance potentially reflects the fact that the MMTV-Alk5T204Dmutant can
still be bound by the inhibitor FKBP12, while MMTV- TflRI(AAD) cannot (Table 1.1).
Further, Muroaka-Cook, et al. crossed the MMTV-Alk5T204Dmutant into the Neu
background, which overexpresses wild type Neu, while Siegel, et al. used constitutively
active forms of Neu in their crosses with MMTV- T/1RI(AAD) mice, which may have
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influenced the results. Nevertheless, combined with the loss-of-function models, the
preponderance of data suggests that TGF-p can suppress primary mammary tumour
progression.
1.9.2 Pro-tumorigenic roles for TGF-p
While the majority of tumour studies suggest that TGF-p has tumour suppressive
properties, the same studies suggest that overexpression of TGF-P signalling can drive
tumorigenesis and metastasis (Table 1.1). Activation of TpRI or overexpression of active
TGF-P 1 promotes the formation and extravasation of pulmonary métastasés driven by
overexpression of wild type Neu or constitutively active forms of Neu (152, 153, 195). In
contrast, expression of the truncated TpRII protein protects against the invasion of Neuinduced lung métastasés into the lung parenchyma (195). A truncated version of TpRII
also reduces tumour cell invasion when crossed to mice expressing transforming growth
factor a (TGF-a) (71). Collectively, these studies demonstrate that TGF-P can behave as
an oncogene as well as a tumour suppressor.
1.9.3 Duality of TGF-P Functions in Breast Cancer
The wealth of information from both cell culture and mouse models demonstrates
that TGF-P can protect against tumour formation in the mammary gland during the initial
stages of breast cancer, but can also result in increased metastasis. How does this happen?
The current dogma in the field says that the TGF-P cytostatic response protects cells
against tumour formation, and that in later stages of progression, this cytostatic response
is lost, leaving other aspects of TGF-P signalling like EMT, invasion, motility, as well as
paracrine responses, to drive metastasis (Fig. 1.8) (10, 138, 162). Many tumour cells,
including breast cancer cells, do become resistant to TGF-P-mediated growth inhibition
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over time in culture. Furthermore, short term culture of breast cancer cells taken from
pleural effusions of patients with metastatic disease demonstrated a partial or complete
loss of TGF-P growth suppression (69). These samples lacked pl5INK4b induction and cMYC repression despite retaining other TGF-P gene responses. This correlates with many
studies demonstrating that members of the G1 cell cycle arrest machinery are aberrantly
expressed in breast cancers (54). This suggests that the cytostatic response is specifically
severed during breast cancer progression. Furthermore, tumour cells often have increased
production of one or more of the TGF-P isoforms, which renders these cells more
invasive and metastatic (138). Certainly, there is a wealth of data implying that TGF-P
proliferative control is an essential aspect of TGF-P tumour suppression. That is not to
say, however, that the less well studied roles of apoptosis and differentiation may not also
protect against tumour formation and progression. Since all mouse models to date have
relied on manipulation of the entire TGF-P pathway, it has been challenging to
conclusively determine the role of each TGF-P response during tumour formation,
progression, and metastasis. Thus, the TGF-P mechanisms of tumour suppression have
remained unknown. In this thesis, the importance of TGF-P growth control as a tumour
suppressive mechanism in the mammary epithelial compartment was examined.

1.10 Gene-targeted Strategies to Study the Function of the pRB LXCXE Binding
Cleft
The primary interest of our lab is to understand how pRB functions. As stated
above, it is still not clear which of pRB’s functions are necessary for its tumour
suppressor activities. This has been complicated by the large number of proteins that bind

54
pRB at multiple binding sites. In order to understand how pRB functions, our lab has
taken a structure function approach, disrupting specific binding sites on pRB, allowing
the study of their significance in isolation. Of particular interest to this thesis, previous
work has yielded mutant forms of pRB where the LXCXE binding cleft are disrupted
(RblM and R blNF). Initial characterization of these proteins demonstrated that RBAL and
RBnf cannot bind to viral oncoproteins or to known LXCXE binding partners, but still
interact with E2F proteins (26, 98). Asynchronously dividing MEFs derived from R b l^
mice express normal levels of E2F target genes, suggesting that LXCXE interactions may
be disepensable for cell cycle control in proliferating cells. Interestingly, R blAL/'*L MEFs
are unable to repress E2F-dependent transcription in response to serum starvation,
although this treatment does induce a G1 arrest (98, 205). Similarly, pRBNF only partially
inhibits E2F transcription in luciferase-based assays, but is able to induce growth arrest
when transfected into RB ~Saos-2 cells (26). In contrast, both E2F target repression and
negative proliferative control are lost in R b l^ MEFs treated with y-irradiation or in
response to oncogenic stress (205). This suggests several intriguing possibilities. First,
this suggests that pRB-LXCXE interactions are dispensable in normal cycling cells, but
are necessary for E2F transcriptional control in response to growth arrest signals. This
could explain why R b l mice are viable, but display more subtle defects (8, 9, 98,
205). Second, it implies that the contribution of LXCXE interactions to a growth arrest
signal may be context-dependent, and more globally, that there may be multiple means by
which pRB induces growth arrest. Finally, it suggests that pRB proliferative control
mediated by its LXCXE binding cleft may be an important tumour suppressive
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mechanism. In this thesis, these issues will be explored within the context of the
mammary gland in mice.

1.11 Objectives
As discussed in this introductory chapter, both pRB and TGF-P interact with
many cellular proteins to elicit a variety of cellular responses and have tumour
suppressive properties. However, relatively little is known about which of these responses
are needed to exert these tumour suppressive effects (20, 162). In particular, because of
the multitude of binding partners that can affect pRB activity, it has been difficult to
discern which of these interactions are important to prevent tumour formation.
Furthermore, while most components of the G1 regulatory pathway are involved in
mammary gland development, the importance of pRB in this process remains unclear.
The aim of this thesis was to use knock-in mouse models where the LXCXE binding cleft
on pRB is disrupted, to study the role of LXCXE interactions in mammary gland
development and tumorigenesis.
First, I examined the effects of loss of pRB-LXCXE interactions on mammary
gland development. I reasoned that R b l and RblNF/NF mice would allow an
opportunity to examine both mammary development and function because they are viable
and do not overexpress the other pocket proteins. I hypothesized that, like other members
of the cell cycle machinery, pRB is necessary for mammary gland development. Since
pRB plays a role in TGF-P proliferative control, and TGF-P is necessary for proper
mammary gland development, I also endeavoured to determine any functional
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connections between the two pathways in mammary gland development. These results
are discussed in detail in chapter 2.
The findings in chapter 2 demonstrated that pRB is critical for proper TGF-(3
growth control and mammary gland development. pRB has been implicated in TGF-P
growth control, but not other aspects of TGF-P signalling. However, it is possible that
pRB has unidentified roles in other TGF-P pathways or can influence them indirectly.
The next objective was to use a combination of molecular and biological techniques to
examine other TGF-P pathways in the mammary gland to determine if they were affected
by loss of pRB-LXCXE interactions. The results of this work are discussed in chapter 3.
Finally, I explored the necessity of interactions at the LXCXE binding cleft for
tumour suppression by pRB. The findings in chapter 2 and chapter 3 suggested that pRB
is necessary for TGF-P proliferative control but not other aspects of TGF-P signalling,
like TGF-P-dependent apoptosis and differentiation. To my knowledge, this is the first
time that TGF-P growth inhibitions has been disrupted in isolation. This allowed me to
address whether TGF-p growth inhibition is necessary to protect mammary cells from
cancer progression. Three different approaches were used to address this question. First,
mice were treated with DMBA, since TGF-P is known to protect against tumour
formation in this model. Two genetic crosses were also used to explore the role of pRB
proliferative control in tumour suppression: Wap-p53

, which results in genomic

instability (126, 127) and Neu, which has been used to define roles for TGF-P in
mammary tumour development and lung metastases (75). This has allowed me to address
pRB’s role in proliferative control in both primary tumour formation as well as
metastasis. These results are discussed in detail in chapters 3 and 4.
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Chapter 2: A functional connection between pRB and TGF-ß in growth inhibition
and mammary gland development

2.1 Introduction
TGF-ß is a potent inhibitor of mammary epithelial cell proliferation and plays a
key role in mammary gland development (55). Specific loss of its ability to arrest
proliferation is considered an essential step in the development of breast cancer, while its
ability to induce other cellular changes is maintained and used to drive oncogenesis (30).
However, selective loss of TGF-ß growth inhibition responses rarely occur at the level of
the TGF-ß receptor or SMAD proteins, which are common to many aspects of TGF-ß
signalling (55). Instead, disruption of the TGF-ß cytostatic response often occurs at the
level of CDK regulation, leaving other pro-tumorigenic aspects of TGF-ß signalling
intact (56). This underscores the importance of understanding all cell cycle regulatory
targets of TGF-ß, as they are candidates for mutation in breast cancer (16).
TGF-ß suppresses proliferation by inducing a growth arrest in the G1 phase of the
cell cycle (54, 55). TGF-ß signalling results in transcriptional repression of pro
proliferative genes such as c-Myc (65) and CDC25A (38), and concomitantly,
transcriptional induction of the CDK inhibitors p21CIP1 (12) and pl5INK4b (31), as well as
stabilization of the p27RIPI protein (66). This creates a global inhibition of CDK activity
that leads to dephosphorylation and activation of the retinoblastoma protein (pRB) in G1
(56). Despite pRB’s requirement in TGF-ß induced cell cycle arrest (34), it is rarely
considered a component of this signalling pathway (55). Because pRB controls the final
regulatory step before commitment to DNA replication (87), activation of any pathway
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that results in G1 arrest regulates pRB function, suggesting that pRB uses the same G1
arrest mechanism independently of the initial stimulus that causes it. However, most
experiments investigating pRB’s growth arrest mechanism have relied on its re
expression in the RBI deficient Saos-2 cell line as the arrest stimulus (6, 7, 15, 35, 68,
76). The artificial nature of these experiments leaves open the possibility that pRB may
have unique activities that are invoked depending on the growth arrest signal.
Mice deficient for TGF-pi, -2, or -3 die as embryos or neonates due to extensive
defects in development (42, 45, 67, 74, 79). Strikingly, disruption of TGF-p signalling
specifically in the mammary gland causes defects such as hyperplastic ductal epithelium
and defective nursing (20, 21, 28, 29, 41). The relative importance of TGF-P growth
inhibition compared to its other morphogenic signals in mammary gland development is
unclear (22, 77). However, many targets and components of TGF-P’s cytostatic
signalling cascade, such as cyclin D1 and p27KIP1, also participate in controlling
mammary epithelial proliferation during development (25, 27, 48, 59, 80, 81).
Surprisingly, it has been suggested that pRB may be dispensable for this process (73).
Complete loss of pRB function in mice results in embryonic lethality shortly after the
formation of the mammary anlagen (8, 40, 49). To study postnatal mammary
development, Robinson, et al. transplanted RbV'' anlagen into clarified fat pads of wild
type females (73). They found no differences in mammary gland development or tumour
formation. However, transplant experiments have a number of shortcomings. For
example, transplanted anlagen do not form a connection with the nipple, preventing a
complete study of mammary function. Furthermore, complete loss of pRB results in
upregulation of the related protein pi 07, which can compensate for some aspects of pRB
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function (37, 71). This highlights our limited knowledge of pRB function in mammary
gland development and emphasizes the need for more sophisticated approaches to study
its potential role in this tissue.
To exert control over proliferation, pRB interacts with E2F transcription factors
and co-repressor proteins to block expression of genes that are involved in cell cycle
progression (5, 18, 82, 83). Most co-repressors contact pRB using an LXCXE peptide
motif. This allows pRB-E2F complexes to recruit chromatin remodelling factors such as
DNA methyltransferases, histone methyltransferases, histone deacetylases, and helicases,
among others, to actively repress transcription (4, 17, 46, 53, 61, 72, 84). The binding
cleft on pRB that contacts the LXCXE motif is a highly conserved region of the growth
suppressing ‘pocket’ domain (50). This hydrophobic cleft was first identified as the site
of contact for LXCXE motifs in viral oncoproteins such as Adenovirus El A, Simian
Virus 40 large T antigen, and Human Papilloma Virus E7 (13, 19, 58, 85). The fact that
so many cellular proteins can use an LXCXE motif to bind to pRB suggests that this cleft
serves an important physiological purpose. However, few LXCXE motif-containing
proteins are known to be required for a pRB-dependent cell cycle arrest (2, 88). Thus, it
remains unclear whether LXCXE-dependent interactions are broadly required for pRB
action, or for a subset of its growth inhibitory activities.
In an effort to understand the importance of the LXCXE binding cleft in pRB
growth arrest during development, I have used two knock-in mutant mouse strains termed
R blAL and RblNF, in which the LXCXE binding site on pRB has been disrupted by
mutagenesis (39). Contrary to previous reports, we demonstrate that pRB has a critical
role in mammary gland development. Loss of pRB-LXCXE interactions leads to defects
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in nursing and epithelial growth control. These phenotypes are linked to a disruption in
TGF-P growth inhibition in RblAL/AL and RblNF/NF mammary glands. The inability of
TGF-p to block proliferation occurs despite inhibition of CDKs, and appears to be
dependent on the ability of pRB to actively repress expression of E2F target genes. This
suggests that pRB has a more intimate role in the TGF-P growth arrest pathway because
TGF-P requires LXCXE-dependent interactions where other pRB-dependent arrest
mechanisms do not. Furthermore, this study reveals an unappreciated role for pRB in
mammary gland development.
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2.2 Materials and Methods
Mouse strains
The R blALmouse strain containing three amino acid substitutions in the Rbl locus
has been previously described (39). Analysis of R blAL/AL mice was performed on a mixed
129/B6 background. To generate the R blNF strain, correctly targeted TCI ES cells were
identified by Southern blotting as shown in Figure 2.1b and c and injected into
blastocysts to generate chimeric mice. Male chimeras were bred to C57/BL6 females, and
agouti progeny were bred to 129 Sv/Ev/Tac mice that contained the Cre recombinase
gene driven by the protamine promoter (PrmCre)(62). Males that carried RblNF(Neo) and
PrmCre expressed Cre recombinase during spermatogenesis, which led to excision of the
Neo cassette in sperm. These mice were then bred to generate R blNF/NF progeny and were
subsequently studied in a mixed 129/B6 background. Genotyping methods and primer
sequences can be found in Appendix I. MMTV-TGF-fJl223 225mice express simian TGFpi carrying serine mutations at cysteines 223 and 225 of the pro region of the TGF-pi
precursor, resulting in the production of a constitutively active form of the mature protein
(64). These mice were obtained from the Jackson Labs on a C57/B6 background and
were bred to the R blM mutation creating a mixed 129/B6 genetic background.
Nursing data was collected from birth (PO) to weaning. Females were considered
unable to nurse if all pups died within the first two days post-parturition, and considered
able to partially nurse if some, but not all, pups survived past P2. Both multiparous and
uniparous females were used in the study. All animals were housed and handled as
approved by the Canadian Council on Animal Care.
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Histology and Mammary Whole Mounts
The second and third thoracic mammary glands were dissected at 8 weeks
of age or the second day post-parturition and fixed in neutral buffered 10% formalin.
Fixed tissues were embedded in paraffin, cut into 5pm thick sections, and stained with
H&E. To determine the extent of hyperplasia, the ductal cross sections present per mouse
were counted and the fraction of hyperplastic ducts per genotype was calculated. Cross
sections from three to nine females per genotype were quantified. Ductal cross sections
with more than three layers of epithelial cells were scored as hyperplastic. For whole
mount experiments, the fourth inguinal mammary gland was removed, mounted on a
glass slide, and stained with Carmine Red using standard methods.
Detection of cytokeratin 18 and cytokeratin 14 was performed on paraffin sections
that had been deparaffinized and rehydrated using a series of xylene and ethanol washes.
Sections were brought to a boil in sodium citrate buffer and then maintained at 95°C for
10 minutes. Cooled sections were rinsed in water three times for five minutes each, then
rinsed in PBS for five minutes. Sections were blocked in 2.5% horse serum/2.5% goat
serum in PBS-0.3% Triton-X for one hour. Sections were incubated with anti-cytokeratin
18 (KS18.04; Fitzgerald) and anti-cytokeratin 14 (AF64; Covance) overnight at 4°C and
then rinsed in PBS three times for five minutes each. Slides were incubated with horse
anti-mouse IgG-FITC and goat anti-rabbit IgG-Texas Red secondary antibodies (FI-2000,
TI- FI-1000; Vector) for 1.5 hours and then rinsed in PBS as above. Slides were mounted
with Vectashield plus DAPI (H-1200; Vector) and sealed with nail polish. Fluorescent
images were captured on a Zeiss Axioskop40 microscope and Spot Flex camera and
coloured using Eyelmage software (Empix Imaging, Mississauga, Ontario).
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Mammary transplants
Mammary transplants were performed as described by Moorehead (57). All
transplants were performed using the fourth inguinal glands. The epithelial portion of 3
week old RblAL/AL mammary glands was removed by harvesting the tissue between the
lymph node and nipple. A 2x2 mm section of this tissue was placed into the cleared fat
pad of Fox Chase SCID mice, and the epithelial tissue from R bl+/+ females was placed in
the contralateral fat pad. SCID females were euthanized at 8 weeks of age and the
fraction of hyperplastic ducts was determined as outlined above.

Cell culture
Primary mammary epithelial cells (MECs) were harvested as described by Hojilla
(36). Each MEC preparation consisted of the mammary glands of four female mice.
RbJ ' and RblAL/AL mammary glands were minced and dissociated in 2 mg/mL
collagenase IV in DMEM:F12, supplemented with 100 pg/mL gentamycin, 60 U/mL
nystatin and lOOU/mL penicillin/streptomycin for 2 hours at 120 rpm at 37°C. Cells were
then washed with PBS supplemented with 5% adult bovine serum (ABS) and plated onto
collagen-coated dishes. MEC cultures were maintained with DMEM:F12 media
supplemented with 1% ABS, 10 pg/mL insulin, 5 ng/mL epidermal growth factor (EGF),
50pg/mL gentamycin, 20 U/mL nystatin, and 100 U/mL penicillin/streptomycin. Finally,
the cultures were passaged and purified using a differential dispase treatment.
Keratinocytes were harvested as previously described (10). P0-P2 animals were
euthanized and immersed in 70% ethanol for 25 minutes at 4°C to sterilize. Limbs, tails,
and heads were removed before the dermis and epidermis were isolated from the mice,

dermis side down, and rinsed in PBS to remove blood. One millilitre of 0.25% trypsin
was added to each skin, prior to incubating at 4°C overnight. Skins were then placed in 2
mL of fresh trypsin and the skins were incubated at 37°C for 30 minutes to 1 hour. The
epidermis was then separated from the dermis, and minced finely with scissors in 15 mL
conical tubes. 15 mL of kératinocyte growth medium (No-calcium EMEM, 8% chelextreated fetal bovine serum (FBS), 74 ng/mL hydrocortisone, 6.7 ng/mL T3, 5 pg/mL
insulin, 10'loM cholera toxin, 5 ng/mL epidermal growth factor, and 0.1%
penicillin/streptomycin) were added to each tube and the tubes were rocked gently at
37°C for 10 to 15 minutes. The suspension was filtered through a 70 pm nylon filter and
plated at 400 000 cells per well onto collagen and poly-L-lysine coated coverslips in 24
well plates. The day after plating the cells were rinsed with PBS and fresh medium was
added. Medium was changed every other day to maintain proliferation.
Rbl^ J and R blAL/AL primary murine embryonic fibroblast (MEF) cultures were
derived as previously described (39). Cell culture experiments were carried out using
passage 2 MECs, passage 4 MEFs, and passage 1 kératinocytes.

TGF-P growth arrest assays
Asynchronously proliferating R bl+/+, R blAL/AL, and R blNF/NFMEFs were treated
with 100 pM TGF-pi (R&D Systems) for 24 hours. Cells were then pulse-labelled with
5-bromo-2-deoxyurdine (BrdU) (RPN201VI, Amersham Biosciences) according to the
manufacturer’s instructions for 1.5 hours. BrdU incorporation was quantified using flow
cytometry as previously described (9). Flow cytometry was carried out on a Beckman-
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Coulter EPICS XL-MCL instrument. Data analysis was carried out using CXP version 2
software.
R bl+ ' and R blAL/AL MECs and keratinocytes were treated with TGF-pi as
outlined above and BrdU incorporation was measured using immunofluorescence
microscopy. Cells were fixed and stained with an antibody against BrdU (1:500)(347580,
BD Biosciences) using methodologies outlined by Foster, et al. (23). The percentage of
BrdU-positive cells was determined from 10 fields of view per treatment group, and the
average fold decrease in proliferation was calculated relative to untreated controls
cultured in parallel.

Retroviral infections
Retroviral infections were performed as previously described (63). BOSC
packaging cells were plated at 107 cells per 15 cm dish in 25 to 30 mL of media 24 hours
prior to transfection. Each dish was transfected by calcium phosphate with 60 pg of
pBabe plasmid containing pl6INK4a, p21CIP1, or vector alone. BOSC media was replaced
with 10-15 mL of fresh media the next morning. Two days later, the viral supernatant was
filtered and supplemented with 4 pg/mL of polybrene before being placed directly on
passage 3 MEFs that had been plated at 8 xlO5 cells per 10 cm dish a day earlier. BOSC
cells were given fresh media and this was used for a second round of infection 12 hours
later. After another 12 hours of incubation with viral supernatant, MEFs were given fresh
media for 8 to 12 hours, at which point infected MEFs were selected for 4 days with
media containing 5 pg/mL puromycin. After drug selection, MEFs were replated at low
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density in drug containing media for BrdU labelling and subsequent flow cytometry
analysis.

Protein and RNA quantification
To isolate milk, female mice were injected with 4.5 U oxytocin (Sigma) four
hours after removal of their offspring. Thirty minutes later milk was extracted manually.
Equal volumes of milk and 2X SDS-PAGE buffer were mixed, denatured, and resolved
by SDS-PAGE. Gels were stained with coomassie blue.
To examine levels of phospho-SMAD2 and phospho-pRB, Rbl ++ and RblA!JAL
MEFs were treated with 100 pM TGF-(31 (R&D Systems) for 2 or 24 hours respectively.
Total cellular extracts were isolated in radio-immunoprecipitation assay buffer. Equal
amounts of total cellular proteins were resolved in each lane by SDS-PAGE, transferred
to membranes, and probed using standard methods. Proteins were detected using the
following antibodies: SMAD2 (sc-6200; Santa Cruz), phospho-SMAD2 S465/467
(AB3849; Chemicon), pRB (G3-245; BD-Pharmingen), phospho-pRB S807/811 (9308;
Cell Signalling).
Messenger RNA levels of E2F target genes were detected using the Quantigene
Plex 2.0 reagent system (Panomics, Freemont, CA) and measured using a BioPlex200
multiplex analysis system according to the manufacturer’s instructions. To measure
expression of MMTV-TGF-/31 mRNA, RNA was extracted from mammary glands of 3
week old and 8 week old females using Trizol reagent (Invitrogen). RNA was then
converted to cDNA using the Reverse Transcription System (Promega) as per the
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manufacturers’ instructions. RT-PCR was performed using primers against the simian
TGF-pi transcript (see Appendix I).

Luciferase reporter assays
Luciferase reporter assays were performed as described by Sarker (75). MEFs
were seeded at 75 000 cells/well in a 6 well plate 24 hours prior to transfection. Cells
were then cotransfected with 3TP-lux (250 ng/well) and cytomegaolovirus (CMV)-Pgalactosidase vector (50 ng/well) using Fugene 6 (Roche) according to the
manufacturer’s directions. Twenty-four hours post-transfection, the cells were treated
with 100 pM TGF-pi (R&D Systems) for 20 hours at 37°C. Extracts were prepared using
Luciferase Assay Buffer (Promega) and luciferase activity was measured on a Wallac
Victor2 1420 multilabel reader. P-galactosidase activity was measured colorimetrically
using 2-nitrophenyl-P-D-galactopyranoside as the substrate. Luciferase activity
(measured in relative light units) was normalized to P-galactosidase measurements.

84
2.3 Results
Two distinct strategies to eliminate pRB-LXCXE interactions
The LXCXE binding cleft is one of the most highly conserved regions of the
retinoblastoma protein (50), and is the contact site for many proteins involved in
chromatin regulation (5). However, it is noteworthy that proteins like Suv39hl, Cdhl,
and the condensin subunit CAP-D3 do not contain a classic LXCXE motif, yet require the
LXCXE binding cleft for interaction with pRB (2, 51, 61). To understand the importance
of interactions between pRB and cellular partners that use this interaction surface, we
generated two knock-in mouse models that use distinct mutation strategies to disrupt
interactions with this region of pRB. The RbJ ALArxl (herein referred to as RblAi) mutant
replaces three well conserved amino acids (1746, N750, and M754) with alanines and has
been previously reported (39) (Fig. 2.1a). These substitutions are predicted to make the
leucine and cysteine residues of the LXCXE motif a loose fit. A different gene targeting
strategy was utilized to block access to the LXCXE binding cleft in the R blN750F(RblNF)
mouse. The R bls h mutant substitutes a bulky phenylalanine for asparagine at amino acid
750, which is predicted to sterically block access to the LXCXE binding cleft (Fig. 2.1a).
The targeting strategy used to create this mouse is shown in Figure 2.IB and a
representative Southern blot shows targeting by homologous recombination (Fig. 2.1c).
The selectable marker was removed by breeding Cre transgenic and chimeric mice. FI
offspring were subsequently intercrossed to eliminate the transgene and produce
homozygous R blNr' Nh animals.
Previous cell culture based studies showed that pRBALand pRBNI are unable to
bind LXCXE-containing proteins including Adenovirus El A, Human Papilloma Virus

Figure 2.1 Two knock-in mouse strains with disrupted LXCXE interactions. (A)
Structural depiction of pRB interacting with the LXCXE motif of HPV E7. Side chains
from amino acids 746, 750, and 754 on pRB mediate the interaction with the LXCXE
peptide and are coloured turquoise. The Rbl

A T W '"* y r

mutation changes these amino acids to

alanines (red), removing one side of the LXCXE binding cleft, while the RblNFmutation
adds a bulky phenylalanine instead of asparagine at amino acid 750 (red). This is
predicted to occupy more space and block access to the LXCXE binding cleft. (B) The
genomic structure of Rbl is shown. The targeting vector containing a LoxP-flanked PGKneo cassette inserted into intron 23 and the mutation of N750F in exon 22 are indicated.
A new Xbal site was introduced into intron 21. Homologous recombination resulted in
the R blNF~ne0allele. Location of the 5’ probe used for Southern blotting is also shown.
Following germ line transmission, the correctly recombined allele was generated by
crossing chimeric males to a Cre-expressing transgenic strain. The structure of the RblNF
allele in which Neo has been correctly excised is shown at the bottom. (C) A Southern
blot of representative ES clones digested with Xbal and probed with the 5’ probe is
shown. (D) The ability of GST-E1A and GST-DPl/His-E2F3 to interact with pRBAL and
pRB

was tested in GST-pulldown assays, and bound pRB protein was detected by

western blot analysis.
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E7, histone deacetylase 1, Retinoblastoma Binding Partner 1, Sin3, and C-terminal
binding protein 1, but these pRB mutants retain normal interactions with E2F

.

transcription factors (7, 39). GST-pulldown experiments further confirm that pRBALand
pRBNF mutant proteins derived from R bl4^ 41 and R blNF/NFcells are defective for binding
to proteins containing a classic LXGXE motif like E1A (Fig. 2.1d). In addition, both
mutant forms of pRB interact with recombinant E2F3-DP1 equivalently to wild type
pRB. These experiments demonstrate that together the two mouse strains have the
necessary properties to define the physiological contexts where pRB-LXCXE interactions
are required, regardless of the nature in which interacting proteins contact this binding
site onpRB.

..................

Nursing defects in R

b l 4^ 4 1

..........

and R

b l NF/SF

...............

female mice

Mice homozygous for LXCXE binding cleft mutations are viable and
indistinguishable from wild type littermates,1however, mutant females display a distinct
defect in mammary gland function. When bred, pups from R bl41/41 and RblNF/NFmothers
frequently did not survive past day 2 post-parturition (P2) (Table 2.1). Furthermore, many
pups that did survive had very small white spots in their abdomens (Fig. 2.2a), indicating
that they were not being nursed regularly.
In the majority of cases, R bl41/41 and R blNF/NF females built nests, and after
delivery, offspring were cleaned and present in the nest. Mothers quickly retrieved
offspring that we removed from the nests, and pups were routinely observed attempting
to suckle. Thus, despite ostensibly normal maternal and offspring behaviour, little or no
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Table 2.1 The effect of pRB LXCXE cleft mutations on the ability of female mice to
nurse. Mothers were considered unable to nurse if their pups died within the first two
days post-parturition (P2). Females that lost at least one pup and had at least one pup
survive past P2 were considered to have partially nursed. Proportions were compared
between relevant groups using a chi-square test.
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Figure 2.2 Defective nursing in R b l ^ ^ and R blNF/NFfemales. (A) Representative
offspring from R b l+/+, R b lAL/AL, and R blNF/NFmothers at day two post-parturition (P2).
Arrows indicate the stomachs of the offspring. (B) Paraffin sections of R b l+/+, R blAL/AL,
'
'
( .
and R blNF/NFmammary glands from post-partum females (P2) were stained with H&E to
verify the presence of milk. Arrows indicate milk-filled alveoli. Scale: 50 pm. (C) SDSPAGE and coomassie staining of milk obtained from R b l+/+and R blAL/AL post-partum
females. (D) H&E staining of sections at P2 also indicated dilation of the ducts in
Rhi^UM. gjjjj jh,] nf/nf females. Arrows indicate dilated ducts. Scale bar: 200 pm.
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milk was observed in the stomachs of newborns from RblAlJAL and RblNF/NF mothers,
indicating that impaired milk intake caused the neonatal lethality (Fig. 2.2a).
To confirm that there were no defects in milk production, we performed
histological analysis of postpartum mammary tissue from R bl+/+, RblAL/AL, and RblNF/NF
females. All had undergone a similar degree of lobuloalveolar formation and alveoli
contained milk at P2 (Fig. 2.2b). SDS-PAGE and coomassie staining of milk obtained
from R b l' ' and R blAL/ALmammary glands revealed no differences in milk protein
content between genotypes, suggesting that neonatal morbidity was not due to poor milk
quality from Rbl mutant mothers (Fig. 2.2c). However, histological analysis of mammary
glands from lactating and multiparous mutant females revealed large, dilated ducts
containing milk (Fig. 2.2d), a phenotype consistent with an inability to secrete milk (43).
These experiments indicate that while RblAL/AL and Rblsl v/ females are able to
produce milk, they have difficulty excreting it from their mammary glands, frequently
resulting in neonatal lethality. The prevalence of this nursing defect in mouse lines from
two separate ES clones of the R blALmutation as well as the RblNhNh mutant indicates
that pRB-LXCXE interactions are critical for mammary gland function. By extension,
we conclude that pRB has an essential function in mammary gland development.

Rb]AL/al an(j jtfrjNFMF femaies develop hyperplasia of the mammary ductal
epithelium
The disruption in milk expulsion exhibited by mutant Rbl mammary glands
prompted us to examine mammary gland development in these mice. Mammary gland
histology revealed hyperplastic growth in RblALAL and R blNF/NFmammary glands
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throughout development (Fig. 2.3a and c, and data not shown). Hyperplasia was
characterized by increased luminal epithelial cell layers (Fig. 2.3f), as well as
invagination of the epithelium into the lumen of the duct. The tables associated with
Figure 2.3A and C show a significantly elevated frequency of hyperplastic ducts in Rbl
mutant mice compared with controls (.PO.OOOl). This data suggests that pRB-LXCXE
interactions are required for proliferative control of mammary ductal epithelium during
development. Conversely, ductal infiltration of the fat pad was similar between wild type
and mutant genotypes as revealed by Carmine Red staining of mammary gland whole
mounts (Fig. 2.3b and d). In addition, branching frequency and overall ductal
morphogenesis appeared normal, suggesting that hyperplasia that is visible at a
microscopic level throughout development does not manifest in more severe
developmental problems.
Both epithelial and stromal factors influence ductal development. To determine
whether disruption of LXCXE interactions within the mammary epithelium was
sufficient to enhance ductal growth, we transplanted mammary epithelial tissue from wild
type and RblAL/AL mutants into cleared fat pads of Fox Chase SCID recipients prior to
puberty. H&E staining revealed that hyperplastic epithelia were evident in R blAL/AL
glands, even in the presence of wild type stroma and endocrine factors (Fig. 2.3e). This
demonstrates that overproliferation of the mammary ductal epithelium in Rbl mutant
mice is not a secondary consequence of altered endocrine signalling, nor signalling from
the surrounding stroma, but rather, is epithelial cell autonomous.
This analysis reveals a striking defect in mammary ductal development in
RblALAI and R blNF/NF virgin mice. This defect is specific to the epithelial compartment,

Figure 2.3 R

b

l

and R

b l NF/NF

females develop hyperplasia of mammary ductal

epithelia. (A) H&E staining of R bl+/+ and R b l mammary tissue sections from 8
week old mice. Each image displays a representative cross section of ducts used to count
epithelial layers. Ducts three or more cells thick were scored as hyperplastic. The
accompanying table displays the proportion of hyperplastic (hp) ducts found in wild type
and R b l mammary glands. (B) Carmine Red-stained mammary whole mounts are
shown from 12 week old mice for the indicated genotypes. (C) An identical analysis to
that performed in A is shown for R bl+/+ and R blNF/NFmice. (D) Whole mount analysis
was also performed on matched wild type and R blNF/NF mice. (E) Mammary epithelial
tissue from R bl+/+and R b l mice was transplanted into clarified fat pads of Fox
Chase SCID hosts. Tissue sections from transplanted mammary glands were stained and
analyzed as in A. The proportion of hyperplastic ducts for each genotype was compared
using a chi-square test. (F) Paraffin sections from 8 wk old mice were stained for the
luminal epithelial and basal/myoepithelial markers, cytokeratin 18 (green) cytokeratin 14
(red). A, C, E scale bar: 200 pm, B, D scale bar: 2 mm, F scale bar: 50 pm.
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as ductal branching, which relies on stromal signalling (41), is intact, and the transplants
reveal that the hyperplasia persists even in the presence of wild type stroma.
Transplantation experiments further demonstrate that the hyperplasia is phenotypically
distinct from the apparently normal development that takes place with transplanted R b l"
mammary anlagen (73). Consequently, these Rbl mutant strains have revealed a key role
for pRB in mammary epithelial proliferation and function.

Defective TGF-P growth inhibition in R

b l and R bl*F/AlFcells contributes to

hyperplasia
TGF-P is essential for growth control and development of the mammary gland
(22, 55). Interestingly, excessive ductal proliferation is seen in mice hemizygous for Tgfp i or expressing a dominant negative TGF-P type II receptor (20, 21, 28, 29, 41).
Furthermore, dominant negative TGF-P type II receptor mice display a nursing defect
(29). The similarity of phenotypes between mice defective for pRB-LXCXE interactions
and mice defective for TGF-p signalling within the mammary epithelium prompted us to
examine the ability of R blALAL and RblNF/NF cells to respond to a TGF-pi growth arrest
signal. We treated primary MEFs from R b l' +, R blAL/AL, and R blNFNF mice with TGFpi for 24 hours, pulse labelled with BrdU, and then quantified the percentage of cells
incorporating BrdU by flow cytometry (Fig. 2.4a). R brA cultures serve as an important
control because they are known to be refractory to TGF-P 1 growth arrest (34). In this
experiment, Rbl" ’ MEFs showed reduced BrdU incorporation in response to TGF-P 1,
while R blALAL and Rbl '1 Nh fibroblasts were unresponsive, indicating that pRB-LXCXE
interactions are necessary for TGF-P-mediated growth arrest.

Figure 2.4 Defective TGF-p growth inhibition in R

b l^ ^

and R

b l NF/NF

ceils. (A)

R b l+/+, R bl'A, R blAUAL, and RblNF/NF murine embryonic fibroblasts (MEFs) were treated
with TGF-P 1 and pulse labelled with BrdU 24 hrs later. BrdU incorporation was
measured by flow cytometry and the percent incorporation is shown for each genotype.
(B) Mammary epithelial cells (MECs), and (C) kératinocytes were treated with TGF-P 1
for 24 hours and pulse labelled with BrdU as described above. The percentage of cells
incorporating BrdU was measured by immunofluorescence microscopy. The fold
decrease in proliferation between treated and untreated cultures was determined. The
average of three independent experiments is shown. *Indicates a statistically significant
difference (Student’s t test; .P<0.05). Error bars indicate one standard deviation from the
mean.
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This analysis of TGF-P growth control was expanded to include other cell types
that are more sensitive to TGF-P-induced cell cycle arrest. We prepared primary MECs,
plated them in duplicate, and TGF-p 1 was added to one of each pair. The percentage of
BrdU positive cells was determined by immunofluorescence microscopy and the fold
decrease of incorporation was calculated using the untreated control as a reference (Fig.
2.4b). We found that the ability to induce a TGF-P 1 growth arrest was drastically
reduced in RblALAL mammary epithelial cells. R b l+/+ MECs had almost a four-fold
decrease in cell proliferation, while R blALAL MECs showed less than two-fold reduction
in BrdU incorporation (.P=0.03). We also performed this experiment with R b l' ' and
Rbl '1' AL primary keratinocytes (Fig. 2.4c). R b l' ‘ keratinocytes displayed a large
decrease in BrdU incorporation, while R blALAL cells demonstrated only a 2.4-fold
reduction in proliferation (/,=0.0113). From these experiments we conclude that pRBLXCXE interactions are critical for TGF-P growth control in multiple cell types.
To validate that resistance to TGF-p growth inhibition contributes to the
developmental defects seen in the mammary glands of mice lacking LXCXE interactions,
we combined the R blAi mutation with an MMTV-TGF-fil transgene to determine whether
hyperplastic ductal growth of RblAL/AL epithelia could be suppressed in the presence of
excess TGF- p i. Figure 2.5 shows our analysis of ductal hyperplasia in 8 week old
Rbl

and RblAl Ai mice overexpressing a constitutively active form of TGF-P 1. H&E

staining of ductal cross sections shows a persistent hyperplastic phenotype that is
indistinguishable from R blAL AL alone (compare Fig. 2.5a with Fig. 2.3a). Furthermore,
the frequency of hyperplastic ducts in RblAL/AL mice overexpressing active TGF-P 1 is
also similar to R blAIAL alone (compare Fig. 2.5b with Fig. 2.3a). We also investigated

Figure 2.5 Mammary ductal hyperplasia is caused by defective TGF-p growth
inhibition in R

b l ^ 41

mice. R b l^ '41 mice were crossed into the MMTV- TGF-/31223/225

background. (A) H&E staining of paraffin sections from mammary glands isolated from 8
week old mice. Cross sections of individual ducts are shown. Ducts that contained three
or more epithelial layers were scored as hyperplastic. Scale bar: 200 pm. (B) The
proportion of hyperplastic (hp) ducts in MMTV-TGF-pl223/225; R b l+/+and MMTV-TGFpi

; Rbl

AT/AT

mammary glands was determined and compared using a chi-square

test. (C) Reverse transcriptase-PCR was used to detect the constitutively active, simianderived TGF-P 1 transcript expressed by the MMTV promoter in MMTV-TGF~pi223/225,
R blAL/AL mammary glands.
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the expression pattern of the MMTV transgene using RT-PCR to detect the simian TGFP1 transcript (Fig. 2.5c). This shows that expression of the transgene is evident as early
as 3 weeks of age. Thus, even after 5 weeks of persistent expression of a constitutively
active form of TGF-pi, the mammary ductal epithelium still overproliferates. This
reveals that resistance to TGF-P growth inhibition is an important component of the
ductal hyperplasia phenotype.
These data link the hyperplastic phenotypes observed in mammary epithelium in
Rbj AL/al an(j R biNF/NF mice with an inability to respond to TGF-P growth inhibition. In
addition, a small increase in BrdU positive basal kératinocytes has been observed in
RbjAL/AL mjce compared to controls (1), suggesting that defective TGF-P growth arrest in
R blAL/AL kératinocytes may have a mild effect on the epidermis. Our experiments have
identified a previously unappreciated role for pRB in mediating TGF-P growth control in
mammary epithelium that is necessary for mammary development and function.

R b l1h/al cejjs trans(juce TGF-pi-dependent signals
We next wanted to address the mechanism by which mutations in the LXCXE
binding cleft of Rbl disrupt TGF-P growth inhibition. TGF-P stimulates its receptors to
phosphorylate SMAD proteins, which translocate to the nucleus, and along with co
regulators, activate or repress gene transcription of a diverse number of genes. Targets for
activation include plasminogen activator inhibitor 1 (11, 14), and the CDK inhibitors
pl5,NK4b and p21CI1>l(12, 70), among others. To determine where pRB-LXCXE
interactions are required in TGF-P-mediated growth arrest, we analyzed the TGF-P
signalling pathway in R blALAL MEFs. Phospho-specific western blots showed that TGF-
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pi treatment of Rbl 4 ' and RblAL/AL MEFs resulted in phosphorylation of SMAD2 (Fig.
2.6a). This suggests that TGF-P receptor expression and function are not significantly
altered in RblALAL cells.
To examine SMAD-dependent transcription, we utilized the 3TP-lux reporter,
which contains TGF-P responsive elements from the promoter of the plasminogen
activator inhibitor l gene driving the expression of firefly luciferase (86). Transfected
Rbl ' ' and RblAL/AL MEFs had comparable levels of luciferase activity when stimulated
with TGF-P 1 (Fig. 2.6b). Importantly, luciferase expression was increased to the same
extent when Rbl 1 and R blALAL cells were treated with TGF-pi. Together with the
phospho-specific western blot analysis, the luciferase assay data indicates that SMADdependent signal transduction functions normally in RblALAL cells. From these
experiments it is clear that the R blAL mutation disrupts growth control, but does not cause
pleiotropic defects in TGF-p signalling.

RbiAL/AL ce|js are unabje to repress E2F target genes in response to TGF-P
Growth inhibition by TGF-P is thought to be the result of multiple, overlapping
means of inhibiting cyclin dependent kinase activity (54, 55). In G1 this leads to the
accumulation of hypophosphorylated pRB and cell cycle arrest (24, 26, 47). To
investigate this aspect of TGF-P growth inhibition, we performed phosphospecific
western blot analysis on MEFs treated with TGF-pi. R bl+4 and RblAL/AL MEFs had
comparable levels of dephosphorylated pRB when treated with TGF-pi (Fig. 2.6c), yet
R blAL/AL cell proliferation was not reduced under these conditions (Fig. 2.4a). This

Figure 2.6 TGF-pi signalling in R

b l^ ^

cells does not repress E2F target genes. (A)

Phospho-SMAD2 levels were measured in TGF-pl treated Rbl 4 and R b l ^ ^ MEFs by
western blot analysis. (B) R b l+/+ and R blAL/AL MEFs were transfected with the 3TPluciferase reporter and (3-galactosidase plasmids. MEFs were then treated with TGF-pl
for 24 hrs. The luciferase activity was normalized to P-galactosidase expression and is
shown as arbitrary units. (C) Total pRB expression levels as well as phospho-pRB levels
were measured in TGF-pi -treated R b l+ and R b l MEFs by western blot analysis.
(D, E) R b l+/+, RbV'\ and R b l MEFs were infected with retroviruses expressing
either (D) p l6 INK4a or (E) p21CIP1. Following drug selection, cells were pulse labelled
with BrdU. BrdU incorporation was measured by flow cytometry and the percent
incorporation is shown. (F) The fold change in mRNA levels in response to TGF-pi
treatment is shown for E2F responsive genes as well as the non-E2F responsive control,
Acidic ribosomal phosphoprotein (ArppPo). Error bars indicate one standard deviation
from the mean. *Indicates a statistically significant difference (Student’s t test; P<0.05).
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indicates that mutant pRB is activated by TGF-pi signalling and suggests that the defect
in growth inhibition is downstream of CDK regulation.
To further confirm that RblALAL cells are unable to arrest despite the inhibition of
cyclin/CDK activity, we sought to inhibit CDK activity directly. Hypophosphorylation
of pRB and G1 arrest can be induced by ectopic expression of INK4 and CIP/KIP family
proteins, and this arrest is known to be lost in cells deficient for pRB (44, 52, 60, 78).
We used retroviral infection to express either pl6INK4a or p21CIPI in Rbl /+, RbP/', and
RbjAL/AL jyf£ps t0 study the effects of representative members of the INK4 or CIP/KIP
protein families on cell cycle arrest. R b l1 cells had decreased BrdU incorporation after
infection with either pl6,NK4a- or p21cip|-expressing viruses, while RblAL/AL MEFs
behaved like Rbl''' MEFs, with no reduction in BrdU incorporation (Fig. 2.6d and e).
Thus, even when inhibitor expression blocked CDK activity, RblALAL MEFs were unable
to arrest growth. Based on this analysis we conclude that TGF-P growth arrest requires a
unique aspect of pRB function beyond becoming dephosphorylated and binding to E2Fs.
To understand the nature of the pRB-LXCXE-dependent function that is required
for TGF-P induced growth arrest, we determined whether mutant pRB still represses
transcription of E2F target genes. We measured the mRNA levels of five E2F responsive
genes under conditions where TGF-pi stimulation inhibits proliferation of R bl++MEFs.
While the levels of Pena, Ccnel, Rbll, Ccna2, and Tyms decreased in wild type TGF-pitreated cells, there was little change in transcript levels for a number of these genes in
R blAL/AL cells (Fig. 2.6f). In some cases expression appeared to increase slightly. Given
that both wild type and mutant pRB became hypophosphorylated under these TGF-P 1
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treatment conditions (Fig. 2.6c), we interpret this to mean that mutant pRB is active but
unable to repress transcription.
This indicates that pRB functions as part of an active repressor complex in TGF-|3
growth inhibition. Presumably this complex contains pRB, an LXCXE motif-containing
co-repressor, and an E2F transcription factor. Since the most obvious defect in RblAUAL
and R blNFNF mice lies in proliferative control during mammary gland development, this
reveals a novel requirement for pRB-LXCXE interactions in the TGF-(3 cytostatic
response that is uniquely important for mammary development and function.
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2.4 Discussion
This study reveals a number of unexpected findings about TGF-P signalling and
pRB in regulating cell proliferation. First, our work highlights a previously unrecognized
role for pRB in mammary gland development. Additionally, mutation of the highly
conserved LXCXE binding region of pRB creates a very discrete functional defect in the
mammary glands of otherwise normal mice. Because TGF-p signalling underlies the
mammary defects in R blAL/AL and Rblx' A/ mice, our work argues that pRB-LXCXE
interactions have a unique functional role in TGF-P-induced growth inhibition.
Our work appears to contradict the report by Robinson, et al., which showed that
complete ablation of pRB in transplanted epithelium results in normal mammary
development (73). However, these apparently paradoxical results may be explained by
differences in experimental approaches. First, we discovered hyperplasia in early
development of virgin animals, a defect that we were unable to detect in densely packed
lactating mammary glands. Since these authors examined only the structure of lactating
R b l" mammary glands, it is perhaps not surprising that they did not detect hyperplastic
growth. Similar to Robinson, et al., we investigated the density and morphology of
alveoli between genotypes in lactating females and did not detect differences. The
inability of transplanted mammary glands to form a functional connection with the nipple
precludes further assessment of a phenotype in Rbl null glands. However, our intact
mouse models clearly showed a defect in expelling milk, indicating that fully functional
pRB is necessary for lactation. To ascertain the importance of pRB in TGF-P proliferative
control, Robinson et al. transplanted WAP-TGF-fil; R b l" epithelium into wild type
recipients. These mice express TGF-p 1 in alveolar cells during pregnancy and lactation.
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Again, these alveoli were indistinguishable from wild type controls. In contrast, the
MMTV-TGF-fil transgene used in our experiments reveals in vivo resistance to TGF-P 1induced growth arrest during early development. The challenges presented by
transplanting embryonic Rbl"' anlagen limits the range of developmental events that can
be investigated, and likely explains why pRB’s role in mammary development and
function has gone undetected until now.
Most breast cancers originate from ductal epithelium and nearly all cell lines
derived from breast cancer patients are unresponsive to the growth inhibiting effects of
TGF-pi in culture (16, 55). Similar to the transplant experiments in Robinson et al., we
have not detected spontaneous mammary tumours in RblAIJAL or RblXh NF mice (73).
However, it is noteworthy that transgenic mice expressing dominant negative TGF-P type
II receptors have similar defects in their mammary glands and either did not develop
spontaneous tumours (3), or developed tumours only after a very long latency (28).
Future studies using transgenic induction of mammary tumorigenesis in our Rbl mutant
mice will allow TGF-(3’s cell cycle control function in cancer development and metastasis
to be studied in isolation.
R blAl/AL and R blNF/NF cells are largely refractory to TGF-pi growth inhibition in
cell culture and our genetic cross to MMTV-TGF-fll mice suggests that loss of this
proliferative control mechanism results in hyperplasia. We speculate that TGF-P
signalling defects also lead to the nursing defect in R blAL,AL and R blFF/NF females, given
that mice expressing a dominant negative TGF-P type II receptor are also reported to
have nursing defects (29). We envision a number of scenarios that could explain this
defect. One possibility is that overproliferation of the ductal epithelium causes physical
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blockage of the lumen, preventing milk letdown, and ultimately leading to dilated ducts.
Another possibility is that the nursing defect is not proliferation-related. Since TGF-(3
signalling is necessary for contraction of smooth muscle cells (32, 33, 69), the distended
milk filled ducts could result from reduced tension in myoepithelial cells. We did observe
some ducts that lacked a complete ring of basal/myoepithelial cells in R blAL/AL sections
(Fig. 31), suggesting that there may be disruption of the myoepithelial layer. Therefore, it
is possible that TGF-p confers a more contractile phenotype on the myoepithelium during
lactation and this is lost in R blAL,AL and R blNF/NF mammary glands.
We have demonstrated that pRB has a much more intimate role in TGF-Pmediated growth arrest than previously anticipated. This interpretation is based on the
fact that TGF-P regulated growth control requires LXCXE interactions. Since Rbl'Amice
are not viable and exhibit numerous proliferative control defects (8, 40, 49) that are
complemented in viable R blAL/Al and R blNF/NF animals, this indicates that pRB-LXCXE
interactions are uniquely needed for a TGF-P cell cycle arrest in a very specific tissue.
We interpret defective repression of E2F responsive genes to be the cause of the TGF-P
arrest defect because pRB is hypophosphorylated after TGF-P stimulation, but transcript
levels of E2F targets remain elevated as the cell cycle continues to advance. The identity
of the exact LXCXE interacting protein(s) that pRB needs to contact in this growth arrest
paradigm is unclear as numerous binding partners have been implicated in chromatin
regulation during transcriptional repression (4, 17, 46, 53, 61, 72, 84). Identifying and
characterizing the co-repressor(s) that cooperate with pRB in response to TGF-P will be
critical to fully understanding how TGF-P inhibits cell proliferation.
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We have demonstrated that pRB has an essential role in growth control of the
mammary gland during development. This study also reveals that pRB is a key
component of TGF-P induced growth arrest because it functions differently in this growth
arrest pathway compared to other pRB-dependent growth suppressing functions in
development. The R blSL and RbJhl mouse strains will be ideal to further advance our
understanding of the mechanism of TGF-P growth arrest in the future.
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Chapter 3: Loss of pRB-LXCXE interactions specifically disrupts TGF-p
proliferative control in mammary epithelial cells

3.1 Introduction
Transforming growth factor-(3 (TGF-P) induces broad cellular effects in vertebrate
development and disease. In epithelial cells, TGF-P signalling on any one target cell is
pleiotropic and potentially regulates many functions, including proliferation, apoptosis,
differentiation, migration, and invasion (28, 38). To date, it has not been possible to
separate the various functions of TGF-P, so the contribution of each of these pathways
during development and disease pathologies remains unclear.
TGF-P can act as a potent inhibitor of cell proliferation in vitro, and loss of this type
of negative growth regulation is thought to be a hallmark of human cancers (14). In some
cancers, such as head and neck, gastric, pancreatic, ovarian, and colorectal carcinomas,
components of the canonical pathway such as the TGF-P receptors or SMAD proteins are
disrupted, resulting in loss of all TGF-P signalling (28). However, in other tumour types,
including breast cancer, downstream targets of the growth regulatory pathway, such as
cyclin dependent kinase inhibitors (CKIs) are deregulated (8, 27, 28). This is thought to
result in the loss of TGF-P growth control, while other morphogenic aspects of its
signalling can drive cancer progression and metastasis (15, 28, 38, 45). Support for this
theory comes from several animal models. In mice expressing a dominant negative type
II TGF-P receptor (dnIIR) in the mammary gland, the entire canonical TGF-p pathway is
disrupted, and when treated with 7,12-dimethylbenz[a]anthracene (DMBA) or crossed to
mice expressing an active form of the Neu proto-oncogene, tumour latency was
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significantly reduced (5, 43). However, the apparent frequency of extravasation to form
lung metastases was also reduced with loss of TGF-|3 signalling in the Neu model.
Conversely, overexpression of TGF-P 1 protects against primary tumour formation
induced by DMBA, overexpression of wild type Neu, or overexpression of active forms
of Neu but drives metastasis in these Neu models of breast cancer (32, 36, 43). The same
holds true in mice expressing constitutively active forms of the transforming growth
factor type I receptor (TpRI) (31, 43). Taken together, these models indicate that some
aspects of TGF-P signalling protect against tumorigenesis. However, these models rely
on manipulating all aspects of TGF-P signalling, and thus cannot conclusively
demonstrate that negative growth regulation by TGF-P acts to protect against tumour
formation and progression. Therefore, there remains a need to validate TGF-p-dependent
proliferative control as a tumour suppressive mechanism.
Previous attempts to address this theory have focused on modulating cyclin dependent
kinase inhibitors (CKIs) such as pl5 INK4b and p21CIP1, which are SMAD-dependent
targets. However, disruption of either CKI alone does not disrupt TGF-P growth control
or result in mammary tumorigenesis in vivo, likely because of functional overlap among
the different CKIs (7, 9, 10, 18, 23, 24, 26, 30, 33). Despite the extensive array of
correlative data suggesting that TGF-P growth inhibition suppresses tumorigenesis, this
model has been difficult to substantiate and the work in this chapter will address this
question.
The activities of these different CKI networks converge upon activation of the
retinoblastoma protein (pRB) (27). I have previously shown that mice with disruption of
the LXCXE binding cleft of pRB (R b l display defective TGF-P growth control in the
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mammary epithelium (11). In contrast, I demonstrate here that other TGF-ß-mediated
processes such as mammary alveolar differentiation and induction of apoptosis during
involution appear unchanged in the mutant mammary gland. Surprisingly, I also
demonstrate that pRB proliferative control does not protect against DMBA-induced
tumorigenesis in RblAL/AL mice. Since this proliferative control relies in part on TGF-ßmediated anti-growth signals, this work raises questions about the importance of TGF-ß
growth inhibition as a tumour suppressive mechanism. Taken together, this work
indicates that TGF-ß growth regulation can be separated from other aspects of TGF-ß
signalling. Furthermore, despite its necessity during mammary gland development, TGFß proliferative control appears to be largely dispensable for protection against
carcinogen-induced tumorigenesis.
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3.2 Materials and methods
Mouse strains and chemical induction of tumours
The R blM' mouse strain has been described previously (19). Analyses of R blAL,AL
mice were performed on a mixed 129/B6 background. Genotyping methods and PCR
primers were provided by the suppliers or are as outlined by Isaac, et al. (See Appendix I)
(19). All animals were housed and handled as approved by the Canadian Council on
Animal Care.
To induce carcinogenesis, mice were treated by oral gavage with lmg/mL of
7,12-dimethylbenz[a]anthracene (DMBA) in canola oil weekly for 4 weeks. Full
necropsies were performed on animals with mammary tumours larger than 2 cm or who
displayed signs of distress, such as weight loss, piloerection, or lethargy.

Immunohistochemistry and immunofluorescence
The second and third thoracic mammary glands were dissected at day post-coital
(dpc) 13.5, the second day of lactation (P2), the second day after pups were weaned (12),
or day 16 after involution (116) (11) and fixed in neutral buffered 10% formalin. Fixed
tissues were embedded in paraffin, cut into 5pm thick sections, and stained with
hematoxylin and eosin (H&E).
To examine apoptosis, pups were removed from lactating females at P2. Two
days post-weaning, females were sacrificed and the second and third thoracic mammary
glands were formalin-fixed. Detection of cleaved caspase-3 was performed as per the
manufacturer’s instructions (9604; Cell Signaling). The total number of cleaved caspase3-positive cells from 10 random fields of view was quantified for each of three mammary
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glands per genotype, and the average number of apoptotic cells per field of view was
calculated for each genotype. Images were captured on a Zeiss Axioskop40 microscope
and Spot Flex camera using Eyelmage software (Empix Imaging, Mississauga, Ontario).

Primary cell culture assays
Mammary epithelial cells (MECs) were harvested and cultured as previously
described (11, 16). Cell culture experiments were carried out on passage one MECs.
TGF-(31 growth inhibition assays were performed as previously described (11).
To examine differentiation in the mammary epithelial compartment, MECs were
harvested from females at dpc 10.5-13.5. Cells were grown to confluence in normal MEC
media (11), and then serum starved in MEC media containing 0.01% adult bovine serum
(ABS) and lacking epidermal growth factor (EGF) for 48 hours. Cells were then induced
to differentiate using MEC media containing 0.01% adult bovine serum (ABS), lpg/mL
hydrocortisone, 5pg/mL prolactin, and lacking epidermal growth factor (EGF), and
supplemented with or without 500 pM TGF-pi for 24 hours. Cells were then harvested
and total RNA isolated using Trizol reagent (Invitrogen). The RNA was converted to
cDNA using the Reverse Transcription System (Promega) as per the manufacturers’
instructions. Quantitative real time PCR (qRT-PCR) was then performed using iQ SYBR
Green Supermix (Bio-Rad) on a PTC-200 Thermal Cycler equipped with a Chromo 4
Continuous Fluorescence Detector, and the data was analyzed using Opticon Monitor 3.1
software (Bio-Rad). qRT-PCR was performed using primers against mouse P-casein and
normalized to Gapdh expression (see Appendix I).
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Migration and invasion assays
Collagen assays were performed in a similar manner as described by Muraoka, et
al. (32). Briefly, MECs were plated onto a collagen bed and grown in MEC media with
0.01% serum and lacking epidermal growth factor (EGF) or insulin for 96 hours. Cells
were then grown in this serum- and growth factor-reduced MEC media supplemented
with or without various concentrations of TGF-pl for 10 days. Cells were photographed
on an Olympus 1X70 microscope.
Scratch wound assays were performed using a protocol modified from Lamouille
and Derynck (25). MECs were grown to confluence in a 24 well plate and then left in the
serum- and growth factor-reduced media outlined above for 96 hours prior to wounding.
Monolayer cells were scratched to create a wound with a p20 or p i000 pipette tip, and
rinsed twice with serum- and growth factor-reduced media to remove debris. Cells were
then treated with serum- and growth factor-reduced media supplemented with or without
various concentrations of TGF-pi for 24 hours. Cells were photographed at 0, 6, 12, and
24 hours on an Olympus 1X70 microscope. Percent of initial wound area was calculated
by measuring the wound area at each time point using Volocity 4 software (Improvision)
and dividing by the initial wound area for three replicates from each treatment group.

Protein and mRNA quantification
pRB expression levels were measured by western blot analysis on nuclear extracts
from R b l+/+, and R b l mammary glands using antibodies against pRB (G3-245; BDPharmingen), and Lamin A/C (MAB3211, Chemicon).
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To measure messenger RNA levels, total RNA was extracted from asynchronous
or TGF-pi treated (lOOpM of TGF-pi for 2 or 24 hours, for Atf3 and Cdkn2b expression,
respectively) MECs as outlined above. qRT-PCR was performed as described above and
levels of mRNA were normalized to those of Actb (encodes P-actin) (see Appendix I).
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3.3 Results
Loss of LXCXE interactions disrupts TGF-ß proliferative control in mammary
epithelial cells
Our lab has previously used the R b l^ knock-in mouse model to disrupt the
LXCXE binding cleft on the retinoblastoma protein (pRB). Disruption of LXCXEmediated interactions results in defective TGF-ß growth arrest of several cell types,
including mammary epithelial cells (MECs). I have previously demonstrated that this
defect occurs downstream of pRB in mutant murine embryonic fibroblasts (11).
However, the mechanisms of TGF-ß growth inhibition are tissue-specific, so it was
essential to first confirm that the TGF-ß anti-proliferative pathway was maintained
upstream of pRB within the mammary epithelial compartment. In MECs, Cdk2nb
(encodes pl51NK4b) is induced by SMAD-dependent transcription, leading to inhibition of
CDKs, hypophosphorylation of pRB, and cell cycle arrest (42). I confirmed that Cdk2nb
expression is induced to equal levels in R bl+/+and R b l MECs (Fig. 3.1a), suggesting
that SMAD-dependent transcription of cell cycle regulatory proteins is functional in
Rb j AL/al

As has been shown previously in MEFs, loss of the TGF-ß proliferative

response is not due to altered expression of pRB in MECs, since pRB levels were not
different in the mammary glands of mice from both genotypes (Fig. 3.1b). These results
complement the previous finding that TGF-ß growth arrest is disrupted in mutant MECs
(11). I have now demonstrated that SMAD-dependent transcription of one of the key
proteins involved in maintaining pRB in a hypophosphorylated, active state in mammary
epithelial cells is functional in R b l MECs. Together with our previous study, this
work demonstrates the importance of pRB for TGF-ß growth control and suggests that

Figure 3.1 Defective TGF-p proliferative control in R

b l u /d

mammary epithelial

cells. (A) RNA was extracted from R b l+/+ and R b l ^ ^ MECs that had been treated with
100 pM TGF-P 1 for 24 hours. The levels of Cdkn2b, which encodes the cyclin dependent
kinase inhibitor plS1™*'41’, were then measured by qRT-PCR. Error bars indicate one
standard deviation from the mean for three MEC pairs. (B) pRB expression levels were
examined by western blot analysis for R b l+/+, R blAU+, and Rbl'^1'41 mammary nuclear
extracts.
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LXCXE interactions are critical for the TGF-|3 cytostatic response in the mammary
epithelial compartment.
TGF-P-dependent differentiation and apoptosis are intact in mutant mice
The growth arrest response is only one aspect of the complex TGF-P signalling
network. While the only known role for pRB is the induction of the TGF-P cytostatic
response, it was possible that pRB disruptions to the LXCXE binding cleft could affect
other TGF-P-dependent pathways. I next determined if other arms of TGF-P signalling
were disrupted by loss of LXCXE interactions in the mammary gland of Rbl mutant
mice. At the molecular level, TGF-P has been implicated in the differentiation of MECs
through activation of ATF3, which, in conjunction with SMAD3, can repress the
Inhibitor of Differentiation 1 (ID1) (22). Atf t message levels were measured by qRTPCR in MECs treated with TGF-P 1. Levels of A tft increased to a similar extent in
R b l+/+ and Rbl‘MjAL MECs, suggesting that this aspect of TGF-P-mediated differentiation
is intact (Fig. 3.2a).
Within the mammary gland, one of the most pronounced periods o f differentiation
occurs during pregnancy, when the epithelial cells differentiate into milk-producing
lobuloalveolar structures. Functionally, TGF-P has been shown to inhibit this process.
Expression of TGF-P family members is downregulated at the end of pregnancy (40), and
mice with constitutive expression of TGF-P 1 in the pregnant mammary gland exhibit
significantly reduced lobuloalveolar formation (21). Conversely, inhibition of TGF-P
signalling in the mammary gland using MMTV-dnIIR results in formation of alveolar
structures in virgin females and the production of P-casein (13). Cell culture studies have
also confirmed that TGF-P inhibits expression of P-casein (6, 29, 39, 44). Using MECs

Figure 3.2 TGF-p-dependent differentiation remains intact in R

b l^ ^

mammary

epithelial cells. (A) R bl+/+ and R b l MECs were treated with 100 pM TGF-pi for
two hours. RNA was then extracted and levels of Atf3 were measured by qRT-PCR. Error
bars indicate one standard deviation from the mean for three MEC pairs. (B) R b l+/+ and
RbjAUAL m e Cs were serum starved for 48 hours and then treated with ethanol (EtOH),
hydrocortisone (1 pM) and prolactin (5 pg/mL) (HP), 500 pM TGF-pi, or HP + TGF-pi
for 72 hours. RNA was then extracted and levels of Csn2 (encodes P-casein) were
measured by qRT-PCR. This trend was confirmed in a second MEC pair. (C) Paraffin
sections of R b l+/+ and R blMJM' mammary glands from pregnant (dpc 13.5) and post
partum females (P2) were stained with H&E to verify differentiation of the mammary
epithelium. Arrows indicate milk-filled alveoli. Scale bar: 100 pm.
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derived from mid-pregnant females, differentiation was stimulated and the effect that
TGF-P had on this process was examined. Stimulation with differentiation media induced
expression of Csn2 (encodes (3-casein) in both wild type and R b l^ '^ MECs (Fig. 3.2b).
Importantly, Csn2 expression was inhibited in cells from both genotypes when TGF-P
was added to the media (Fig. 3.2b). This demonstrates that the role of TGF-P during
hormone-dependent differentiation of MECs is not affected by disruption of the LCXCE
binding cleft. While this is in stark contrast to the pro-differentiation signal induced in the
previous assay, the two experiments recapitulate two known roles for TGF-P (6, 22, 29,
39, 44).
It is possible that the opposing cellular outcomes in the above experiments (pro
or anti-differentiation) result from differences in microenvironment and extracellular
signals in the two assays. Therefore, in order to understand the physiological relevance of
TGF-P differentiation control, I examined the mammary glands of wild type and mutant
females during pregnancy and lactation. Mice from both genotypes underwent a similar
degree of lobuloalveolar formation during pregnancy and had milk-filled alveoli during
lactation (Fig. 3.2c). This is consistent with previous data showing that R b l mice are
able to produce milk with levels of milk protein comparable to wild type females (11).
Together, these data suggest that the TGF-P-dependent effects on mammary epithelial
differentiation are not affected by loss of LXCXE interactions.
TGF-P can also control cell survival in epithelia (15, 28). In the mammary gland,
TGF-P-dependent apoptosis occurs during involution of the post-lactational epithelia (1,
12, 34). To determine if TGF-P-dependent cell death was disrupted in mice lacking
LXCXE interactions, I examined the levels of cleaved caspase-3 in paraffin sections from
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R b l+/+ and R b l ^ ^ 12 mammary glands, a period of extensive TGF-P-mediated
apoptosis. Immunofluorescence staining revealed no difference in cell death between
genotypes (Fig. 3.3a and b). Consistently, histological analysis of paraffin sections from
involuting mammary glands (12) showed the presence of cells being shed into the lumens
of the alveoli during this period, a common characteristic of apoptosis during involution
(Fig. 3.3c) (37). Furthermore, mammary glands from mice of both genotypes had
reverted back to a virgin-like state by 16 days post-weaning (Fig. 3.3c). This is in contrast
to studies where overexpression of TGF-p3 in the mammary epithelium caused aberrant
apoptosis and loss of Tgf-^3 or expression of a dominant negative form of the type II
receptor led to decreased apoptosis during involution (4, 12, 34). These experiments
suggest that apoptosis during involution is unaffected by loss of pRB-LXCXE
interactions. Since this apoptosis is dependent, in part, on TGF-P signalling, it suggests
that TGF-P apoptosis is intact in the R blAL/AL mammary epithelial compartment.
The biological data demonstrates that apoptosis and differentiation occur in an
overtly normal manner in the R b l mammary gland. This was complemented by
molecular studies demonstrating that known roles for TGF-P in differentiation and
apoptosis in mammary cell lines are intact in mutant mammary epithelial cells. In
contrast to the TGF-p cytostatic response, these experiments suggest that TGF-Pdependent differentiation and apoptosis are unaffected by the loss of pRB-LXCXE
interactions in the mammary gland.

Figure 3.3 TGF- (¡-dependent apoptosis is similar in wild type and R b l
mammary glands. (A) Apoptosis in R b l+/+ and R b l mammary glands from females
two days post-weaning (12) was examined by cleaved caspase-3 staining (green) and
counterstaining with DAPI (blue). Scale bar: 10 pm. (B) The average number of cells
stained positive for cleaved caspase-3 per field of view was quantified for each genotype.
Error bars represent one standard deviation from the mean of 30 fields of view for each
genotype. (C) Paraffin sections of R bl+/+ and R b l mammary glands during
involution (12 and 116). Arrows indicate cells shed into the lumen of the ducts, which is
characteristic of apoptosis. Scale bar: 50 pm.
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Invasion and motility occur independently of TGF-0 signalling in primary murine
mammary epithelial cells
Finally, the ability of TGF-P to control motility and invasion in mutant mammary
epithelial cells was examined. Expression of TGF-P has been shown to enhance motility
and invasion of murine mammary epithelial cell lines (3, 25), however this has not been
investigated in primary MECs. To determine the effect of TGF-P on motility of cells
derived from the ductal epithelium, I performed scratch wound assays on wild type and
mutant MECs. These cultures were pre-treated with serum- and growth factor-reduced
media for 4 days prior to wounding and TGF-P 1 treatment so that proliferative effects
would be minimized. Serum starved NMuMG cells normally migrate slowly to fill in a
scratch wound, and the rate of wound healing is increased upon treatment with TGF-P 1
(25). However, a significant difference in the rate of wound closure was not observed
between TGF-pi treated and untreated primary MECs of either genotype (Fig. 3.4a). The
assay was repeated with increased amounts of TGF-p 1, however, this did not
significantly alter the primary observation on wound healing (Fig. 3.4b). The wound size
and time of serum starvation were also varied and differences were not found between the
treatment groups or genotypes (data not shown). Pre-treatment with TGF-P 1 was also
unable to stimulate the cells to migrate into the wound more rapidly (data not shown).
Importantly, TGF-pi induced growth arrest in parallel cultures of the TGF-P-sensitive
HaCaT cell line (data not shown). Because both wild type and R b l cells could not be
stimulated to migrate by TGF-P under any of the above conditions, it appears that
motility may occur independently of TGF-P in primary mammary epithelia.

Figure 3.4 Migration and invasion occur independently of TGF-p in primary
mammary epithelia. The percent of initial wound area was calculated for Rbl*/+ and
R blALAL MECs that were untreated or treated with (A) 2 nM or (B) 5 nM TGF-P over a
24 hour time course. Error bars represent one standard deviation from the mean. (C)
R b l+/+ and R b l MECs were grown in serum- and growth factor-reduced medium on
a collagen matrix supplemented with the given concentrations of TGF-P 1. Representative
micrographs are shown. Scale bar: 100 pm.
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This result is counter to the known TGF-(3-dependent motility demonstrated in
multiple human and mouse immortalized or cancer cell lines. To confirm that motility
and invasion are TGF-P-independent effects in primary MECs, the migration properties
of cells grown on collagen in the presence of TGF-P were tested. When grown on an
artificial extracellular matrix and treated with TGF-[3, cancer cells have been shown to
migrate and form projections into the matrix (32). However, treatment with varying
amounts of TGF-P 1 for 10 days did not affect the migration and invasion potential of
MECs of either genotype grown on collagen (Fig. 3.4c). I interpret this to mean that the
migration and invasion properties of primary MECs are not stimulated by TGF-p. I
further conclude that the general motility and invasive properties are comparable between
wildtype and R bl00^ mammary epithelial cells.
This work suggests that invasion and motility of primary murine MECs is not
dependent on TGF-P signalling. In contrast, primary MECs appear to respond to TGF-Pdependent apoptotic and differentiation signals in a manner consistent with previous
reports on mammary epithelial cell lines. Importantly, using a combination of biological
and functional assays, I have demonstrated that TGF-P-mediated differentiation and
apoptosis take place normally in R blAL!AL mammary epithelial cells. Together with our
previous study (11), these analyses demonstrate that the R bl01 mutation disrupts TGF-P
growth control, but does not appear to cause pleiotropic defects in the TGF-P pathway in
MECs. To the best of my knowledge this is the first time that TGF-P growth control has
been separated from other aspects of TGF-P signalling.
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TGF-p growth inhibition does not protect against DMBA-induced tumorigenesis
Disruption of LXCXE interactions results in defective TGF-(3 proliferative
control, while leaving other TGF-P signalling events intact. A similar phenomenon is
thought to occur during breast cancer progression, where the TGF-P cytostatic response is
severed, leaving pro-tumorigenic functions such as motility, invasion, and epithelial-tomesenchymal transition to drive cancer progression (2, 28, 35). Thus, I next wanted to
address the role of LXCXE interactions during mammary tumorigenesis. Defects caused
by the R b ^ mutation were not sufficient to cause spontaneous tumour formation in the
mammary gland during the natural lifespan of the mice (Fig. 3.5a). Importantly, Rb JZ"dZ'
mice did not develop pituitary or thyroid tumours, which are associated with loss of a
single allele of pRB (Fig. 3.5b) (17, 20). In contrast, R b l ^ ^ mice have a life expectancy
similar to wild type controls and do not display any distinct pathology at time of
euthanasia. However, this does not exclude the possibility that pRB-LXCXE interactions
can protect against mammary tumour formation, since spontaneous mammary
tumorigenesis does not occur in many mouse models of disrupted TGF-P signalling (see
Table 1.1). Instead, a tumour suppressive role for TGF-P in the mammary gland was
established by exposing those mice to carcinogens or using transgenic induction of
mammary tumorigenesis.
To determine if pRB-LXCXE interactions play a tumour suppressive role in the
mammary gland, wild type and R

b females were treated with DMBA. Two previous

reports have examined the role of TGF-P in DMBA-induced carcinogenesis. In the
MMTV-TGF-(}1S223/225 model, mammary cells were protected from DMBA-mediated
tumour formation, while loss of TGF-P signalling using the dominant negative type II

Figure 3.5 R

b

l

mice do not develop spontaneous tumours. (A) Kaplan-Meier

survival curves are shown for Rbl* " , R bl+/', and R b l mice. (B) Photographs of
normal Rbl* * and R b l pituitaries at the time of necropsy. A pituitary tumour from
an R bl+/' control is shown for comparison. Scale bar: 2 mm.
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Figure 3.6 LXCXE interactions do not protect against DMBA-induced
carcinogenesis. (A) Overall survival for all tumour types is shown for both genotypes
(log rank test; P=0.0534). (B) The tumour spectrum from R bl+/Jr and R

b l females

treated with DMBA. SubQ, subcutaneous. (C) Survival of the subset of mice that
developed mammary tumours is shown for each genotype (log rank test; P=0.4558).
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3.4 Discussion
Using the R blAL knock-in mouse, I have revealed several novel findings about
TGF-P signalling. First, by disrupting interactions at pRB’s LXCXE binding cleft, I
provide evidence that TGF-P growth control can be separated from other aspects of its
signalling such as apoptosis and differentiation in mammary epithelial cells. I also
demonstrate that migration of primary mammary epithelia in culture occurs via TGF-(3independent mechanisms. Finally, I report the striking finding that LXCXE interactions
are not required for suppression of DMBA-induced carcinogenesis. By extension,
because TGF-P proliferative regulation is disrupted in this model, this work argues that
other aspects of TGF-P signalling may be more important than negative growth control
for TGF-P-mediated tumour suppression for DMBA-driven tumorigenesis.
TGF-P can act as a strong inducer of motility and invasion in a variety of cell
types. To determine if this aspect of TGF-P signalling was intact in the mutant mammary
gland, I performed scratch wound and collagen assays on R bl++and R b l MECs.
Surprisingly, primary wild type mammary epithelial cells treated with TGF-P 1 did not
show an increase in motility in either the scratch wound or collagen assays compared to
untreated controls. It is possible that the TGF-P 1 used in the assay had lost its biological
activity, and that is why no effect was seen. I do not favour this possibility because
different aliquots of TGF-P 1 from the same lot were able to induce a growth arrest signal
in HaCaT cells. Furthermore, TGF-P 1 did stimulate expression of Atf3 in both wild type
and R

b l cells, suggesting that the TGF-pi used in these assays were biologically

active. It was also possible that more TGF-pi is required to induce TGF-P-dependent
motility than a growth arrest response. To test this theory, cells were treated with varying
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concentrations of TGF-P in both experiments, yet this did not elicit a response in wild
type cells, even at the highest concentrations. Instead, I hypothesize that primary cells
respond differently to TGF-P invasion and motility cues than cells from established
immortalized cell lines. A comparison of primary mammary epithelial cells versus
NMuMG cells in motility and invasion assays may clarify this situation. However, using
a combination of functional and biological assays, I have shown that differentiation and
apoptosis, which are regulated in part by TGF-p, are intact within the R blAlAL mammary
gland. I cannot entirely rule out the possibility that some morphogenic signals transmitted
by TGF-P family members are lost or reduced in the RblAL/AL mutant mice. However, I
interpret the phenotypes of R b l mice as the first proof of principle that TGF-P’s cell
cycle arrest signals and other morphogenic signals are separable.
To examine the role of LXCXE interactions in tumorigenesis, I used a chemical
model of tumour induction. DMBA has been used extensively to induce mammary
tumorigenesis in mice and rats. Surprisingly, DMBA-treated mice developed a wide array
of tumours but only a small proportion was mammary in origin. It is possible that
differences in mouse strain or dosage schemes resulted in the low number of mammary
tumours in this study. It was also surprising that the overall tumour latency was
unchanged in the mutant mice compared to wild type controls. One interpretation of this
result is that RbM confers protection against DMBA. Saenz-Robles, et al. have shown
that epithelial cells expressing the SV40 Large T antigen (TAg) contain significantly
lower amounts of mRNA for several drug metabolizing/detoxifying enzymes (41). This
effect depends on an intact LXCXE motif in TAg, suggesting that pRB plays a role in
drug metabolism in an LXCXE-dependent manner. Therefore, it is possible that loss of
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LXCXE interactions disrupts expression of cytochrome P450 enzymes that metabolize
DMBA into its more carcinogenic form. This could counter the loss of proliferative
control in R b l ^ ^ mice and mask a tumour suppressive role for the LXCXE binding
cleft. Future studies examining the levels of various drug metabolizing enzymes in wild
type and R b l animals may shed light on this possibility.
An alternative interpretation is that TGF-P growth control is dispensable for
tumour suppression in the DMBA model. Overexpression of TGF-p 1 in the mammary
gland has been shown to protect against DMBA tumour formation (36). Conversely,
DMBA has been shown to induce mammary tumours with a shorter latency in mice
expressing a dnIIR in the mammary gland (5). In that study, all aspects of the TGF-P
signalling pathway were lost, but the more aggressive phenotype was attributed to loss of
TGF-P’s ability to induce a cell cycle arrest. In contrast, TGF-P growth control was the
only aspect of TGF-P signalling disrupted in the mammary gland of the Rbl

mice,

yet tumorigenesis was not enhanced. This suggests that other aspects of TGF-P
signalling, such as apoptosis and differentiation may play stronger tumour suppressive
roles than the cytostatic response. Future studies looking at the role of these aspects of
TGF-P signalling in isolation will help to clarify their specific roles in tumour
suppression and/or progression.
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Chapter 4: The role of proliferative control by the retinoblastoma protein in
mammary cancer and metastasis

4.1 Introduction
Cellular proliferation is a tightly regulated process and the loss of responsiveness
to negative growth signals is a hallmark of cancer cells (16). This is especially evident in
the breast, where epithelial cells undergo constant fluctuations in proliferation,
differentiation, and apoptosis during the menstrual cycle and as a result of pregnancy
(17). Tight growth control of the mammary epithelial compartment is crucial, and
disruptions to the balance of mitogenic and anti-growth signals can leave this highly
proliferative tissue susceptible to the formation of cancer (27, 39). Therefore, delineating
how proliferative control of breast epithelial cells is lost during tumour formation is
essential to understand the pathogenesis of breast cancer.
The decision for a somatic cell to remain quiescent or re-enter the cell cycle is
coordinated by the retinoblastoma protein (pRB) pathway (27, 39). In response to
mitogenic signals, pRB is inactivated by cyclin dependent kinase (CDK) complexes by
phosphorylation. Simultaneously, growth inhibiting signals can activate pRB by
blocking cyclin dependent kinase activity through the actions of cyclin dependent kinase
inhibitors (CKIs) such as pl5INK4b, p\6™K4a, p21CIP1, and p27KIP1 (27, 40). In cell culture,
disruption of an individual CKI, such as p21clpl, can result in deregulated proliferation
despite signals from negative growth regulatory stimuli such as DNA damage (4, 5).
However, this does not cause a complete loss of responsiveness to double stranded DNA
breaks, and residual growth inhibition in the absence of p21CIP1 suggests that there is
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redundancy amongst the Ink4 and CIP/KIP protein families (5). Indeed, negative growth
regulators such as transforming growth factor p (TGF-P) are capable of inducing a cell
cycle arrest in the absence of any one of these CKI proteins (13, 19, 29, 31). Furthermore,
individual ablation of these genes in mice has no effect on viability and is accompanied
by surprisingly few developmental abnormalities. Interestingly, each knockout mouse
strain develops tumours in a specific subset of tissues, but none of these mice develop
mammary tumours (9, 12, 21-24, 31,38). This is surprising because pRB pathway
components such as cyclin D are commonly amplified and pRB itself is sometimes lost in
human breast cancers and these are direct targets of CKI regulation (2, 3, 11, 32, 37).
Thus, even though the current body of literature suggests that anti-proliferative effects
greatly influence mammary epithelium, mouse models reveal layers of complexity and
variation that make it challenging to understand how negative growth responses protect
mammary epithelial cells from aberrant proliferation.
Activation of pRB is the last opportunity to arrest proliferation in G1 and avoid
inappropriate cell cycle entry (27). Breast epithelial cells frequently respond to anti
growth signals from DNA damage, exogenous growth factors like TGF-(3, and other
cellular stresses. All of these serve to activate pRB and induce cell cycle arrest in the G1
phase (43). Using a knock-in mouse model (R b l^) with a discrete defect in its growth
suppressive pocket domain that eliminates interactions with LXCXE-motif containing
proteins, we have demonstrated the importance of pRB in proliferative control during
mammary gland development (14). Loss of LXCXE interactions prevents pRB from
recruiting co-repressors, such as histone deacetylases, to E2F responsive promoters. This
results in an inability to silence transcription and in turn causes defects in proliferative
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control, including insensitivity to TGF-(3 and senescence cues (14, 42). Furthermore, cells
from these mice fail to arrest proliferation in response to ectopic expression of the CKI
proteins p l6 rNK4a and p21CIP1, suggesting that there are likely additional negative growth
signals to which cells from these mice are resistant (14). In the mammary gland, this
results in hyperplasia of the mammary ductal epithelium (14), a known risk factor for
human breast cancer (10, 35). Since pRB-dependent negative growth control is reduced
in the mammary glands of R b l^ mice, it provides us with a unique opportunity to
examine the function of proliferative control in mammary cancer and metastasis.
In order to understand the role of pRB LXCXE-dependent proliferative control
during mammary tumour formation and progression, I have crossed our mice with a Wapp53R,72H transgenic strain. Wap- p53RI72H; R b l females developed mammary tumours
more frequently and at a faster rate than control mice. In many cases these animals also
developed metastases. In contrast, co-expression of Neu and Rbl2^ did not accelerate
mammary tumour progression or metastasis. Our data indicate that pRB LXCXEdependent proliferative control forms a barrier to primary tumour formation.
Surprisingly, the contrasting data between the two transgenic mammary tumour models
indicates that the response to negative growth signals by pRB is context-dependent.
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4.2 Materials and Methods
Mouse strains
The R b l^ mouse strain has been described previously (20). Analyses of RblAL/AL
mice were performed on a mixed 129/B6 background. Wap-p53RI72Hmice were obtained
from the Mouse Models of Human Cancer Consortium on an FVB background. These
mice express the p53R172H mutation driven by the whey acidic protein (Wap) promoter
(25). These mice were bred to the R bl41 mutation, creating a mixed 129/B6/FVB genetic
background. Wap-p53RI72H; R b l+/+and Wap-p53RI72H; R b l ^ females were bred
through five or six rounds of pregnancy to induce expression of p53

. Live pups were

removed at P2 to allow equivalent timing of transgene expression between genotypes.
Tg(MMTVneu)202Mul mice express the wild type form of the rat Neu oncogene driven
by the murine mammary tumour virus promoter (MMTV) (15). These mice were obtained
from Jackson Labs on an FVB background and were bred to the R b l^ mutation, creating
a mixed 129/B6/FVB genetic background. Genotyping methods and PCR primers were
provided by the suppliers or are as outlined by Isaac, et al. (20)(Appendix I). All animals
were housed and handled as approved by the Canadian Council on Animal Care.
Histology and mammary whole mounts
Full necropsies were performed on tumour-bearing animals after 60 days or at the time
of euthanasia. Mammary tumours, lung tissues, and any other tissues that appeared
abnormal were fixed in formalin and sectioned as previously described (14). The mitotic
indices were manually counted in 5 high-power fields of view (400x) for mammary
tumours from each genotype. Lung métastasés were identified by gross morphological
analysis (surface métastasés) and microscopic analysis (micro métastasés). Percent
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metastatic surface area (SA) was calculated by measuring the total two dimensional area
occupied by lung metastases in five hematoxylin and eosin (H&E) stained lung sections,
divided by the total area of the lung in these sections using Volocity 4 software (Perkin
Elmer, Waltham, MA). Analysis of hyperplasia in H&E stained sections of R blAL/+
mammary glands, as well as Neu expressing mammary glands, was performed as
described previously (14). For whole-mount analysis, unaffected mammary glands from
tumour-burdened mice were removed, mounted on glass slides, and stained with Carmine
Red using standard techniques.
Primary cell culture assays
Mammary epithelial cells (MECs) were harvested and cultured as previously
described (14, 18). Cell culture experiments were carried out on passage 1 or 2 MECs.
TGF-pi growth inhibition assays were performed as previously described (14).
Soft Agar Colony Formation Assay
R b l+/+and R blAL/AL mouse embryonic fibroblasts (MEFs) were retrovirally
transfected with the pLXSN dominant negative (dn) p53/RasV12 virus as previously
described (33, 36). Infected cells were then grown in soft agar according to standard
protocols (8). Cells were allowed to grow for 2 weeks, at which time colonies were
photographed and counted. The cut-off for scoring a colony as transformed was that its
size needed to correspond with the volume of at least 5 cells (as judged by neighbouring
single cells). In this way we were confident that these colonies represented multiple cell
divisions.
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4.3 Results
pRB-LXCXE interactions act as an initial barrier to tumour formation
Our lab has previously generated a knock-in mouse model (R b l^) to disrupt the
LXCXE binding cleft on the retinoblastoma tumour suppressor protein (pRB) (20). Loss
of LXCXE-dependent interactions disrupts proliferative control in the mammary gland
during development, leading to hyperplasia of the ductal epithelium that is ubiquitously
detectable in virgin animals between four and 16 weeks of age (14). Surprisingly, the
R b l^ mutation alone does not predispose mice to mammary cancer (14). Since
hyperplasia of ductal epithelia is considered a risk factor for human breast cancer (10,
35), I postulated that LXCXE interactions play a tumour suppressive role in the
mammary gland when combined with other oncogenic changes. To explore this
possibility, a soft agar colony assay was performed using R bl++ and Rbl^ ^ mouse
embryonic fibroblasts infected with a dominant negative form of p53 and an oncogenic
allele of Ras (pLXSN dn p53/RasV12) (33). This dominant negative form of p53 has been
shown to cooperate with Ras to form colonies in soft agar, and loss of LXCXE
interactions led to an increase in the number of colonies formed (Fig. 4.1a, b). Rbl
colonies were also larger than control colonies (Fig. 4.1a), suggesting that cells lacking
LXCXE interactions were able to transform earlier. This provided preliminary evidence
that LXCXE-dependent anti-proliferative effects can protect cells from oncogenic
transformation.
To validate that LXCXE interactions can play a tumour suppressive role in the
mammary gland, I crossed our mice into the Wap-p53

background. Wap-p53

a dominant negative form of p53 driven by the whey acidic protein promoter, which is

is

Figure 4.1 The R b lM mutation confers sensitivity to oncogenic transformation. (A)
MEF cells corresponding to the indicated genotypes were transduced with retroviruses
expressing dominant negative (dn) p53 and RasV12 and plated in soft agar to allow
colonies to form. Photomicrographs were taken after a two-week growth period. Scale
bar: 200 pm. (B) The percentage of wild type and mutant cells that transformed and grew
into a colony was calculated from five randomly photographed microscopic images. A
cell was counted as transformed if it formed a colony whose size appeared to be at least 5
cells. * indicates a statistically significant difference (Student’s t test; P<0.005). Error
bars indicate one standard deviation from the mean for at least three replicates.
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expressed in the mammary gland during pregnancy and lactation. Cohorts of Wapp53RI72H; R b l+/+ and Wap-p53R,72H; RblAL/AL females were bred through five rounds of
pregnancy in order to induce transgene expression (Fig. 4.2a). Since R blAL,AL females are
frequently unable to nurse their pups (14), all live pups were removed two days after birth
•

R 1 7014

to ensure consistent timing of transgene expression between genotypes. Wap-p53

expression leads to genomic instability (25, 26), so I reasoned that expression of Wapp53R172H during pregnancy and lactation would create random mutations. I expected that
some of these mutations would drive tumorigenesis later, after the transgene was turned
off, and this would allow us to assess how a diminished response to negative growth
regulators affects mammary tumorigenesis. Both Wap-p53R,72H; R bl+/+ and Wapp53RI72H; R b l females developed high grade mammary adenocarcinomas,
characterized by high cytological variability. Many cells exhibited large cellular and
nuclear size and tumours from both genotypes displayed high rates of mitosis (Fig. 4.2b,
c), which is comparable to other studies using Wap-p53

mice (25, 26).

While mice from both genotypes developed similar types of tumours, I did find an
increased frequency of tumour formation in Wap-p53RI72H; RblAL/AL females. 63.6% of
Wap-p53R,72H; R blAL/AL females compared to 44.4% of Wap-p53RI72H; R b l++females
developed tumours over the course of the study. Importantly, loss of LXCXE interactions
in the Wap-p53R,72H background resulted in a statistically significant decrease in tumour
latency (Fig. 4.2d) (Log rank test, /*=().0238). Like the data from our soft agar colony
assay, this suggests that LXCXE-dependent proliferative control can act as a barrier to
tumour initiation. To explore this concept further, I examined tumour-free mammary
glands from our tumour-burdened mice. Some mammary glands had extensive

Figure 4.2 pRB-LXCXE interactions protect against tumour formation caused by
the

W a p - p 5 3 RI72H

transgene. (A) Experimental outline for the Wap-p53RI72H tumour

study. Mice were bred through five rounds of pregnancy (thin arrows) to transiently
induce p53RI72H expression within the mammary gland. After the fifth pregnancy, males
were removed and females were palpated weekly to monitor tumour formation. Median
tumour-free survival for each genotype is marked with the colored arrows. (B)
Representative H&E stained paraffin sections from tumours harvested from Wapp53RI72H; R b l+/+ and Wap-p53R,72H; R blALAL mice. Arrows indicate mitotic figures. Scale
bar: 50 pm. (C) The mitotic index for Wap-p53RI72H; R b l++and Wap-p53Rn2H; Rbl
mice is indicated, along with the average mitotic index for each genotype. Values were
derived by quantifying the number of mitotic figures in five random fields of view for
each mouse. (D) Kaplan-Meier graph of mammary tumorigenesis is shown for Wapp53R,72H; R b l+/+ and Wap-p53R,72H; R blALAL females (log rank test; P=0.0238). Values
in brackets indicate the number of mice that developed tumours.

O

Mitotic figures

t/* iW :Hzu»CSd-deM ■

TvnvWU

+/+WV

■^1
to
cn
o
ui
____cn
i_____i____
_i
3II

◄<
<

3II
cn

Tumour-free survival (%)
◄■

II

1O« 1pi
Co

» Coa
1 „1
Cr cr

3

o

II 3—
II
-A
-* oo4
3 5°

O
IsJx

163

lobuloalveolar development, preventing an assessment of abnormal proliferation by
whole mount staining. However, among the remaining necropsied animals, I examined
glands where tumours were not palpable, and discovered that there was an increase in the
number of hyperplastic lesions in the Wap-p53R,72H; R blAL/AL mice (Fig. 4.3). Together
with the increased frequency of tumours and shortened timing of tumour onset in Wapp53R,72H; R

b l females, these data indicate that LXCXE-dependent growth control

acts as an initial barrier to tumour formation in the mammary gland and loss of LXCXE
interactions leaves cells vulnerable to oncogenic transformation.
The data from our Wap-p53RI72Hcross revealed that LXCXE interactions can act
as an important barrier to tumour formation. I next asked whether loss of LXCXE
proliferative control could also affect the formation of métastasés at secondary sites. Both
Wap-p53RI72HR b l+/+ and Wap-p53RI72H; R b l tumours were able to metastasize to
the lungs, and there were no major differences in the appearance of the métastasés, or the
number, or size of these métastasés (Fig. 4.4). Of note, one female from the Wapp53RI72H; Rbl ALAI' cohort developed a metastasis in the spleen and had extensive
colonization of the lungs (Fig. 4.4). However, there were generally no major differences
in metastatic potential between the two genotypes. Coupled with the primary tumour
data, I conclude that reduced responsiveness to negative growth signals likely has a
limited role in tumour progression and metastasis, but functions as a barrier to tumour
initiation at a very early stage in cancer pathogenesis.
LXCXE interaction-dependent anti-tumorigenic effects are context-dependent
The advantage of the Wap-p53RI72H model is that it introduces random mutations
into the genome and this creates a selection for mutations that can cooperate with defects

Figure 4.3 Hyperplastic nodule formation in the Wap-p53RI72H background. Carmine
Red-stained mammary whole mounts from tumor-free glands in mice that had mammary
tumours are shown for both genotypes in the Wap-p53RI72H background. Arrows indicate
hyperplastic nodules and LN indicates lymph nodes. Scale bar: 2 mm. The number of
hyperplastic nodules in each whole mount section was also quantified for each genotype
along with the average number of hyperplastic nodules.
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Figure 4.4 Métastasés form in the Wap-p53RI72H; J?67+/+and Wap-p53R172H; Rbl
mice. (A) Representative H&E stained paraffin sections of lungs harvested from tumourburdened mice of each genotype. M denotes metastasis, and L denotes neighbouring lung
tissue. Scale bar: 100pm. (B) The surface area (SA) occupied by lung métastasés relative
to the total lung area in tissue sections was quantified for mice from each genotype along
with the average SA. Values in brackets indicate the number of mice that developed
métastasés and f indicates a female that developed métastasés to both the lung and
spleen.
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found in R blAL/AL mice. However, this also prevents us from knowing what the initiating
oncogenic mutations were and how they engaged negative growth responses that activate
a pRB-LXCXE-dependent arrest. For this reason I also used a transgenic line that
expresses a dominantly acting oncogene so that the origin of oncogenesis would be
known. To determine how pRB-dependent responses to negative signals affect mammary
tumorigenesis in this context, I crossed our mice into the Tg(MMTVneu)202Mul (herein
referred to as Neu) background, where expression of the rat version of the Neu proto
oncogene is driven by the MMTV promoter. These mice normally develop focal
mammary tumours with a high rate of metastasis to the lung (15). This transgenic line
was chosen because Neu is known to activate the Ras pathway (7) and our data in Figure
4.1 indicates that pRB-dependent growth arrest opposes it. Furthermore, the Neu mouse
has been used extensively to examine the influence of TGF-P on tumorigenesis.
Expression of active forms of Neu in mice with disrupted TGF-P signalling results in
reduced tumour latency (41). Conversely, when crossed to mice that overexpress TGF-P
or a constitutively active receptor, primary tumour formation is delayed or tumour growth
is slowed (30, 41). This anti-tumour effect is commonly attributed to TGF-P-induced cell
cycle arrest although this aspect of its signalling has not been testable in isolation before
now. In these same mice, activation of the TGF-P pathway leads to increased metastasis
to the lungs, presumably because pro-tumorigenic aspects of TGF-P signalling such as
epithelial-to-mesenchymal transition, migration, and invasion drive the metastatic
cascade (28, 30, 34, 41).
Since TGF-P is a key regulator of proliferation in the mammary epithelial
compartment and induces a G1 arrest in a pRB-dependent manner, I next wanted to
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characterize the Neu; RbI A, AI‘ genotype to ensure that this experimental system would
allow us to address the role of negative growth responses during tumorigenesis as I
expected. To this end I tested R b l+/+, RblAUALi and R b l^ +mammary epithelial cells
(MECs) for their ability to respond to TGF-P-induced Gl arrest (Fig. 4.5a). This
confirmed our previous results that TGF-P’s cytostatic response is vastly diminished in
^

j Al al ce|js

Surprisingly, R blAL/+MECs have a similar defect in TGF-P growth

control, indicating that mutation of only one copy of Rbl is sufficient to abrogate its
arrest mechanism. Consistent with this observation, examination of mammary epithelia
in R blAU+ virgin female mice revealed they have a similar degree of hyperplasia as we
have previously reported for R bl^ ^ mice (Fig. 4.5b). I also examined the mammary
glands of 8 week old Neu mice combined with each Rbl genotype in the 129/B6/FVB
background (Fig. 4.5c). Expression of Neu raised the basal level of hyperplasia in these
mice. However, the complete loss of LXCXE interactions in R b l mice still
exacerbated this phenotype. This confirmed that the proliferative control defects caused
by the R b l^ mutation, which led to hyperplasia of mammary epithelia, are present in
these experimental animals too.
To assess the importance of LXCXE-dependent negative growth control in
suppression of primary tumour formation and growth, I followed cohorts of Neu; Rbl ++,
Neu; R blAL/+ and Neu; R

b l females throughout their natural lives and palpated them

weekly to determine the onset of mammary tumour formation. Unfortunately, the long
latency before tumour formation resulted in excessive grooming in many of our mice and
the need to euthanize them before palpable tumours formed. This was particularly true of
the Neu; R blALAL mice. However, the Neu; RblAL/+ animals

Figure 4.5 Defective TGF-0 proliferative control in R b l ^ ^ and R b lAL/+ mice. (A)
R bl+/+, R blAL+, and R b l mammary epithelial cells were treated with TGF-pi and
pulse-labelled with BrdU 24 hrs later. The percentage of cells incorporating BrdU was
measured by immunofluorescence microscopy. The fold decrease in proliferation
between treated and untreated parallel cultures was determined and the average of three
independent experiments is shown. * indicates a statistically significant difference from
wild type (Student’s t test; P<0.05). Error bars indicate one standard deviation from the
mean. (B, C) H&E staining of paraffin sections of (B) R bl+/+, R bl^ a n d R b l and
(C) Neu; Rbl +/+, Neu; R blAL+, and Neu; R b l mammary tissue from 8 week old
mice. Each image displays a representative cross section of ducts. The table below
displays the proportion of hyperplastic (hp) ducts found in R bl+/+, R blAL/+, and Rbl
mammary glands. Proportions were compared between genotypes using a chi-square test.
Scale bar: 100 pm. f denotes previously published data that has been provided for
comparison purposes.
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Genotype
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455
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have a similar response to TGF-P, indicating that they offer an equally valid means to
address how negative growth signals impact tumorigenesis in this transgenic model. In
stark contrast to the Wap-p53RI72H; RblAL/AL mice, there was no difference in tumour
latency between the remaining Neu; R b l ^ ^ females or the Neu; R b l' and Neu;
RblAL/+females (Fig. 4.6a). The frequency of tumorigenesis in the Rbl mutant genotypes
was also relatively unchanged from wild type (85.7% for RblALAL and 77.4% for RblAL/+
vs. 90% for wild type).
This result suggests that negative growth regulatory signals do not significantly
influence cancer pathogenesis in Neu transgenic mice. Because this was unexpected, I
also investigated other tumour characteristics to determine if the Rbl mutant genotypes
altered the tumour type of these mice in such a way that the direct comparison in Figure
4.6a is misleading. To this end, I classified the tumours histologically and discovered
that they all fit the characteristics of solid or acinar carcinomas that have been reported
previously for Neu mice (Fig. 4.6b) (6). Our expectation from the Wap-p53RI72H cross is
that negative growth responses are most important at the initiation step. However,
Muraoka et al. found that overexpression of TGF-P did not affect tumour latency of Neu
mice, but instead reduced tumour proliferation (30). For this reason I measured the
number of mitotic figures in five randomly selected microscopic fields for each tumour as
a means to compare proliferation and this revealed no significant differences (Fig. 4.6c).
Furthermore, there were no significant differences in the final tumour volume (Fig. 4.6c).
Lastly, I investigated unaffected mammary glands from tumour burdened animals for
evidence of premalignant nodules by whole mount preparations. Again, there were no

Figure 4.6 Loss of pRB-LXCXE interactions does not affect Aten-driven
tumorigenesis. (A) Onset of mammary tumorigenesis is shown for the indicated
genotypes (log rank test; P=0.6788). Values in brackets indicate the number of mice that
developed tumours. (B) Representative H&E stained paraffin sections from tumours
harvested from Aten; R b l+/+, Neu; R blAU+, and Aten; RblSJAI~mice 60 days after initial
tumour palpation. Arrows indicate mitotic figures. Scale bar: 50 pm. (C) The mitotic
index and final tumour volumes for Neu; Rbl /f, Neu; R blAL/+, and Neu; R blALAL mice
are indicated, along with the average values for each genotype. Mitotic indices were
derived by quantifying the number of mitotic figures in five random fields of view for
each mouse. Final tumour volume was calculated using the formula V=0.52xW xL. (D)
Carmine Red-stained mammary whole mounts from tumour-free glands in mice that had
mammary tumours are shown for the given genotypes. Arrows indicate hyperplastic
nodules and LN indicates lymph nodes. Scale bar: 2 mm. The number of hyperplastic
nodules in each whole mount section was also quantified for each genotype along with
the average number of hyperplastic nodules.
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statistically significant differences between the three Rbl genotypes and, if anything,
there was a trend toward fewer nodules in mice bearing the R b l^ mutation (Fig. 4.6d).
In an effort to better relate the combination of the Wap-p53R,72H and Neu
transgenes with our Rbl mutant, I also investigated metastasis in Neu; Rbl * \ Neu;
RblAL/+ and Neu; R b l11 ^ female mice. This revealed that the number of lung surface
metastases that formed during the 60 day period from initial palpation to euthanasia were
relatively similar (Fig. 4.7a). Furthermore, these metastatic lesions occupied a similar
proportion of lung volume when quantified microscopically in lung sections (Fig. 4.7b).
Lastly, there were no differences in histology between metastases from the respective
genotypes (Fig. 4.7c). From these experiments it is clear that the R b l^ allele does not
enhance the metastatic potential of mammary tumours whether they form in the Neu or
Wap-p53R,72H backgrounds.
This reveals that pRB-LXCXE interactions can confer responsiveness to negative
growth signals that protect against p53R172Htumorigenic effects, but surprisingly, they
cannot protect against 7Vew-driven oncogenesis. By extension, since one aspect of
LXCXE-dependent proliferative control is linked to the TGF-P cytostatic response (Fig.
4.5) (14), and TGF-P has been shown to protect against jVew-driven mammary
oncogenesis (30, 41), this suggests that TGF-P’s other tumour suppressive functions may
be most important in this cancer model (1, 28). Regardless of the explanation for the
differential sensitivity of these mouse models of breast cancer to our Rbl mutation, these
data reveal that the ability of pRB to arrest proliferation in response to negative growth
signals is highly context-dependent.

Figure 4.7 Loss of pRB-LXCXE interactions does not affect metastatic potential in
Neu mice. (A) The number of lung surface metastases (LSM) was quantified for
individual mice and plotted along with the average number of LSM per genotype, f
indicates lungs with >59 LSM and %indicates a lung where each of the two metastases
encompassed an entire lobe. (B) The SA occupied by lung metastases relative to the total
lung area in tissue sections was quantified for mice from each genotype along with the
average SA for each genotype. (C) Representative H&E stained paraffin sections of lungs
from tumour-burdened mice are shown for each genotype. Scale bar: 100 pm.
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4.4 Discussion
Using two transgenic mouse models of breast cancer, I have examined the
importance of pRB-LXCXE interactions during cancer formation and progression. Our
work has revealed that LXCXE-dependent proliferative control can act as a barrier to
tumour formation in the mammary gland. Surprisingly, this anti-oncogenic effect is
context-dependent, protecting against Wap-p53R,72H- induced tumour formation, while
having no effect in the Neu transgenic background.
Our experiments utilize the Wap-p53RI72Hmodel differently than in previously
published studies. Specifically, these mice display very low levels of spontaneous
tumorigenesis during the first year of life (25). As a result, previous investigators have
coupled expression of the transgene with other oncogenic stimuli such as DMBA or the
Neu oncogene (25, 26), to rapidly induce tumorigenesis. In contrast, I did not experience
the robust enhancement shown in these reports. I envision two possibilities to explain
these differences that are not mutually exclusive. First, the R blAL mutation and its effects
on proliferation may be more subtle than DMBA or Neu. Indeed, the R blAI mutation
alone does not cause cancer (14, 42). Alternatively, our experiments were performed in a
mixed 129/B6/FVB background and this may have delayed tumour induction. However,
our experimental design, in which tumour onset was relatively late, created an
opportunity for our Rbl mutation to enhance the Wap-p53RI72Hcancer phenotype. This
longer latency period may have also permitted the opportunity to compare metastatic
disease in Wap-p53R172H; R bl+/+ and Wap-p53RI72H; R b l mice.
The precise pRB-LXCXE-dependent anti-proliferative mechanism that protects
against Wap-p53R,72H driven tumours is unclear since mutant p53 acts as a random
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generator of mutations that drive tumorigenesis almost a year after the transgene has been
silenced. Loss of TGF-0 growth regulation is an attractive candidate since it is a potent
inhibitor of cell proliferation in the mammary gland and it induces cell cycle arrest in an
LXCXE-dependent manner (14). However, tumour incidence in the Neu background
suggests that the TGF-P cytostatic response may not be the reason that TGF-P is tumour
suppressive in mouse models of mammary cancer. For this reason, loss of TGF-Pdependent growth arrest may not be the defect that allows more rapid mammary tumour
formation in Wap-p53RI ,2H; RblAL'AL mice. Other possibilities for why the R b l^ mutation
cooperates with the Wap-p53RI72H transgene in tumour initiation are that R blM Al cells
also fail to arrest in response to cellular stresses like DNA damage and oncogene induced
senescence (42). Future experiments to better elucidate this question will include crosses
to transgenic strains that challenge these specific anti-proliferative pathways to ascertain
their importance in pRB’s tumour suppressor function.
Regardless of the exact mechanism of anti-proliferative control that is responsible
for the enhanced cancer phenotype in Wap-p53RI72H; R blALAL mice, I have demonstrated
that pRB plays a critical role in protecting mammary epithelial cells from oncogenic
transformation. This tumour suppressive role depends on the ability of pRB to make
contacts at its LXCXE binding cleft, suggesting that recruitment of co-repressors to
silence E2F target gene expression is key to blocking tumour formation. Interestingly, our
work suggests that the role of proliferative control in cancer pathogenesis may be more
complicated than previously thought. Unresponsiveness to negative growth signals is
described as a hallmark of cancer, implying a ubiquitous need for it to be eliminated
during tumorigenesis (16). But how extensive a defect in responding to external cues is

180

required? For example, some cancer derived cell lines that are pRB deficient reliably
growth arrest as monolayers in culture. This suggests that in the absence of pRB, some
growth arrest signals can be retained and are compatible with tumorigenesis. The
molecular context that dictates the requirement for pRB-dependent growth arrest, versus
other proliferative control mechanisms, in preventing cancer initiation is unknown.
Coming to an understanding of what these factors are in vivo will greatly influence our
understanding of proliferative control in cancer, and will undoubtedly impact the
classification and treatment of cancer.
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Chapter 5: Summary and Perspectives

5.1 Summary of Findings
As highlighted in this thesis, pRB proliferative control is essential for TGF-P
growth inhibition and mammary gland development. Furthermore, pRB plays a contextdependent role in tumour suppression. In chapter 2 ,1 demonstrated that loss of LXCXE
interactions results in a nursing defect and hyperplasia of the mammary ductal
epithelium. Because these phenotypes are similar to those described for mice lacking a
functional TGF-P pathway, I next examined if disrupting LXCXE interactions affected
TGF-P growth inhibition. Mutant forms of pRB were unable to induce a proper TGF-P
growth arrest, and this contributed, in part, to the hyperplastic phenotype in vivo. Finally,
I demonstrated that this defect occurs downstream of pRB in the TGF-P signalling
pathway, and results in the disruption of E2F target gene regulation.
These data suggested that the cytostatic arm of TGF-P signalling is disrupted with
loss of pRB-LXCXE interactions. However, I next wanted to know if other aspects of
TGF-P signalling were intact in the R b l ^ ^ mice. In chapter 3, a combination of
molecular and biological assays was used to demonstrate that TGF-P-mediated apoptosis
and differentiation are intact in the R blALAL mammary gland. Interestingly, invasion and
motility of primary murine mammary epithelial cells appear to occur independently of
TGF-P signalling. Together, these data suggest that only TGF-P growth control is
affected by loss of pRB-LXCXE interactions.
Finally, knowing that loss of LXCXE interactions disrupts proliferative control in
the mutant mice, I sought to understand if this was an important aspect of pRB tumour
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suppression. Because the pRB and TGF-ß cytostatic responses are linked, this also
allowed me to address the importance of TGF-ß proliferative control as a tumour
suppressive mechanism. Using three mouse models of breast cancer, I demonstrated that
pRB proliferative control can block tumour initiation in the mammary gland. However,
this effect is context-dependent, because loss of pRB-LXCXE interactions did not change
the tumour latency in Neu mice or mice treated with DMBA. Furthermore, since TGF-ß
has been shown to protect against tumorigenesis in these two contexts (39, 43, 48), these
data suggest that TGF-ß growth inhibition may not be required for suppression of
mammary tumour formation and progression.
Overall, this work identifies a unique functional connection between pRB and
TGF-ß in mammary gland development and proliferative control. Surprisingly, these
studies demonstrate that pRB-LXCXE interactions can suppress tumorigenesis in the
mammary gland, but only in specific circumstances. This highlights the complexity and
context-dependence of pRB growth control as a tumour suppressive mechanism. The
implications of these findings are discussed in the following sections.

5.2 Mediators of pRB Proliferative Control
In Chapter 2 ,1 demonstrated that pRB-LXCXE interactions are critical for pRB
proliferative control in the mammary epithelial population. This is due, in part, to an
inability of pRBAL to induce a full growth arrest in response to TGF-ß. While these pRBLXCXE interactions are necessary for full suppression of E2F target genes upon
treatment with TGF-ß, the underlying mechanism remains unclear. Although greater than
30 LXCXE-dependent interacting partners of pRB have been identified, very few have

186

been demonstrated to play a role during G1 arrest (3, 60). Thus, it is difficult to predict
which LXCXE-interacting proteins are necessary for pRB to induce the TGF-P cytostatic
response. Below, the candidate proteins are described, along with the evidence for and
against their potential for mediating pRB-LXCXE-dependent proliferative control.
5.2.1 CDH1 and the Anaphase Promoting Complex/Cyclosome
An interaction between pRB and CDH1 was recently identified using a
combination of GST pulldowns and mass spectrometry (3). CDH1 is a component of the
anaphase promoting complex/cyclosome (APC/C), which targets proteins for degradation
in a cell cycle-dependent manner. One such target is SKP2, a component of the SCFslcP2
E3 ubiquitin ligase. The SCFskp2 complex targets the CDK inhibitor, p27Klpl, for
degradation to allow progression through the cell cycle (7, 51, 54). Intriguingly, during
cell cycle arrest, pRB can bind SKP2 at the C-terminus and CDH1 at the LXCXE binding
cleft. The APC/C then targets SKP2 for degradation, and p27K1P1accumulates in the cell,
inhibiting CDK phosphorylation of target proteins, including pRB. In its active state,
pRB can then block cell cycle advancement (Fig. 1.3) (3, 17). APC/C-mediated
stabilization of p27KIPI has been demonstrated in a TGF-P growth arrest paradigm,
highlighting CDH1 interactions at the LXCXE binding cleft as a candidate mechanism
for cell cycle exit in response to TGF-P (30). However, several lines of evidence indicate
that this interaction may be dispensable for mediating this pRB anti-growth signal. First,
overexpression of two different CKIs, pl6INK4a and p21CIP1, was unable to induce arrest in
Kbj AL/al ^E Fs, suggesting that the defect is independent of CKI activity (Fig. 2.6).
Furthermore, pRB became hypophosphorylated in R b l ^ ^ cells when treated with TGFpi, suggesting that CKIs were active in those cells (Fig. 2.6). Together, these data
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demonstrate that the R blALAL defect occurs downstream of CKI-dependent activation of
pRB, suggesting that CDH1 may not be the LXCXE-interacting protein that cooperates
with pRB to induce proliferative control in the context of TGF-P signalling.
5.2.2 HDAC, BRG1, and hBRM interactions
Several chromatin remodelling factors can interact with pRB in an LXCXEdependent manner and are thought to create a closed chromatin structure at E2F target
genes to repress transcription. Interestingly, the coordinated expression of HDAC, BRG1,
hBRM, and pRB, has been shown to control cell cycle exit (60). All three of these
chromatin remodellers can interact with pRB in an LXCXE-dependent manner and act as
co-repressors of E2F target gene expression (6, 9, 31, 32, 49, 53). Zhang, et al.,
demonstrated that overexpression of pRB and HDAC could repress E2F-dependent
transcription, while the hSWI-SNF complex was additionally required to induce cell
cycle arrest (60). However, the authors did not demonstrate that all four proteins interact
simultaneously, so it is unclear if these proteins function as a complex or independently
to exert this growth arrest. Several studies have shown that BRG1 can control cell cycle
arrest indirectly by upregulating expression of p21CIP1 and this induction does not require
interactions between BRG1 and pRB (14, 18). Therefore, it is possible that HDAC,
BRG1, and hBRM using both pRB-interaction-dependent and -independent mechanisms
to induce a full growth arrest. The artificial nature of the overexpression experiments also
makes it difficult to interpret the biological context of these results. For instance, it is
unclear if these proteins can induce cell cycle exit in response to various stimuli in
physiological settings. Therefore, whether an HDAC-BRGl-hBRM-pRB complex
mediates the TGF-P cytostatic response remains to be determined.
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5.2.3 The Sin3 Complex
HDAC is a constituent of two other cellular complexes: the Sin3 and
Mi2/nucleosome remodelling and deacetylase (NuRD) complexes. The core sin3
complex in mammals contains mSin3A and mSin3B, SAP30, SAP 18, HDAC1 and 2, and
the histone binding proteins RbAp46/48 (21). The core complex can also recruit other
chromatin modifiers and transcriptional repressors, such as MeCP2, Ski, and Ikaros, to
elicit specific effects depending on the cellular context (21). The Sin3-SAP30-HDAC
complex is recruited to pRB by another LXCXE-interacting partner, RBP1 (25). In terms
of a functional connection to pRB growth control, the Sin3 complex co-localizes with
pRB-E2F4 repressor complexes in quiescent human cells at sites that may represent the
initial origins of DNA replication following growth stimulation. Therefore it is possible
that pRB-induced cell cycle arrest is mediated in part by recruiting this repressor complex
to alter the chromatin structure at origins of replication (25). However, using chromatin
immunoprécipitation (ChIP), another group demonstrated that recruitment of the Sin3
complex to E2F target gene promoters in quiescent cells required p i07 or p i30 activity,
while an anti-pRB antibody did not pull down E2F target promoter sequences (45). Since
E2F-dependent transcription is deregulated in RblAL/AL cells, this implies that the Sin3
repressor complex is not a strong candidate mediator of pRB growth control in the
context of TGF-P signalling. However, it is possible that pRB-Sin3 interactions have a
different role during quiescence than pl30-Sin3 or that pRB plays a more transient role of
recruiting Sin3 to E2F target genes while pi 30 is required for maintenance of this
complex. Finally, different pocket proteins may interact with the Sin3 complex depending
on the arrest signal. Therefore it is possible that components of the Sin3 complex interact
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with pRB during a TGF-P-induced growth arrest to alter chromatin structure and repress
E2F target gene transcription.
5.2.4 The NuRD Complex
HDAC-RbAp46/48 can also interact with the NuRD complex (21). This complex
contains Mi-2|3, which has a DNA helicase/ATPase domain, MTA2, methyl-DNAbinding protein 3 (MBD3), and the core HDAC complex. Lysine specific demethylase 1
(LSD1) also interacts with the NuRD complex in human cell lines (58). Thus, NuRD
allows the coordinated activity of multiple chromatin remodelling factors in one repressor
complex. Interestingly, the Caenorhabditis elegans RB-related gene, lin-35, as well as
many of the worm homologues for NuRD components, fall into a similar class of genes
involved in vulval development (55). In C. elegans, vulval formation is triggered by an
EGF-like (LIN-3) signal to specific vulval precursor cells, while synthetic multivulva
(synMuv) proteins repress expression of LIN-3 in the surrounding epidermis. SynMuv
genes fall into three classes, designated A, B, and C. Mutants from different classes
develop a Muv phenotype when combined with mutants from either of the other two
classes, suggesting that redundant mechanisms block LIN-3 expression (55).
Interestingly, LIN-35 and LIN-53, HDA-1 and LET-418 (C. elegans homologues of RB,
RbAp48, HDAC, and Mi2 respectively) are all class B synMuv proteins (55). This
suggests that either members of this NuRD-like complex are candidate in vivo partners of
pRB or that they contribute independently to a common process in worm vulval
development. The HDAC subunit common to both Sin3 and NuRD interacts with the
pRB LXCXE binding cleft in human cells (6, 26, 32), implying that pRB may interact
with the NuRD repressor complex in certain cellular contexts. Interestingly, the same
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GST pulldown/mass spectrometry screen that identified the interaction between CDH1
and pRB also found that pRB interacted with the Sin3 and NuRD complexes in an
LXCXE-dependent manner (Dr. Fred Dick, personal communication). Thus, components
of both the Sin3 and NuRD complexes are candidate pRB LXCXE binding cleft
interacting proteins that cooperate with pRB to induce TGF-(3 growth arrest.
5.2.5 The DREAM complex
Recent work in Drosophila identified a multi-subunit complex consisting of the
fly pocket protein RBF, drosophila E2F2, and dMyb-interacting proteins (dREAM) that
repressed transcription of numerous developmentally regulated E2F target genes (23).
This complex is conserved in flies (dREAM), worms, (DRM) and mammals (DREAM)
(13, 23, 27, 29, 44, 55). Of note, components of the worm DRM complex also fall within
the B class of synMuv genes, but they form a complex that is distinct from NuRD and
interact with LIN-35 (13). Intriguingly, in vitro binding experiments have demonstrated
that this complex contains subunits that bind to pRB in an LXCXE binding cleftdependent manner (23). However, if the dREAM and DRM complexes regulate an
extensive array of developmentally regulated genes, how is the R blZ‘z/di mouse viable? A
recent study provided some insight, demonstrating that pi 30 is the main pocket protein
that interacts with the mammalian DREAM complex during quiescence (29). This does
not exclude the possibility that subunits of the DREAM complex can bind the LXCXE
binding cleft on pRB to repress transcription of a subset of target genes or in specific
cellular contexts. Therefore, while p i30 interacts with the DREAM complex during
serum starvation, it is possible that pRB can interact with the complex during other
growth arrest paradigms, such as TGF-|3-dependent negative growth control.
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5.2.6 Histone methyltransferases
Many of the complexes outlined above contain subunits capable of modifying the
chromatin environment and disruption of epigenetic modifications at E2F target genes
could result in the loss of pRB proliferative control. This has been demonstrated in the
case of cellular senescence (52) where the trimethylation of histone 3 lysine 9
(H3K9Me3) is reduced at E2F target genes in senescent R b l cells. Loss of this
repressive mark is associated with deregulation of target gene expression as well as re
entry into the cell cycle. The methyltransferases responsible for the placement of this
marker, Suv39hl and 2, interact with pRB through the LXCXE binding cleft (40, 56). It
is also noteworthy that long term exposure to TGF-(3 can induce cellular senescence (28).
Therefore, it is possible that heterochromatization of E2F target genes may be necessary
for TGF-P-dependent growth inhibition in much the same way it is required for
senescence. This places the Suv39h methyltransferases as potential LXCXE-interacting
proteins involved in TGF-P growth control.
5.2.7 An Unbiased Approach to Identify Mediators of pRB-dependent TGF-p
Growth Control
The studies outlined above have identified many potential candidates that may
interact with pRB at the LXCXE binding cleft in order to induce the TGF-P cytostatic
response. This includes several chromatin modifiers that form large complexes to repress
transcription during development and cell cycle exit. However, it also includes other
classes of proteins, such as CDH1, that mediate cell cycle arrest via degradation of
proteins that drive cell cycle progression. Many other proteins also interact with pRB at
the LXCXE binding cleft, although the biological outcomes of these interactions are not
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known (reviewed in (8)). With such a diverse list of candidates, an unbiased approach is
necessary to determine the mechanism of pRB-LXCXE-dependent TGF-P G1 arrest. One
such approach would involve GST pulldown/mass spectrometry on GST-tagged wild
type pRB or pRBAL mixed with TGF-P 1-treated or untreated extracts. Alternatively,
candidates could be identified by knocking down proteins at random using an shRNA
library. Knock down cells would then be tested for TGF-P-induced cell cycle arrest.
These approaches could be used alone or in tandem to identify target proteins that interact
with pRB during TGF-P-induced growth arrest. They could also be repeated in the
context of DNA damage and senescence cues, which are also disrupted in RblALAL MEFs
(52). Together, these experiments would provide new insight into how pRB coordinates
various protein interactions to assert proliferative control in different cell cycle arrest
paradigms.

5.3 TGF-P-Mediated Tumour Suppression
The current dogma in the TGF-P field suggests that TGF-P proliferative control
suppresses tumorigenesis early in breast cancer development, but is selectively lost
during cancer progression, leaving other pro-tumorigenic aspects of TGF-P signalling to
drive metastasis (reviewed in (2, 33, 35, 41, 57)). However, attempts to separate various
aspects of TGF-P signalling have proven complicated, leaving open the question of which
of TGF-P’s many functions suppress tumorigenesis in vivo. Here, I have shown that TGFP cytostatic control is disrupted in mutant mammary epithelial cells. In contrast, this work
demonstrates that TGF-P-dependent apoptosis and differentiation occur in an overtly
normal manner in R blAL/AL mammary glands. Furthermore, motility and invasion appear
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to occur independently from TGF-P signalling in both wild type and mutant primary
MECs. To the best of my knowledge this is the first model selectively disrupting TGF-P
proliferative control, while leaving other aspects of TGF-P signalling intact. This allowed
the role of TGF-p growth inhibition as a protective mechanism during mammary tumour
progression to be addressed.
In both the DMBA study and the cross into the Neu background, there was no
increase in tumorigenesis with loss of pRB-LXCXE interactions and the TGF-p cytostatic
response. This is in striking contrast to previous studies where constitutive expression of
TGF-P signalling protected against primary mammary tumour formation while driving
lung metastases (39, 43, 48). If TGF-P growth control normally protects against breast
cancers, I would have anticipated that loss of TGF-P proliferative control in these models
would lead to a decrease in tumour latency or more aggressive tumours. Instead,
disruption of pRB-LXCXE interactions had no effect on primary tumours in these
models. If that is the case, how does this work fit with the protective effect associated
with TGF-P overexpression in the mouse models outlined above? I envision two possible
explanations for this outcome. The first is that there is a threshold of TGF-p growth
suppression necessary for effective tumour suppression. Loss of LXCXE interactions in
MECs reduced TGF-P growth arrest, but did not abrogate the activity entirely (Fig. 2.4).
Therefore, I cannot rule out the possibility that residual TGF-P growth control was
sufficient to suppress tumorigenesis.
An alternative explanation for the protective effect found in previous models
exploring the role of TGF-P during tumorigenesis is that other TGF-P-dependent
mechanisms such as apoptosis or differentiation mediate tumour suppression. These other
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TGF-p-dependent mechanisms could work in conjunction with, or instead of, the
cytostatic response to protect cells from tumour formation. For example, the use of
patient-derived metastatic breast cancer cells also showed defects in TGF-(3-induced
differentiation. ID1 is normally downregulated in response to TGF-P signalling, but in
metastatic breast cancer cells, ID1 is actually induced by TGF-p (42). It is not clear how
this pathway is disrupted in metastatic cells, but ID1 expression has been shown to
correlate with relapse in ER- patients and metastatic potential in xenograft models (12,
37). This places TGF-(3-mediated differentiation and ID1 repression as another potential
tumour suppressive mechanism that may contribute to the phenotypes displayed in the
various mouse models presented in this thesis and in the literature.
TGF-P-mediated apoptosis may also be lost during breast cancer progression. As
outlined in the introduction, depending on unknown factors and environmental cues,
TGF-P can either induce or suppress apoptosis. One possibility is that TGF-P triggers
growth arrest or apoptosis depending on the intensity of proliferative signals in the
environment (33). In the adult virgin mammary gland, TGF-P proliferative control
appears to balance out local mitogen signals. However, in the case of intense mitogenic
stimulation that occurs during late pregnancy, constitutive TGF-P signalling induces
apoptosis (16, 48). Similar phenomena have also been described in the transition epithelia
of the anogenital region (11, 33). It is possible that TGF-P-dependent apoptosis is
induced early during tumour progression to protect against aberrant mitogenic signalling
in premalignant cells as well, and disruption of this mechanism contributes to more
aggressive metastatic tumours.
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There are still many gaps in our knowledge of how TGF-P differentiation and
apoptosis are mediated in the mammary gland. TGF-P can block ID1 expression in breast
cancer cells (19), which should induce differentiation, but other studies show that TGF-p
can block full differentiation and milk production of alveolar cells (5, 10, 22, 36, 46, 50).
In a similar manner, TGF-P can have both pro- and anti-apoptotic effects in the cell.
Clearly, the molecular mechanisms underlying these TGF-P responses, as well as the
cellular contexts where they are relevant need to be discerned before their importance as
tumour suppressors can be addressed in full. This will require the development of new
model systems where these pathways can be disrupted in isolation. These types of studies
will be critical to gain a better understanding of how TGF-P acts as a tumour suppressor.

5.4 TGF-P as a Therapeutic Target
One of the biggest debates in the TGF-P field is whether drugs should be
developed against this signalling pathway. As outlined earlier, a wealth of data suggests
that constitutive activation of TGF-P can drive invasion and metastasis in tumour cells,
and high amounts of TGF-P are often produced by the tumour cell (33). TGF-P is also
involved in mediating paracrine effects in the mammary gland, which modulate the
tumour microenvironment and the host immune system to enhance tumour growth
(reviewed in (33)). This highlights TGF-P as a prime target for anticancer therapies. On
the other hand, many TGF-P responses, like proliferative control, apoptosis, and the
induction of differentiation are anti-tumorigenic. Thus, in mouse models, constitutive
expression of TGF-P signalling protects against tumour formation while driving
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metastasis (39, 48). Because of the dual roles that TGF-p can play during tumorigenesis,
the risks of such a therapeutic strategy must be determined.
TGF*Ps and their receptors are expressed in many mammalian tissues (35). This
poses a potential problem because long-term exposure to TGF-P antagonists is likely to
have adverse side effects. A major perceived risk of blocking TGF-P signalling is the
potential for chronic inflammation or autoimmune effects. TGF-pi, in particular has a
clear role in the immune system. Mice lacking TGF-P 1 die shortly after birth due to
systemic inflammation (24, 47) and mice lacking Smad3 also have an impaired
inflammatory response (1). In humans, loss of normal TGF-P function has been
implicated in the pathogenesis not only of cancer, but also autoimmune and inflammatory
diseases, while excess TGF-P has been implicated in immunosuppression and fibrosis, as
well as metastasis (4, 34). However, lifetime exposure to a soluble TGF-P antagonist did
protect Neu mice from lung metastasis without significant adverse immune effects (59).
This raises optimism for the use of TGF-P antagonists in cancer therapies.
Since TGF-P is a potent inhibitor of proliferation in epithelial cells, perhaps the
greatest risk is potential acceleration of preneoplastic lesions or cancers where TGF-P
still exerts growth restraint. This was found when a gene encoding a soluble truncated
form of TPRII was transfected into a hepatoma cell line (20). However, in two models of
breast cancer, similar antagonists did not have tumour-promoting effects (38, 59). At the
same time, treatment reduced metastases in these mice. The data from this thesis lends
further support to the potential efficacy of blocking TGF-p during cancer therapy. Loss of
TGF-P growth inhibition did not affect the rate of tumorigenesis in either the DMBA or
Neu studies. Together with the previous work with soluble antagonists (59), the data
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presented here suggests that TGF-P antagonists should have minimal effects on TGF-p
growth control. The developmental studies also reveal that it is dispensable for the
formation and homeostasis of most tissues in the mouse. However, to test whether TGF-P
growth inhibition or other TGF-P-dependent mechanisms protect against tumorigenesis in
this model system, the Neu; R b l^ ^ experiment should be repeated in the MMTV-TGFp i background. If excess TGF-pi suppressed tumorigenesis in both Neu; R bT +and Neu;
RblMjA> mice, it would suggest that TGF-P-dependent apoptosis, differentiation, or other
mechanisms may block tumour formation and progression. These types of studies will be
critical to gain a better understanding of how TGF-P acts as a tumour suppressor. If this
hypothesis holds true, the RblALiAL mouse should prove a valuable tool to test new TGFP therapies, not only for cancer but also other diseases affected by changes in TGF-P
levels, as they are developed.
In a clinical setting, one would want to selectively neutralize the TGF-P pathway
that is involved in disease pathogenesis without affecting the normal protective and
homeostatic roles of TGF-P in unaffected tissues. Since the work presented here suggests
that TGF-P growth inhibition is not important for most development and tumour
suppression, it is of even greater importance to understand when and how TGF-P
mediates apoptosis and differentiation, so that more selective TGF-P drug targets can be
developed that do not disrupt these aspects of TGF-P signalling.

5.5 Perspectives
The work in this thesis has extended our knowledge about the roles of pRB and
TGF-P in mammary gland development and cancer. First, using knock-in mouse models

198

where pRB LXCXE interactions are disrupted, I showed that pRB is necessary to
maintaining proliferative control within the developing mammary gland. This growth
regulation is intimately tied to the ability of pRB to induce TGF-P growth inhibition. In
the TGF-P field, pRB represents the end point in the cytostatic response, and little
attention has been paid to how it exerts this effect. The work presented here demonstrates
that pRB-LXCXE interactions are critical for inducing a full arrest. With the use of
affinity purification, mass spectrometry, and shRNA technologies, further expansion of
the downstream effectors and mechanisms involved in TGF- p growth control can be
expected. Similar techniques should also help to identify the LXCXE binding partners
that mediate a variety of cellular processes that pRB has recently been implicated in, such
as senescence control, DNA damage, and genomic stability (15, 52).
Second, I examined the importance of pRB-dependent negative growth regulation
for blocking tumour formation. This work has identified pRB proliferative control as a
tumour suppressive function of pRB in the mammary gland. However, since treatment
with DMBA and the cross into the Neu background did not yield changes in tumour
latency or aggressiveness, it reveals that pRB proliferative control is activated in a
context-dependent manner. As already outlined, this data also suggests that in the Wapp53R,72H model, TGF-P growth suppression is not the mechanism by which pRB-LXCXE
interactions block tumorigenesis. A major challenge in the future will be identifying the
upstream signals that induce pRB proliferative control. The use of transgenic mouse
models that disrupt other pathways mediated by LXCXE interactions as outlined above
should give rise to a fuller understanding of how pRB proliferative control protects
against tumour formation.
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Appendix I: PCR Methods and Primers
Reagents for Genotyping PCR

Component

10X PCR
buffer
dNTPs (2
mM)
MgCI2 (50
mM)
Primers (20
MM)

Rb1 (Intron
20LoxP)
2pL

MMTV-Neu

MMTV-TGFQ*S223rt25

2pL

2pL

Wapp 5 3 *72H
2pL

2 pL

2 pL

2 pL

2 pL

0.5 pL

0.5 pL

0.5 pL

0.5 pL

0.25 pL of:
FD134,
FD135

0.25 pL of:
0.25 pL of:
0.25 pL of:
IMR042,
T022
IMR042,
IMR043,
T023
IMR043,
IMR386,
IMR086,
IMR387
IMR087
12.8 pL
12.3 pL
12.3 pL
12.8 pL
h 2o
0.2 pL
0.2 pL
Taq (5U/pL)
0.2 pL
0.2 pL
2 pL
DNA*
2pL
2 pL
2 pL
TOTAL
20 pL
20 pL
20 pL
20 pL
*DNA for lntron20LoxP and Wap-p53R172H genotyping may be isolated by the Hotshot method. DNA 1
the MMTV-Neu and MMTV-TGF-p1S223/22S must be isolated by Proteinase K digestion and ethanol
precipitation
Thermal Cycling Conditions for Genotyping (PTC-100 or -200 Thermal Cycler)

Program
Annealing
Temperature
Number of
cycles

Rb1 (Intron
20LoxP)
SL01
60°C

30

MMTV-Neu

MMTV-TGFP^S223/225

SL01
60°C

SL01
60°C

WapP5j 72h
SL01
60’C

30

30

30

RT-PCR and qRT-PCR
RNA was extracted from tissues or cells using Trizol reagent (Invitrogen) and
then converted to cDNA using the Reverse Transcription System (Promega) as per the
manufacturers’ instructions. RT-PCR was performed on a PTC-100 or -200 Thermal
Cycler. Quantitative real time PCR (qRT-PCR) was then performed using iQ SYBR
Green Supermix (Bio-Rad) on a PTC-200 Thermal Cycler equipped with a Chromo 4
Continuous Fluorescence Detector, and the data was analyzed using Opticon Monitor 3.1
software (Bio-Rad).
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Reagents for cDNA Synthesis and RT-PCR

cDNA synthesis

Component
(Promega kit)

4 pL
2 pL
2 pL
0.5 pL

MgCI2 (25 mM)
RT 10X Buffer
dNTPs (10 mM)
Ribonucléase
Inhibitor (40 U/pL)
Random primers (0.5
mg/mL)
AMV Reverse
Transcriptase (25 U/
ML)
RNA*

Component
(standard
reagents)
10X PCR buffer
dNTPs (2 mM)
MgCh (50 mM)
Primers (10 pM)

RT-PCR

1 pL DEPC-H2O

2 pL
2 pL
0.2 pL
0.8 pL
each
11.7 pL

0.68 pL Taq (5U/pL)

0.5 pL

1 pg up to 9.82 cDNA"
2 pL
pL in DEPC-H2 O
20 pL
TOTAL
20 pL TOTAL
‘ heat RNA at 70°C for 10 minutes and then place on ice prior to cDNA synthesis
"A fter cDNA synthesis, dilute cDNA to 100 pL in DEPC-H2 O prior to RT-PCR or qRT-PCR

Program
Primers
Annealing
Temperature
Number of
cycles

MMTV-TGF^^8223/225
TGFRT
SFOIand
SF02

Cdkn2b

Atf3

60°C

TGFRT
p15 for and p15
rev or p15 for2
and p15 rev
60”C

TGFRT
ATF for
and
ATF rev
60”C

35

35

35

Csn2

Actb

Gapdh

TGFRT TGFRT TGFRT
cas m for act for2 GAP for
and
and cas m and act
rev2 GAP rev
rev
60°C
60°C 55-60”C
35

30-35

30-35

Reagents for qRT-PCR_____

Component (Bio-Rad) qRT-PCR
DEPC-H2 O
7pL
iQ
10pL
Primers (10 pM)
1 pL each
cD N A"________________________ 1pL
______________TOTAL
20 pL
" After cDNA synthesis, dilute cDNA to 100 pL in DEPC-H2O prior to qRT-PCR
Thermal Cycling Conditions for qRT-PCR (PTC-200 Thermal Cycler with Chromo
4 Continuous Fluorescence Detector)

_______________ All reactions
Program
Opticon 3.1
Protocol
Sarah F, 63
Annealing
63‘C
Temperature
Number of
35
cycles_______________________
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Primer Sequence Information

Gene/iocus/
transgene
MMTV-TGFß jS 2 2 3 /2 2 5

Application
genotyping

Primer
name
IMR0186

MMTV-TGF-

genotyping

IMR0187

MMTV-Neu

genotyping

IMR386

MMTV-Neu

genotyping

IMR387

112

genotyping

IMR0042

ß jS 2 2 3 /2 2 5

112

genotyping

IMR0043

Provided by
MMHCC

R b 1 -136
bp; Rb1/sL21A bp (with
FD135)

FD135

CAC ACA AAT CCC
CAT ACC TAT G

R b 1 -136
bp; R b1*~
274 bp (with
FD134)

SF01

AAG GAC CTC GGC
TGG AAG T

196 bp (with
SF02)

Amplifies
intron 20 for
Rb1, intron
20 + LoxP
for Rb1*
Amplifies
intron 20 for
Rb1, intron
20 + LoxP
for R b1*
Amplifies
simian TGFp jS 2 2 3 /2 2 5 .

196 bp (with
SF01)

does not
align with
mouse TGF01
Amplifies
simian TGFp jS 2 2 3 /2 2 5 ,

genotyping

T023

Rb1

genotyping

FD134

Rb1

genotyping

MMTV-TGF-

RT-PCR

Cdkn2b
qRT-PCR
(encodes p15)
Cdkn2b
qRT-PCR
(encodes p15)

and MMTVNeu PCR
Provided by
JL; internal
ctl for
MMTV-TGFp jS 2 2 3 /2 2 5

1300 bp
(with T022)

Wap-53"1UH

RT-PCR

324 bp (with
IMR0042)

Provided by
JL
Provided by
JL
Provided by
JL
Provided by
JL
Provided by
JL; internal
ctl for
MMTV-TGF^S22V 225

1300 bp
(with T023)

T022

MMTV-TGF-

GTA GGT GGA AAT
TCT AGC ATC ATC C

Comments

CCG TCG ACG GCC
ACA GTG AAG ACC
TCC GGC CAG
GCC TGA AAA TGT
CTC CTG GCT CAG
AGG G
AGC TTC ATA CAG
ATA GTT GGG

genotyping

ß j S 2 2 3 /2 2 5

TCA CTC CTC AGG
TGC AGG CTG CCT
ACA GCT ATG ACT
GGG AGT AGT CAG
TTT CCT GCA GCA
GCCTAC GC
CGG AAC CCA CAT
CAG GCC
CTA GGC CAC AGA
ATT GAA AGA TCT

Amplicon
size
502 bp (with
IMR0187)
502 bp (with
IMR0186)
500 bp (with
IMR387)
500 bp (with
IMR386)
324 bp (with
IMR0043)

and MMTVNeu PCR
Provided by
MMHCC

Wap-5ri/M

ß ^ S 2 2 3 /2 2 5

Primer sequence

SF02

p15 for
p15 for2

TAG TAC ACG ATG
GGC AGT GGC T

TGC CAC CCT TAC
CAG ACC TGT G
CAA GTG GAG ACG
GTG CGG CAG C

167 bp (with
p15 rev)
322 bp (with
p15 rev)

does not
align with
mouse TGF01
Within exon
2
Within exon
1; used to
confirmed
amplification
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of cDNA
from p15 for
Within exon
2

Cdkn2b
qRT-PCR
(encodes p15)

p15 rev

GCA GAT AC C TCG
CAA TGT CAC G

Atf3

qRT-PCR

ATF for

CCT CTC ACC TCC
TGG GTC ACT G

167 bp with
p15 fori);
322 bp (with
p15 for2)
214 bp (with
ATF rev)

Atf3

qRT-PCR

ATF rev

ATT TCT TTC TCG
CCG CCT CC

214 bp (with
ATF for)

Csn2
(encodes (5casein)

qRT-PCR

cas m for

TAT CAA TGA GCA
GAA ACT TCA GAA
GGT

130 bp (with
casein m
rev)

Csn2
qRT-PCR
(encodes Pcasein)
Actb (encodes qRT-PCR
P-actin)

cas m rev

GGT TTG AGC CTG
AGC ATA TGG

Spans
intron-exon
boundary
(between
exon 5/6)
130 bp (with Within exon
casein m for) 6

act for

AT GGAGAAGAT CTGG
CAC

616 bp (with
act for)

Actb (encodes qRT-PCR
p-actin)

act rev

CGTCACACTTCATGA
TGG

616 bp (with
act rev)

Actb (encodes qRT-PCR
P-actin)

act for2

CTG TCG AGT CGC
GTC CAC CC

128 bp (with
act rev2)

Actb (encodes qRT-PCR
P-actin)

act rev2

ACA TGC CGG AGC
CGTTGT CG

128 bp (with
act for2)

Gapdh

qRT-PCR

GAP for

CAA CGA CCC CTT
CAT TGA CCT

634 bp (with
GAP rev)

Gapdh

qRT-PCR

GAP rev

ATC CAC GAC CGA
CAC ATT GG

634 bp (with
GAP for)

JL - Jackson Laboratories
MMHCC - Mouse Models of Human Cancers Consortium
ctl - control

Within exon
2
Within exon
3

Obtained
from Berube
lab; within
exon 3; qRTPCR ctl
Obtained
from Berube
lab;
unknown
origin; qRTPCR ctl
Within exon
1; qRT-PCR
ctl
Within exon
2; qRT-PCR
ctl
Within exon
4; qRT-PCR
ctl
Within exon
6 qRT-PCR
ctl
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Appendix II: Animal Use Protocol - Letter of Approval
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